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Abstract 
Background: Quantum dots (QDs) have emerged as one of the most exciting 
fluorescent nanoparticles with a potential for diagnostic and therapeutic application in 
the field of nanomedicine. The aim of this study was to synthesize water soluble 
QDs; bio-conjugating these QDs with RGD peptides prior to linking the QD-
conjugated peptide to cancer cells with the aim to study cytotoxicity and assess its 
feasibility for in vivo studies. 
Methods: Water soluble Cadmium Telluride (CdTe) QDs were synthesized by the 
reaction of cadmium chloride with sodium tellurite in the presence of buffer solution 
of Mercaptosuccinic acid (MSA) as a capping ligand. Water soluble red emitting QDs 
thus obtained were characterized using spectrophotometric analysis. These QDs 
revealed a wide absorption spectrum with an excitonic absorption peak of 380nm 
and a narrow symmetrical emission spectrum of 630nm. The size and pattern of 
these QDs were studied using Transmission Electron Microscopy (TEM). These 
nanocrystals revealed their configuration in the form of isolated crystals or clusters 
measuring from 5-10nm in diameter. X-ray microanalysis combined with TEM 
permitted analysis of the elemental configuration of these QDs. These CdTe QDs 
were subsequently bound to HT 29 colon cancer cells to study the interaction of QDs 
in vitro. As colon cancer cells over-express integrins, QDs were conjugated with 
RGD (Lysine) and RGD (Cysteine) peptides for the purpose of active binding with 
HT29 colon cancer cells. The conjugated QDs were applied to colorectal cancer cells 
to assess their affinity to cellular adhesion molecules. The toxicity of naked and 
conjugated QDs was also assessed by analyzing cell survival and cell death after 
exposure to C2C12 mouse skeletal muscle cells. In vivo experiment using Sprague 
   5 
 
Dawley (SD) rat established feasibility of biodistribution studies with a small dose of 
10µg/ml. 
Results: These water soluble fluorescent CdTe nanocrystals were synthesized 
using relatively stable precursors. It was possible to demonstrate binding of these 
red emitting QDs to the HT29 colon cancer cells in vitro. Significant and stable 
binding was noted after QDs were conjugated with RGD peptides. Toxicity assay 
evaluation studies suggested that both nonconjugated and conjugated QDs were 
nontoxic to C2C12 mouse skeletal muscle cells at a concentration of 50 μg /ml 
indicating that they are less toxic to normal cells, and are safe to be applied to in vivo 
models. Further in vivo experimentation in SD rats established feasibility for imaging 
sentinel lymph nodes following interdigital web space injection of QDs. 
Conclusions: RGD-conjugated QDs can selectively target HT29 colorectal cancer 
cells with low toxicity to normal muscle cells offering a potential novel detection 
strategy for colorectal cancer. This property can be explored for early diagnostic and 
therapeutic purpose by selectively targeting cancer cells. Further studies are 
required in an in vivo model to analyze systemic biodistribution and toxicity studies. 
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Hypothesis 
1. Novel CdTe quantum dots can bind / be taken up by cancer cells therefore 
demonstrating potential for clinical application. 
 
2. Nonconjugated and RGD conjugated CdTe quantum dots are less toxic to 
normal cells than to cancer cells. 
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1.1 INTRODUCTION 
Nanotechnology has been at the forefront of research in the last two decades. This 
deals with design, synthesis & fabrication of structures at the molecular scale. The 
ever expanding field of bionanotechnology aims at revolutionizing biomedical 
research and clinical practice and has the potential of being incorporated into 
modern medicine with the aid of exciting physical and chemical properties of 
nanoparticles aiming at early and precise diagnosis of various life threatening 
diseases and selective targeting of drugs as well as minimizing the systemic side 
effects responsible for the morbidity.  
Nanotechnology is a multidisciplinary field that involves design and engineering of 
objects less than 100nm in size. At this size the particles acquire unique physical, 
chemical, biological, structural and functional properties not presented by their 
discrete molecules or bulk materials. 
Tumors result from genetic alterations of cells, which may involve over or under 
expression of normal genes, or mutations generating abnormal gene products. This 
may affect any of the molecules within the cell, the cell membrane or the cancer-cell 
milieu. In addition, stromal and vascular endothelial cells are important for the 
exponential growth and spread of the tumour by providing appropriate 
microenvironment1. 
Cancer nanotechnology is  a rapidly expanding field of diagnostic medicine and its 
allied fields and is expected to rapidly conquest the advances in early diagnosis  and 
effective  curative treatments alongside providing in depth knowledge of cancer 
biology in order to treat aggressive and lethal cancer phenotypes2,3,4. 
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Quantum Dots (QDs) are semiconductor nanoparticles in the order of 2-10 
nanometers containing approximately 200-10,000 atoms. These nanosized particles 
have structural and functional properties that are not available from discrete 
molecules or bulk materials. Structurally, these nanoparticles encompass large 
surface areas for the attachment of multiple diagnostic (optical, magnetic or radio 
isotopic) and therapeutic agents. When conjugated with biomolecular affinity ligands 
such as antibodies, peptides or small molecules, these nanoparticles can be used to 
target malignant tumors with high affinity and specificity. 
In general, QDs are produced using atoms from group II and VI of the periodic table 
e.g. Cadmium–Selenide (CdSe),Cadmium Tellurium (CdTe), Zinc-selenium ( ZnSe),  
group III-V elements  e.g. Indium phosphate (InP), Indium arsenate (InAs),Gallium 
arsenate (GaAs) Gallium nitride (GaN)  or group IV-VI elements e.g. Lead-selenium ( 
PbSe). 
Most commonly used QDs are CdSe or CdTe with a passivation shell made of ZnS 
which protect the core from oxidation and increases the photoluminescence quantum 
yield. The surface of the QD is further coated with solubilization ligand making them 
water soluble for their use in cell biology. 
As illustrated in fig. 1.1 The QD core determines optical properties of the probe and 
provides structural scaffolding for engineering of nanodevices. 
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Fig. 1.1 Structure of quantum dot 
 
Quantum dots have emerged as one of the most exciting nanoparticles with a 
potential for diagnostic and therapeutic application in the field of nanomedicine. The 
current fluorophores such as organic dyes, fluorescent proteins and lanthanide 
chelates suffer the problems of instability, photobleaching and sensitivity to 
environmental conditions such as pH variations. The unique optical and 
spectroscopic properties of QDs offer a compelling alternative to traditional 
fluorophores due to their high quantum yield, high molar extinction coefficient 
(~600,000 M-1 cm-1, roughly an order of magnitude higher than even the strongly 
absorbing Rhodamine 6G), exceptional resistance to photobleaching as well as to 
photo and chemical degradation5,6. In addition, the intensity of fluorescence 
produced by the quantum dots is 10-20 times brighter than the organic dyes. 
Conventional dyes suffer from narrow excitation spectra. This requires excitation by 
light of specific wavelength, which varies between particular dyes. In addition, they 
Biomolecules – Covalently attached to the 
polymer shells 
Organic coating – water solubility. Provide 
functional group for bioconjugation 
Inorganic shell (ZnS) – Stability and 
improves brightness 
Core nanocrystal   e.g. .CdSe /  CdTe – 
Determines emission  
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have broad emission spectra. This means, the spectra of different dyes may overlap 
to a large extent limiting the number of fluorescent probes that may be used to tag 
different biological molecules. 
Bulk semiconductor materials have a fully populated valence band and an empty 
conduction band separated by a relatively small band gap (less than 4 eV) between 
valence and conduction bands, thus behaving like insulators at ambient conditions 
and exhibiting electrical conductivity only under external stimulation. When an 
energy exceeding the band gap is supplied, valence-band electrons acquire 
sufficient energy to populate conduction band and enable electric current flow. In 
nanoparticles, valence and conduction bands split into discrete energy levels, with 
the energy gap between closest possible valence and conduction levels increasing 
with decreasing particle size (and increasing degree of confinement of charge 
carriers as illustrated in fig. 1.2). 
Quantum dots are semiconductors whose excitons are confined in the three spatial 
dimensions. When a photon enters the semiconductor, an electron is released. This 
electron possesses enough energy to cross the band gap by migrating from the 
valence band to populate the higher energy conducting band. When this occurs, a 
hole which is of opposite charge to the electron is created into the valence band. The 
radiative recombination of the charge carriers (hole and pair) results in fluorescent 
emission when the electron falls back into the valence band giving rise to the 
exciton. This  relaxation of an electron results in the release of bandgap energy in 
the form of light (fluorescence)7,8,9.   
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Fig. 1.2 Electronic structure of bulk conductor, semiconductor, and insulator 
materials (top panel) and semiconductor nanoparticles  (bottom panel)10. 
 
 
 
Besides retaining bulk property of the material from which these QDs are derived, 
they also acquire novel properties in view of their nanosize. These include large 
absorption spectra, narrow and symmetric emission spectra (full width at half 
maximum of 25-35nm) with a light spectrum ranging between Ultraviolet (UV) to 
Near- Infrared (NIR) (400-1350nm) and the stokes shifts that can be greater than 
200nm. As the QDs have broad absorption spectra, excitation by a wide range of 
wavelengths is feasible. This property can be exploited to simultaneously excite 
different coloured QDs using a single wavelength. QDs have narrow emission 
spectra. This can be controlled in a simple manner by producing variations in the 
size, composition and surface coating.  
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Besides possessing the ability to produce  a very high quantum yield of up to 90% ( 
ratio of emitted to absorbed photons), they also have large absorption cross sections 
and long fluorescence lifetimes (> 10 ns) As a result these quantum dots have 
emerged as a new class of fluorescent bio-probes. Other properties of QDs include 
large absorption cross section (extinction coefficient), good quantum yield and large 
saturation intensity. These properties render the quantum dots brighter than any 
available fluorescent dyes.  
Physical size smaller than the exciton Bohr radius results in a 3-dimensional 
quantum confinement of charge carriers within the QD and limits the number of 
possible energy states that an electron can occupy, thus giving nanoparticles novel 
properties not achievable in bulk materials. Additionally, relatively small size 
comparable to that of large biomolecules (e.g. antibodies) aids in engineering of 
biologically functional materials. The inorganic nanoparticle core provides a rigid 
foundation for the development of QD probes. Manipulation of the core chemical 
composition, size, and structure controls the photo-physical properties of the probe. 
Quantum Dots offer tunable photoluminescence (PL) due to quantum confinement 
effects related to the size and composition of these nanocrystals. The inherent 
benefits of narrow emission bands, large stokes shifts and long half-lives is that the 
mixture of QDs can be used to concurrently track different targets in multiplexed 
analysis and imaging. Manipulation of QD size & composition permits tuning of PL 
emission in NIR region within the optical windows of 700-1100nm. This allows for 
effective deep tissue imaging uninterrupted by optical interference from biological 
components. The size, shape and composition of QDs determine the PL emission 
range which can vary between Ultraviolet and infrared region of electromagnetic 
spectrum11. 
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Fluorescence lifetime is the measure of  decay of fluorescence emission after 
excitation. Autofluorescence of cells lasts 2 nanoseconds. The fluorescence lifetime 
of organic fluorophore lasts between 1-4ns however that of QDs is between 20-30ns. 
Autofluorescence of cells provide background fluorescence reducing detection 
sensitivity. This can be easily overcome by the prolonged fluorescence lifetime of the 
QDs which continue to emit photons long enough benefiting fluorescent cellular 
imaging of biological samples12. 
 
1.2 BACKGROUND 
To date, QDs have been synthesized by different methods including organic and 
aqueous synthesis. Bare QDs are not routinely employed for biological application as 
a result of structural imperfections associated with blinking, predisposition to 
photochemical degradation and toxicity. Passivation with high band gap inorganic 
shell result in the synthesis of more stable QDs with superior photoluminescent 
properties. High temperature synthesis involving pyrolysis of organometallic 
precursors has been the most frequently used method for synthesis of high quality 
QDs in organic solvents. Often the precursors used in this synthetic process are 
highly toxic and unstable. By using alternative cheaper and safer Cadmium 
precursor materials, QDs with reasonable photoluminescence can be synthesized in 
the organic solvents. However being water insoluble, these surfactant coated QDs 
need surface modification either in the form of encapsulation in phospholipid micelle 
or amphiphilic polymers. Alternatively, ligand exchange method can be applied to 
switch hydrophobic surface ligands with hydrophilic ones in order to be safely utilized 
in the biological environment. Aqueous synthesis although result in fabrication of  
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QDs with poor size distribution and low fluorescence efficiency, it carries the 
advantage of being simple, less toxic and reproducible.  
Ying et al24  published  a simpler one pot approach to synthesize water soluble CdTe 
QDs  using Sodium Tellurite as a Te source totally eliminating the need for highly 
toxic  H2Te (Tellurane) or highly unstable  NaHTe  as a Tellurium precursor. Using 
Thiol stabilizer Mercaptosuccinic acid (MSA) as a capping ligand, they could improve 
the QY from < 20 % to 83% at pH 5 and in excess of 70% at pH 6-8. The authors 
highlighted the influence of pH, molar ratio and the reaction temperature in the 
synthesis of high quality water soluble CdTe QDs. This technique forms the basis of 
present study. 
1.3 AIM OF THE THESIS 
This study aimed at designing and synthesizing water soluble CdTe QDs from the 
stable precursors cadmium chloride and sodium tellurite in the presence of 
mercaptosuccinic acid as a capping ligand. The QDs thus synthesized were intended 
to be studied for following features- 
a) To assess the stability of these QDs. 
b) Spectrophotometric analysis to identify excitation and emission spectrum. 
c) To measure the size of these QDs at TEM studies. 
d) Analysis of chemical composition at X-ray microanalysis. 
e) To evaluate cytotoxicity assay of nonconjugated and conjugated QDs. 
f) To study interaction of these QDs with HT-29 colon cancer cells in vitro  and 
g) To explore the feasibility of application of these QDs in the animal experiment 
in vivo. 
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DESCRIPTION OF CHAPTERS 
Chapter 1 This chapter gives a brief introduction of structure and physico-
chemical properties of quantum dots in general and mentions the aims 
of this thesis. 
Chapter 2 This chapter critically reviews of development of QDs and their 
biomedical application. 
Chapter 3 This chapter elaborates the method of synthesis of water soluble 
CdTe QDs and describes characterization of these QDs. 
Chapter 4 This chapter describes materials and methods used in the cell culture 
experiments, transmission electron microscopic studies and 
cytotoxicity assay. 
Chapter 5 This chapter explains cytotoxicity assay of nonconjugated and 
conjugated CdTe QDs. 
Chapter 6 This chapter mentions about the outcome of QD interaction with 
cancer cells in vitro. 
Chapter 7 This chapter enumerates the feasibility of quantum dots for in vivo 
application. 
Chapter 8 This chapter summarizes the results of these various studies and 
gives an insight into the future direction of these novel fluorescent 
nanoparticles for diagnosis and treatment of various cancers. 
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Chapter 2. 
Development of quantum dots and 
their biomedical application – a review  
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2.1 QUANTUM DOT SYNTHESIS 
The QD core defines the optical properties of the probe and exemplifies a structural 
scaffold for engineering of various nanodevices. The QD core has to be stable and 
compact with precisely controlled size distribution, chemical composition, geometry 
and surface chemistry. QD synthesis was first described by Efros and Ekimov in 
1982 when they grew nanocrystals and microcrystals of semiconductors in glass 
matrices. Subsequently researchers prepared QDs in different media such as 
aqueous solution, high temperature organic solvents and solid substrates. QDs 
synthesized in aqueous media resulted in poor size distribution and low fluorescence 
efficiency. 
Bare core QDs have their own disadvantages. The crystalline structure of these 
nanoparticles impart themselves to imperfections resulting in emission irregularities 
particularly blinking in which single QDs switch between fluorescent and 
nonfluorescent states despite continuous illumination. Also, in view of their large 
surface area: volume ratio they are prone to photochemical degradation. Core-shell 
QDs has several advantages over core only QDs in the form of higher physical, 
chemical stability and photoluminescence, quantum efficiencies when shelled by 
higher band-gap semiconductors and polymers. The photostability results from hole 
confinement in the core. Electronic accessibility results from electron spreading into 
the shell. In addition, the shell provides a platform for conjugation of various 
biologically active molecules for diagnostic and therapeutic purpose without 
interfering with the optical properties of the core compound. The surfaces of these 
nanocrystals are made up of atoms that are not fully coordinated and hence they act 
as defects unless passivated. Overcoating these nanocrystallites such as CdSe with 
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higher bandgap, inorganic materials such as ZnS have been shown to improve the 
photoluminescence quality yield by passivating surface nonradiative recombination 
sites. These passivated quantum dots with inorganic shell structures provide a 
robust crystal lattice in building up complex bioconjugated chemical agents. The 
core, shell and the coating characteristics affect the photochemical properties of the 
QDs. So the synthesis of the QDs can be tailored accordingly using precise growth 
techniques involving high annealing temperatures. 
Advances in synthetic procedures and surface chemistry have enabled production of 
water soluble QDs with high quantum yield (40-50%) and relatively narrow size 
distribution. High temperature synthesis is the most commonly used method of 
Quantum Dot production. Bawendi et al  in 1993 first reported synthesis of high 
quality monodisperse QDs from Cadmium Sulfide (CdS), Cadmium Selenide (CdSe) 
and Cadmium Telluride (CdTe) through high temperature organometallic 
procedure13. In this procedure pyrolysis of organometallic precursors at high 
temperature yielded nucleation and growth of nanocrystals, while coordination of 
trioctyl phosphine/trioctyl phosphine oxide (TOP/TOPO) base with unsaturated metal 
atoms on the QD surface prevented the formation of bulk semiconductor. But 
utilization of a highly toxic, volatile, explosive, pyrophoric and expensive Cadmium 
precursor (dimethyl cadmium) had their own disadvantage of imposing restrictions 
on the equipment with limited flexibility in the QD core design. During the synthesis 
of QDs using organometallic procedure, precise kinetic control can be achieved over 
growth of the nanocrystals. So QD population with a narrow size distribution can be 
easily achieved. Relatively simple reaction conditions along with slower nucleation 
and growth rates offer extensive flexibility in engineering of QD chemical 
composition, geometry, and photo-physical properties. As the difference in energy 
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between the discrete ground and excited states increases with increasing degree of 
confinement (i.e. decreasing particle size), the size of the band gap and, 
consequently, the colour of emitted light can be fine-tuned by adjusting the QD size. 
Qu et al. used alternative cheaper and greener Cadmium  precursor materials such 
as Cadmium oxide and  Cadmium acetate14-16.  
Gaponik et al in 2002 synthesized biocompatible CdTe QDs capped with thioglycolic 
acid (TGA) by the reaction between an aqueous solution of cadmium perchlorate 
hexahydrate (2.35 mmol, 125 mL) and H2Te gas in the presence of TGA (5.7 mmol) 
at 100 °C and ∼11.5 pH; H2Te gas was prepared by adding aluminum telluride (0.46 
mmol) into a dilute sulfuric acid solution (30 mL, 0.5M) under N2 atmosphere. The 
advantage of aqueous synthesis over organometallic synthesis was simplicity and 
high reproducibility at a significantly lower cost. The authors however did agree that 
the nanocrystals synthesized by aqueous approach do not possess the degree of 
crystallinity of the organometallically prepared QDs produced at high annealing 
temperature (200-360ºC) by so called hot injection technique resulting in very 
effective separation of nucleation and growth stages. However it was possible to 
synthesize  smaller CdTe and CdSe QDs using size selective precipitation procedure 
which was more reproducible14;17.  
Dabbousi et al in 1997 synthesized CdSe /ZnS QDs via the pyrolysis of the 
organometallic precursors, dimethylcadmium and trioctylphosphine selenide in a co-
coordinating solvent Trioctylphosphine oxide (TOPO). They prepared a solvent 
mixture (10:1 weight: weight) composed of TOPO and TOP by heating TOPO at 190 
°C under vacuum, cooling to 60 °C and adding TOP. Also, a CdSe QD (0.4 mmol) 
suspension was prepared in hexane, transferred into the solvent mixture, and 
hexane was distilled out. A solution of Diethylzinc (ZnEt2) and hexamethyldisilathiane 
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((TMS)2S) in TOP was added drop-wise into the CdSe suspension kept at 140– 220 
°C, and ZnS shells were grown at this temperature. When required thickness for ZnS 
shells was attained, judged from the absorption spectrum, the reaction was stopped 
by adding 1-butanol.The reaction mixture was cooled to room temperature, and the 
core/shell QDs were separated by precipitation from a mixture of 1-butanol and 
methanol14;18. 
There are two major approaches to synthesizing QDs. One of these is the ‘bottom-
up’ approach, more familiar to the chemists. This process utilizes molecular or ionic 
precursors of QDs that are allowed to react together in solution to produce the 
nanocrystals as colloids. The other approach, more familiar to engineers, is the ‘top-
down’ approach where feature sizes on the 1–10-nm scale are carved out 
lithographically or electrochemically from a semiconductor substrate. More recently, 
a third class known as the hybrid route has been proposed as an alternative for QDs 
synthesis. Researchers make molecular precursors for the QDs, which then react in 
the gas phase and are deposited as thin films on substrates. So far, the colloidal 
route has become the most popular process for QDs synthesis. In fact, QDs used in 
bioapplications are exclusively colloidal nanocrystals. They are commonly 
synthesized through the introduction of semiconductor precursors under mild and 
simple reaction  conditions that thermodynamically favor slower nucleation and 
crystal growth, in the presence of semiconductor-binding agents, which function to 
kinetically limit particle growth and maintain their size within the ‘quantum 
confinement’ size regime. The size-dependent optical properties of QDs can only be 
achieved if the semiconductor nanocrystals are prepared within narrow size 
distributions19. As the difference in energy between discrete ground and excited 
states increases with increasing degree of confinement (decreasing particle size), 
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size of the band gap and consequently the colour of emitted light can be fine-tuned 
by adjusting the QD size. By varying the chemical composition of the nanocrystals 
and application of band gap engineering, it is possible to produce QDs emitting light 
from UV, throughout the visible spectra into the infrared spectra. (400-4000nm). 
QDs have a huge surface area: volume ratio which makes them extremely unstable 
in solution causing them to agglomerate forming clusters because of the high surface 
energy. Hence, any route one chooses to synthesize QDs should consider stabilizing 
the just formed nanocrystals by minimizing surface energy via ‘capping’ and avoiding 
further structure growth. The QDs thus produced by organometallic procedure have 
low quantum yield. Moreover TOPO coated QDs are unstable with respect to photo-
oxidation resulting in degradation of nanocrystals and potential toxicity due to 
release of free Cadmium ions. As the radius of the spherical particle decreases, the 
ratio of its surface area to volume rapidly increases exposing larger number of atoms 
on its surface. These surface atoms lack their neighbors to form chemical bonds. As 
a result, unoccupied electron orbitals commonly known as dangling bonds or surface 
trap sites can trap charge carriers to either prevent or delay electron-hole 
recombination with subsequent photon emission reducing the fluorescence quantum 
yield. In addition, these sites might exhibit enhanced chemical reactivity and 
compromise chemical stability of the nanoparticles. In order to prevent these adverse 
effects, these surface trap sites can be saturated by organic and inorganic capping 
layers. 
Several groups have utilized high band gap energy inorganic shells made up of 
several atomic layers thick CdS or Zns to effectively passivate the photoactive core 
of QDs. The wider bandgap of these shells effectively confine the exciton to the QD 
core reducing the nonradiative relaxation pathways and increasing the quantum 
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yield. Although thin shells made up of 1-2 monolayers produce highest fluorescence 
yield, thicker shells consisting of 4-6 monolayers provide more core protection from 
photo-oxidation and degradation. Peng et al synthesized CdSe/CdS core/shell QDs 
by adding 15 mL anhydrous pyridine to TOPO capped CdSe nanocrystals (2–13 mg) 
and by refluxing the mixture overnight under an argon atmosphere. Temperature of 
the CdSe solution was set at 100 °C, and a precursor solution was added for CdS 
consisting of hexamethyldisilathiane and CdMe2 dissolved in tributylphosphine 
(TBP). The shell growth was carried out at 100 °C, and the reaction was stopped by 
removing heat when desired shell-thickness was obtained. The CdSe/CdS QDs were 
separated from the reaction mixture by adding dodecylamine. Shelling CdSe QDs 
with CdS resulted in considerable red-shifts in the absorption and 
photoluminescence bands of QDs20. They observed confinement of the hole created 
during excitation within the CdSe core by a higher band-gap CdS shell. As a result of 
this confinement the hole dependent photo-oxidative processes causing QD 
degradation resulting in loss of fluorescence are impeded. They also suggested that 
thicker shell might reduce QD blinking associated with charge trapping and un-
trapping at surface defect of the nanomaterial. 
Alternative approaches to improve fluorescence efficiency by optimizing surface 
structure of the nanocrystals and minimizing the number of surface trap sites have 
proven to be successful. These include improving surface coating with multiple 
organic ligands by use of alkylamine surfactants such as (hexa/octa/do) decylamine 
along with TOPO to achieve QY of up to 40-50%. 
Advances in synthesis and surface passivation technologies have opened a new 
platform for these QDs to be used as biological probes with advantages of enhanced 
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photostability, improved brightness, tunable fluorescence and single source 
multicolor excitation. 
QDs are synthesized in nonpolar organic solvents such as toluene, hexane or 
chloroform in presence of surfactants at a high temperature. These surfactant coated 
QDs have hydrophobic chains protruding from the surface of inorganic QD core. Due 
to the presence of a hydrophobic surface layer, they are not soluble in aqueous 
media. In order to be useful for biological applications QDs must be made water 
soluble. Water solubilization procedure should render these nanocrystals soluble and 
stable in biological buffer solutions preserving the original photophysical properties 
without alteration in their size and providing reactive groups for subsequent 
conjugation to biomolecules. 
To achieve this either the surfactant layer can be shielded with an additional layer 
introducing hydrophilic moieties such as polymer or the surface hydrophobic ligands 
can be exchanged with the amphiphilic ones.  
The surface shielding in the form of encapsulation in phospholipid micelles or coating 
with amphiphilic polymers can retain the original hydrophobic surface ligands 
preserving the original QD photophysical properties and minimally affecting the 
fluorescence quantum yield. During this process the original native TOPO coating is 
retained and the hydrophobic QDs are encapsulated with amphiphilic molecules 
such as polymers or phospholipids. The hydrophobic portion of this molecule 
intercalates with alkyl-chain-terminated surface ligands and the hydrophilic portion 
protrudes outwards interacting with the aqueous solvent and rendering the particle 
water soluble. The water soluble QDs thus synthesized are exceptionally stable with 
preserved optical properties. However the disadvantage of this process is the 
increase in the resultant diameter of the quantum dot which is three –four times the 
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original size. As a result, difficulties may be encountered during experiments in live 
cells and in vivo applications. The increased thickness of the polymer coating might 
preclude utilization of QDs in Forster resonance energy transfer (FRET) based 
applications. 
In contrast, the original hydrophobic surface ligands can be replaced with hydrophilic 
ones by means of ligand exchange. This can be accomplished by substitution of 
native TOPO coating with bifunctional ligands, which present both, a surface 
anchoring thiol group and a hydrophilic end group such as carboxyl or hydroxyl 
group. Examples include deployment of negatively charged carboxy-terminated 
thiols such as Mercaptoacetic acid (MAA) and Mercaptopropionic acid (MPA) and 
thiol-containing Zwitterionic molecules such as cysteine. These QDs provide various 
reactive groups such as amine (-NH3), carboxyl (-COOH) or mercapto (-SH) for 
conjugation to various biomolecules. The ligand exchange method involves mixing 
the solution containing excess of heterobifunctional ligand to the suspension of 
TOPO coated QDs to displace hydrophobic TOPO ligands to be replaced by 
adsorption of bifunctional ligands. The example of this method includes coating of 
CdSe –ZnS QDs with mercaptoacetic acid in order to bind the basic thiol groups to 
the surface of QDs yielding QDs displaying carboxylic acids. By this method, it is 
possible to synthesize water soluble QDs with ultra-small hydrodynamic diameter 
(below 6 nm) providing amine and carboxylic acid groups for cross-linking to 
proteins, peptides and nucleic acids. The disadvantages of QD synthesis by this 
method include detachment of ligands from QD surface leaving behind surface trap 
sites resulting in nanoparticle aggregation and decreasing fluorescence efficiency, 
photochemical stability as well as decrease in the shelf life of the probes. 
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Another ligand exchange approach is available involving the formation of 
polymerized silanol shells on the surface of QDs using 3-(mercaptopropyl) 
trimethoxysilane (MPS) to displace the native TOPO molecules have been 
described. These polymerized siloxane coated nanoparticles are highly stable 
against flocculation however residual silanol groups on the surface of the QDs often 
leads to precipitation and gel formation at neutral pH. 
Polyethylene Glycol (PEG) is one of the most widely used molecules for the purpose 
of QD solubilization in the amphiphilic organic surface layer. Addition of PEG 
(pegylation) prolongs the half-life of these QDs possibly from decreased 
opsonisation and delays recognition and clearance by reticuloendothelial system. 
Other advantages of pegylation include improved aqueous solubility and reduction in 
the nonspecific adhesion to the biological cells of the QDs. 
Yin et al in 1999 prepared Zinc Sulfide (ZnS) QDs using γ-Irradiation. Tsuji et al in 
2005 synthesized gold (Au) QDs using microwave assisted synthesis. The authors 
observed that microwave irradiation resulted in stabilization of water soluble 
surfactant at the surfaces on the gold metal and accelerated precipitation as well as 
nucleation processes leading to synthesis of uniform QDs. Besides the preparation 
of Au QDs, microwave heating has also been used to synthesize cadmium sulfide 
(CdS), cadmium selenide (CdSe), lead sulfide (PbS), copper indium diselenide 
(CuInSe2), and molybdenum diselenide (MoSe2) QDs. The advantages of using 
microwave radiation in the synthesis of QDs include absence of a convection 
processes while heating giving a homogeneous vessel temperature for uniform 
nucleation and growth, as well as shorter crystallization time. 
Utilization of Langmuir- Blodgett surfactant films using stearate and n-
octadecylacetoacetate as a matrix has also been used  for synthesis of ZnS, PbS, 
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and a PbS–CdS combination of QDs  in order to provide restricting environments 
giving specific size, shape, and orientation to the QD9. 
Since then significant advances have been made in the synthesis of fluorescent QDs 
with particular focus on Cadmium Selenide (CdSe) QDs with their vast biological 
applications. QD production is now a molecular engineering process. Most 
commonly available QDs are CdSe-ZnS core shell complexes containing Cadmium 
Selenide (CdSe) core synthesized in a nonpolar solvent coated with Zinc Sulfide 
(ZnS) shell subsequently encapsulated with an amphiphilic polymer capable of cross 
linking to various biomolecules to specifically target molecular agents21. 
In designing the Quantum dot probes, the QD core composition is determined by a  
desired wavelength of emission.eg CdSe QDs to emit in the range of 450-650nm or 
CdTe QDs to emit in the range of 500-750nm. InAs or PbSe which can emit above 
800nm22.QDs are then synthesized by adding the precursors in presence of a co-
coordinating ligand under inert conditions grown to the appropriate wavelength-
dependent size. 
In a typical synthesis of CdSe QDs, selenium precursor trioctylphosphine –selenide 
or tributyl phosphine –selenide at room temperature is injected into a hot mixture of 
cadmium precursor dimethylcadmium or cadmium oleate and a co-coordinating 
ligand trioctylphosphine oxide or hexadecylamine at an approximate temperature of 
300°c under inert conditions (nitrogen or argon atmosphere) to form the nuclei of 
CdSe nanocrystals. The remaining cadmium and selenium precursors grow on these 
existing nuclei at lower temperature of 240-270°c and a slower rate. Once the QDs 
reach the desired size and wavelength, the reaction mixture is cooled to room 
temperature to arrest the growth of these crystals. To enhance the 
photoluminescence efficiency and to reduce the rate of oxidative photobleaching, the 
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CdSe cores are coated with ZnS shell. Zn2+atoms on the surface of QDs bind more 
strongly to ligands such as phosphines and alkyl amines as well as they increase the 
colloidal stability of the nanoparticles23. 
Ying et al 24 in 2008 published a simpler approach to prepare luminescent cysteine–
coated CdTe nanocrystals with QY of 10% using Sodium Tellurite as the Te source. 
This eliminated the need for highly toxic H2Te or highly unstable NaHTe as a 
Tellurium precursor for the aqueous synthesis of Thiol-capped CdTe nanocrystals in 
the inert atmospheric conditions. As the QYs of CdTe nanocrystals synthesized in 
the aqueous phase is < 20%, the authors used thiol stabilizer Mercaptosuccinic acid 
(MSA) as a capping ligand. They demonstrated that by optimizing the growth 
conditions, such as pH of solution and the concentration of precursor solutions, the 
QY can be dramatically improved up to 83% at pH 5 without any post-treatment and 
up to in excess of 70% at pH 6-8. 
The predominant chemicals used during the synthesis of CdTe nanocrystals by this 
method included  Cadmium chloride (CdCL2), Sodium Tellurite (Na2TeO3), 
Mercaptosuccinic acid (MSA) and Sodium tetrahydridoborate (NaBH4) in the 
presence of buffer solution consisting of Borax (Na2B4O2)and citric acid. The 
presence of buffer solution is crucial for successful synthesis of highly luminescent 
CdTe QDs. 
The following chemical reaction takes place during the synthetic process- 
                    TeO3
2-  +  BH4
-  → Te2- + B(OH)3 + H2O      (1) 
                    CdL + Te2  → CdTe + L , Where L =  MSA  (2) 
During this reaction,  NaBH4   reduces TeO3
2-  to Te2- . Cd2+ reacts with this fresh Te2- 
to generate CdTe. The citrate is added to this mixture to avoid deposition of 
Cadmium Tellurite ( CdTeO3). 
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Te2- is very sensitive to the oxygen.  During the above process, initially formed Te2- 
may possibly be reoxidized to higher valence of Tellurium by the oxygen dissolved in 
the water but is instantly reduced back to Te2- by an excess of NaBH4 . Thus NaBH4 
not only acts as a strong reductant but produces an inert atmosphere to avoid 
reoxidizing Te2-. 
An excess of NaBH4 is either hydrolyzed or oxidized by the oxygen diffused from air 
through one of the following reactions- 
 
                       BH-4
  + H2O → B(OH)3  + OH
- + H2  
                                 BH
-
4
   +  O2   → B(OH)3  + H2O  
 
During this method of CdTe synthesis, air-stable sodium tellurite was used as a 
source of Te.  MSA proved to be protective even at lower pH aqueous solution ( pH 
<8). The CdTe Quantum dots thus produced continued to retain bright 
photoluminescence over a few months when stored in the refrigerator at 4 º C. 
 
Bao et al 25 in 2006 synthesized cysteine- capped CdTe nanocrystals by this 
technique. They observed absorption and photoluminescence spectrum serially 
during time gated QD growth stages as shown in fig. 2.1. 
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Fig. 2.1    Absorption (A) and photoluminescence (PL) (B) spectra of L-cysteine- 
capped CdTe nanocrystals recorded after particle growth for 45 min Green),75 min 
(yellow), 180 min (orange; λex=400 nm), and 12 hr. (red; λex=450nm
25 
 
 
Ying et al24 from the same institute synthesized highly luminescent  
Mercaptosuccinic acid coated CdTe using similar technique24 Their observation of 
photoluminescence spectrum  published in 2008 remains as shown in fig. 2.2. 
 
                            
 
 Fig. 2.2, The image of MSA-coated CdTe QDs with different sizes  and the              
corresponding absorption spectra (bottom); photoluminescence were at  a) 493 nm, 
b) 519 nm, c) 551 nm, d) 589 nm, e) 617 nm, f) 647 nm. 
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2.2 BIOCONJUGATION  & INTRACELLULAR DELIVERY OF  
QUANTUM DOTS  
The QDs thus synthesized are inert nanoparticles. In order for these to be utilized for 
biological applications, the surface of these QDs needs alteration in order to allow 
conjugation of biomolecules without altering the biological activity of the conjugated 
form. This can be achieved by conjugating them with proteins, peptides, nucleic 
acids or other biomolecules. One of the simplest and most popular bioconjugation 
methods involves covalent bond formation between reactive functional groups such 
as primary amines, carboxylic acid, hydroxyls and thiols. An example includes linking 
of proteins to carboxylic acid containing QDs through naturally existing amine groups 
via carbodiimide- mediated amide formation. This reaction does not require 
additional chemical modification of proteins thereby preserving their natural 
structure. However no precise control can be achieved over molecular orientation of 
the attached proteins. This may result in partial or complete loss of biological 
functionality of the ligand. 
 Another covalent bonding procedure involves active ester maleimide- mediated 
amine and sulfhydryl coupling. However during this procedure, ligands such as 
antibodies may require additional treatments in the form of reduction with 
dithiothreitol in order for the free sulfhydryl groups to be made available. This 
procedure may yield stable QD-ligand complexes but the chemical treatment might 
alter the biological activity of the ligand reducing the sensitivity and specificity of the 
biological probe. 
Covalent binding provides simple, effective and more stable bioconjugation to 
achieve specific targeting abilities using biomolecules such as  oligonucleotides, 
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antibodies26 or small molecule ligands,  streptavidin, avidin, biotin, Immunoglobulin 
G, transferrin peptides, nucleic acids, adenine, serotonin, adenine monophosphate 
or wheat germ agglutinin  in order to specifically target the cellular organelle  of 
interest. 
Silanized Quantum Dots are one of the most popular bioconjugated nanocrystals. 
Coating with polymerized silica increases the stability of the QDs in buffer solutions 
under physiological conditions. The optical properties of the QD are still retained. 
The silica coating allows easy introduction of biological functional groups and the 
toxicity of inorganic nanocrystals is diminished too22,27 During synthesis silica, silane 
derivatives, or other coatings can include functional groups capable of direct 
conjugation. Such cross-linking strategies exploit the functional groups present on 
both the quantum dot surface and the biomolecule. For example: carbodiimide 
compounds are commonly used to link amino-functionality with carboxyl-groups. 
Another very commonly applied conjugation scheme involves the biotin–streptavidin 
linkage, which requires coupling of the quantum dot to streptavidin. Quantum dot–
streptavidin conjugates are useful because a wide range of proteins and other 
biomolecules can be biotinylated. These conjugates have applications in staining 
and labeling, live tracking, and drug screening. For the large majority of applications 
QDs entities act simply as nonfunctional probes and have minimal impact on the 
experiment, the binding event or the surroundings. Nonspecific attachment to 
unintended molecules and aggregation of quantum dot-conjugates is possible and 
may negatively impact on the results of an experiment. Some strategies have been 
developed seeking to minimize or even eliminating possible nonspecific binding. 
Example of which include coating QDs with an inert hydrophilic polymer, such as 
polyethylene glycol (PEG).  
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Fluorescence microscopy is a widely used optical imaging modality for the evaluation 
of healthy cell phenotypes, and for the detection of the molecular signatures of 
disease. Histological techniques such as fluorescence in situ hybridization (FISH) 
and immunohistochemistry (IHC) are used to detect nucleic acids and protein 
biomarkers within cells and tissue specimens with a very high degree of sensitivity 
and spatial resolution. As labeling biomarkers; organic fluorophores have been 
widely utilized. However due to quick photobleaching, spectral overlap between 
probes and the need to excite fluorophores at unique wavelengths their application 
for multiplexed imaging and for quantitative analysis for molecular profiling is limited. 
However QD probes are able to overcome these shortcomings of organic 
fluorophores. 
Lidke et al successfully demonstrated the use of red light emitting CdSe –ZnS QDs 
coupled with epidermal growth factor to bind to cultured human cancer cells 
expressing erb/HER membrane receptor to which they had specific affinity. They 
could continuously track the protein diffusion and internalization of these fluorescent 
quantum dots within these cancer cells successfully. Wu et al demonstrated utility of 
QD-streptavidin and QD-antibody bioconjugates for simultaneous labeling of 
membrane –associated HeR2 receptor and of a nuclear antigen in breast cancer 
cells as shown in fig. 2.3. Since then QDs were used to monitor binding to various 
plasma membrane proteins such as integrins, tyrosine kinases and G-protein 
coupled receptors. The procedure of receptor labeling and receptor dynamics has 
also been described recently.  QDs have been successfully used for in vitro 
bioassay, fixed cell labeling, imaging of tissue specimens and imaging of membrane 
proteins on living cells.  
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Fig. 2.3 labeling of surface and intracellular targets with QD probes. In single-color 
examples membrane-associated Her2 receptors are detected with primary 
antibodies and QD-labeled secondary IgG (A, green), while intracellular nuclear 
antigens (B, red) and microtubules (C, red) are visualized with primary 
IgG/secondary IgG-biotin/ QD-Streptavidin cascade. Both labeling routes can be 
applied simultaneously for a two-color staining (D). The nuclei are counterstained 
with Hoechst 33 342 (blue) in A and C28. 
 
 
 
 
The process of staining fixed cells and tissue specimens provides valuable 
information regarding expression of biomarkers and their distribution within the cells. 
However real-time imaging of live cells enables the study of physiological, dynamic 
processes occurring at the molecular level. The relatively large sized QD probe often 
tends to target biomarkers expressed on the surface of the cell membrane. During 
live cell imaging, QDs tend to aggregate inside the cells trapped in the endocytotic 
vesicles as endosomes and lysosomes. Quantum dots can be internalized into a 
variety of cells using various techniques. The cells take up particles from the 
extracellular space through endocytosis. This type of passive uptake is diffuse, slow 
and nonspecific. Some small diameter QDs can even enter the nuclei. However, 
labeled QDs with antibodies, targeting peptides or receptor ligands can be 
selectively targeted to intracellular organelle or plasma membranes. This process of 
quantum dot uptake can be facilitated by coupling the QDs to membrane receptors 
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which results in the rapid uptake and isolation of QDs in the vesicles within the cells. 
Though selective targeting of intracellular organelles is not possible by this method, 
cells can be labeled with QDs very effectively. Chemically mediated delivery involves 
translocation of the plasma membrane using cationic lipids or peptides. Mechanical 
delivery methods include microinjection of QDs into individual cells or electroporation 
using pulsed electric fields to improve membrane permeability in order to deliver 
QDs within the cells Despite of difficulties encountered in organelle led intracellular 
target imaging several reports have been published in their success. In 2004 Derfus 
et al demonstrated that QDs conjugated to organelle targeting peptides, when 
microinjected into fibroblast cytoplasm, could selectively stain mitochondria or 
cellular nuclei29. Chen and Gerion used electroporation to overcome the plasma 
membrane barrier to target peptide –QD conjugates to cellular nuclei30. Strategy of 
QD cell loading using osmotic lysis has been explores widely to encourage efficient 
uptake by the cells. This involves inducing pinocytosis by incubation of cells in a 
hypertonic solution followed by osmotic lysis of the vesicle and cytoplasmic release 
of QD. This process enables uniform loading of all cells within a population by intact 
single QD probes. Courty et al demonstrated that it was possible to image individual 
kinesin motors in HeLa cells using QDs which were delivered into the cytoplasm via 
osmotic lysis of pinocytotic vesicle31. However during this process of external 
triggering of osmotic lysis can interfere with QD loading of fragile cells and requires 
extensive optimization of procedure. 
An alternative approach using engineering of on-demand endosome disrupting 
capacity within the QD probes. Kim et al employed 100 nm external biodegradable 
delivery vesicles made of poly (D, L-lactide-co-glycolide) (PLGA). These vesicles 
were further bioconjugated with antibodies for specific interaction with the cell 
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surface markers. Once taken up within the cells, PLGA charge reversal within low pH 
endosomal environment results in membrane destabilization and endosomal escape. 
Upon entering the cytosol, the polymer nanosphere undergoes hydrolysis, thus 
releasing the QD bioconjugates. This approach facilitates multiplexed labeling of 
subcellular structures inside live cells32.  Duan and Nie reported a new generation of 
QDs based on the use of multivalent and endosome-disrupting surface coating. They 
coated QDs with hyperbranched copolymer ligand such as PEG grafted 
polyethylenimine (PEI) to encapsulate and solubilize luminescent QDs through 
ligand exchange reactions. Due to the positive charges and ‘Proton sponge effect’ 
associated with multivalent amine groups, these ligand exchanged QDs were found 
to penetrate the cell membranes and to disrupt the endosomal organelles in living 
cells. Polyethylenimine has been known to be cytotoxic. The grafted highly 
hydrophilic PEG segment was found to significantly reduce the toxicity, improve 
overall nanoparticle stability and biocompatibility. In addition, these QDs were 
smaller in size with a HD of 15-22nm and exceedingly stable in acidic environment. 
As a result when incubated with live HeLa cells, these QDs were internalized 
escaped from the endosomes and became distributed throughout the cytosol. 
However ligand exchange method and direct interaction of PEI with the QD surface 
did result in undesirable drop in the fluorescence QY and detection sensitivity.  
Lovric et al reported that size of the QDs contribute to their subcellular distribution. 
They observed in murine microglial N9 cell lines that  red cationic QDs ( 5.2nm) were 
distributed throughout the cytoplasm however similarly charged smaller green QDs 
(2.2nm) were found in the nucleus of the cells following cellular uptake through 
passive endocytosis.33 Nabiev et al proposed that nonfunctionalized QDs exploit the 
cell’s active transport machineries for delivery to the specific intranuclear destination. 
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In live human macrophages they observed rapid uptake and accumulation of QDs in 
distinct cellular compartments depending upon the QD size and charge. They also 
concluded that smallest QDs (2-3nm) specifically target histones in the cell nuclei 
and nucleoli by combination of endocytosis, active cytoplasmic transport finally 
entering the nucleus via nuclear pore complexes. The authors also proposed that 
the’ proton sponge effect’ was responsible for endosomal escape of the QDs due to 
protonation at acidic pH resulting in increase in intra-endosomal pH and a charge 
gradient provoking water influx, endosomal swelling and their disintegration34. 
2.3  IN VIVO IMAGING 
Various imaging modalities are currently being for examination of internal structures, 
molecular targets and metabolic processes such as MRI, CT , PET and SPECT. Out 
of these MRI and CT scans  provide structural information with poor sensitivity. PET 
and SPECT scans which are based on detection of radioactive labels suffer from 
poor spatial resolution. QD based fluorescence imaging can provide  high resolution 
multiplexed cellular and vascular  imaging, real time cell tracking and intraoperative 
image guidance such as sentinel lymph node mapping.  
In vivo imaging of QDs involves injection of QDs intravenously into the blood stream 
of the animal to be imaged. Upon intravenous administration the QDs are distributed 
to the various organs and peripheral tissues within the body. In the intravascular 
compartment, these particles encounter blood cells, platelets, coagulation factors 
and plasma proteins. Depending upon the size, composition and charge, they may 
undergo adsorption or opsonization by serum proteins. This alters the effective size 
of the QDs and results in a particle diameter referred to as the in vivo hydrodynamic 
diameter (HD) which is considerably larger than the in vitro diameter. This 
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hydrodynamic diameter in turn affects the blood clearance and the half-life of these 
nanoparticles. The vascular endothelial monolayer offers a pore size of 
approximately 5 nm for the transport of fluid and macromolecules between 
intravascular and extravascular extracellular space. QDs with a HD of less than 5 nm 
achieve rapid equilibrium with the extravascular extracellular space. However larger 
particles experience prolonged circulation time. Lymphatic vessel endothelial cell 
layer is slightly more permeable allowing particles with a HD of up to 6 nm in 
diameter. 
Hepatobiliary system is the primary route of excretion of QDs that do not undergo 
renal clearance. QDs after intravenous injection are non-specifically taken up by 
reticulo-endothelial cells including liver, spleen and lymphatic system. Ballou et al 
demonstrated that CdSe-ZnS QDs were rapidly removed from the bloodstream into 
the reticulo-endothelial system where they remained fluorescent for 4 months. 
Electron microscopy didn’t reveal any sign of breakdown of these QDs. They 
concluded that the stability to the QDs was a result of appropriate coating which 
preserved the fluorescence and prevented  degradation of the QDs35. Fischer et al's 
work on biodistribution of QDs with different coatings revealed that albumin coated 
QDs were rapidly removed from the circulation and sequestered in the liver, 
predominantly within the kupffer cells at the edges of liver sinusoids. They were also 
localized in the red pulp of the spleen, subcapsular sinus in the lymph nodes and in 
the vascular sinus periphery within the bone marrow36. 
Kidneys are capable of rapidly clearing the QDs from the vascular compartment 
unaltered from their original form. As no intracellular enzymatic modification occurs 
during this process, there remains reduced possibility of retention and cytotoxicity. 
The functional or physiologic pore size within the glomerular capillary wall is 4.5-5 
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nm in diameter. Therefore, molecules with a HD of less than 6nm are typically 
filtered and ones with a HD of more than 8nm in diameter are not capable of 
glomerular filtration.   
Choi et al examined renal clearance of QDs and defined the relationship between 
HD, renal clearance and total body retention of QDs of different sizes. They 
observed that QDs with hydrodynamic diameter less than 5.5nm resulted in rapid 
and complete elimination of quantum dots via urinary excretion. Serum half-life of 
particles ranging from 4.36 to 8.65 nm was shown to positively correlate with size, to 
range from 48 min. to 20 hours. They also demonstrated that the charge affected 
renal clearance of the QDs. Due to charge related adsorption by serum proteins, 
purely cationic or anionic charge increased the HD to more than 15 nm in diameter, 
thereby shifting the route of excretion from kidneys to the liver. Zwitterionic coating 
prevented serum protein adsorption and improved renal filtration. The authors  
concluded that hydrodynamic diameter of QDs and renal filtration threshold need 
consideration for designing and development of QDs to be utilized for biomedical 
applications37. 
Biodistribution studies have confirmed that quantum dots have significantly long half-
life ranging from weeks to months. This obviously increases the potential of QDs to 
inflict toxic adverse effects to the surrounding tissues. Zhang et al used PEG coated 
QD 621  containing Cadmium selenide core surrounded by Cadmium Sulfide shell 
with a hydrodynamic diameter of 39 ± 1mm to demonstrate their capability of 
penetrating only the uppermost layers of stratum corneum of porcine skin 24 hours 
after exposure and localizing in the outer root sheath of the hair follicle as well as 
within the intercellular spaces of this outermost stratum corneum layer as a result of 
penetration of intercellular bilipid layer. They also demonstrated cytotoxic and 
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inflammatory potential of QD 621 in Human epidermal keratinocyte (HEK) cells with 
dose and time dependent decrease in viability from 1.25nm to 10nm dose38.  
Schipper et al evaluated quantitative biodistribution of commercially available CdSe 
quantum dots in mice. They radiolabeled larger 800-nm emission wavelength 21nm 
diameter QDs and smaller 525-nm emission wavelength 12 nm diameter QDs with  
64Cu with or without 2000 MW (molecular weight) polyethylene glycol ( PEG). These 
were injected intravenously into the tail vein of mice and were studied using 
conventional well counting or by serial micro PET and region-of interest analysis. 
Both methods demonstrated rapid uptake by liver and spleen. Pegylated QDs 
demonstrated slower uptake into liver and spleen (6vs 2 min) and showed additional 
low level bone uptake. Size of the particles had no influence on biodistribution39. 
Yang et al studied tissue deposition and pharmacokinetics of commercially available 
QD 705 in mice after single intravenous injection of 40 pmol  for a period of 28 days 
after injection to observe increasingly continued deposition of QDs in the spleen, 
liver and kidney without any fecal or urinary excretion over these 28 days indicating a 
very long half-life potentially weeks or even months40. 
Near Infrared Imaging- Unlike in vitro imaging where monolayer of cells or thin 
tissue sections are used for imaging, in vivo imaging is encountered with technical 
difficulties as a result of thickness of the tissues limiting the penetration depth and 
attenuation of the signals used for optical imaging resulting from high absorption and 
autofluorescence of the biological tissues across most of the electromagnetic 
spectrum. 
Near-infrared (NIR) Fluorescence imaging provides sensitive, specific and real time 
imaging of surgical anatomy with high spatial resolution. In the near-infrared region 
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(700-1000 nm), the absorbance spectra for most biomolecules is at the minimum 
e.g. oxy-and deoxyhaemoglobin (λmax < 600 nm) and water (λmax > 1150 nm). This 
‘spectral  imaging window’ provides a real opportunity for in vivo optical imaging. As 
a result NIR light penetrates deeper into and out of the tissue than does the 
traditional UV light as haemoglobin, muscle and fat are least absorbent in this light 
range. Also the endogenous cellular components produce very little 
autofluorescence diminishing background interference, enhancing signal-to-noise 
ratios and provide very low detection limit with NIR fluorescence.  
In comparison to Type I QDs,  Type II QDs consist of materials for which both 
valence and conduction bands in the core are lower (or higher ) than in the shell. As 
a result, one carrier is mostly confined to the core and the other is confined to the 
shell. This property is known as spatial separation of carriers. Fluorescence emission 
results from the radiative recombination of the electron- hole pair across the core-
shell interface. So the energy of emission depends on the band offsets of the two 
materials producing the core and the shell. Hence the type- II QDs can emit at 
energies that are smaller than the band gap of either material, which allow access to 
higher wavelengths that would otherwise not be available with a single material41. 
Kim et al first produced CdTe/CdSe and CdSe /ZnTe core-shell type-II colloidal QDs 
and  coated these with polydentate phosphine to allow solubility and serum stability 
in mouse and pig models . They injected 400 pm concentration of quantum dots  
intradermally for sentinel node imaging. This method of sentinel node lymphography 
was then shown to be equivalent to the traditional ‘blue dye’ method, demonstrating 
nodes up to 1 cm deep, along with the lymphatic vessels42.  
Hama et al. have shown the ability of fluorescence lymphangiography using two NIR 
quantum dots with different emission spectra to visualize two separate lymphatic 
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flows that drain into a common nodal basin. Two quantum dots with emission peaks 
of 705 and 800 nm were injected simultaneously into the mouse mammary fat pad 
and the middle phalanx of the upper extremity, respectively. The lymphatics were 
successfully imaged as they drained into the axillary lymph nodes as shown in fig. 
2.443. 
 
Fig. 2.4 A two-color optical lymphatic image of lymphatic drainages from the breast 
tissue (red) and the upper extremity (green) obtained using 2 NIR QDs (QD 705 and 
QD 800) and a spectral fluorescence imaging technique is shown together with a 
schematic illustration43. 
 
 
Successful sentinel node real time imaging by several researchers have opened a 
new horizon in the field of cancer diagnosis and successful detection of sentinel 
lymph nodes on research settings.44,45,46,47,48  Current methods of identifying sentinel 
lymph nodes such as computerized tomography (CT), positron emission tomography 
( PET) or endoscopic ultrasonography ( EUS) are 60-80% accurate. Sentinel lymph 
node mapping with blue dye or radioactive tracer has its own limitations. Intra-
operative sentinel lymph node mapping in thorax with blue dye only can successfully 
identify the sentinel node in less than 50% of cases due to poor tissue penetration 
and anthracotic mediastinal lymph nodes. Even hand held gamma camera can miss 
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the sentinel node in approximately similar number of cases. Near-infrared 
fluorescent type II quantum dot has been used to label the sentinel nodes for 
mapping and imaging.  The near-infrared QDs are able to detect and image objects 
that are not detectable by QDs that emit in the visible range by virtue of the 
increased depth of penetration into the living tissues. This type of QD technology 
provides the surgeon with an image of the lymph node, allows real-time visualization 
of organ during surgery, and can be used for confirmation that the operation has 
been complete by observing the loss of concentrated QD fluorescence in the lymph 
node area.45,49 In the treatment of oesophageal cancer, though extensive 
lymphadenectomy can improve survival, it is not without associated morbidity or 
mortality. Selective removal of sentinel lymph node can provide accurate staging and 
local control, minimizing unnecessary extensive lymphadenectomy. Parungo and 
coworkers used Type II core/shell QDs containing inorganic core of cadmium 
telluride, inorganic shell of cadmium selenide and outer organic coating of 
solubilizing oligomeric phosphines. They were engineered to fluoresce in the NIR, 
with peak emission at 840 nm. After submucosal injection of QD into the 
oesophageal wall their migration to a single sentinel node was observed in real time 
within 5 minutes. These NIR fluorescent lymph tracers continued to demonstrate the 
fluorescence for up to 4 hours providing great flexibility in administration as shown in 
fig.2.545. 
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Fig. 2.5. QDs migrate from esophagus to specific lymph nodes of pig. Top row 
shows in vivo esophagus of pig visualized with color video (left column), NIR 
fluorescence middle column), and color- NIR merge images (right column). Lymph 
nodes shown are positive (arrows) and negative (arrowheads) for QD uptake. 
Bottom row shows same lymph nodes after resection.45 
 
 
 
The presence of lymph node metastasis is an important prognostic marker in the 
patients with non-small cell lung cancer. In order to develop an optimal noninvasive 
tool for intra-operative sentinel lymph node mapping for real time image guided 
localization and resection Soltesz et al  successfully synthesized Type II NIR 
fluorescent QDs with hydrodynamic diameter of 15-20 nm , fluorescent emission of 
840-860 nm with a stable oligomeric phosphine coating and demonstrated 
successful real time imaging of pulmonary sentinel lymph nodes in animal studies  
as demonstrated in fig.2.6 46. 
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Fig.2.6 NIR fluorescence images of the surgical field before QD injection 
(autofluorescence), during QD injection, 45 seconds after injection (lung retracted), 1 
minute after injection, and after SLN resection. For each time point, color video (left), 
NIR fluorescence (middle), and color-NIR merge (right) images are presented. 
Fluorescence images exhibit identical exposure times and normalization. QDs 
rapidly localize to the SLN (white arrow). Lack of fluorescence in the nodal basin 
after resection confirms complete removal of the sentinel nodal tissue46. 
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IN VIVO VASCULAR IMAGING  Larson et al used QDs to image capillaries 
within the adipose tissue and skin of living mouse following intravenous injection of 
water soluble  QDs50. Smith et al, using intravitally injected QDs imaged 
chorioallantoic membrane (CAM) vessels and capillaries superiorly as compared to 
routinely   used FITC –dextrans. QDs exhibited more uniform illumination across the 
vessel lumens , had longer residence times, had low background interference with 
improved depth of imaging and  could be used at much lower concentrations50. 
 
2.4 DIAGNOSTIC AND THERAPEUTIC APPLICATIONS IN 
CANCER–  
As compared to normal cells, cancer cells are unique in that they have abnormal 
growth and abnormal differentiation. Once  solid tumors grow approximately beyond 
2 mm in size they stimulate their own blood supply to deliver the oxygen and 
nutrients to sustain their growth. This is achieved through production of angiogenic 
factors such as VEGF resulting in increased microvascular density within the tumor. 
These vasculatures tend to be highly permeable due to leaky capillaries resulting in 
increased interstitial pressure which makes macroparticle drug delivery less efficient. 
Wu et al  successfully demonstrated the expression of Her2 on the surface of human 
Sk-BR-3 breast cancer cells, fixed &  live SK-BR-3 cells  and fixed mouse mammary 
tumor tissue sections by labeling with QDs bound to  humanized  anti- Her2 
antibody28. 
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A QD-based assay for the detection of the ovarian cancer marker CA125 in various 
specimen types (fixed cells, tissue sections, and xenograft tissues) was successfully 
developed by Wang et al51.  
Monitoring of tumor progression and bone/bone marrow metastases after injecting  
MDA-MB-231 breast cancer cells was demonstrated by Henriquez et al52. 
Kaul et al. used QD immunoconjugates to show that mortalin  could be a reliable 
marker for distinguishing between normal and cancer cells53.  
Angiogenesis is a prime feature of most tumours. Formation of new vessels is 
extremely essential for tumor growth and progression. A cell adhesion molecule 
Integrin αvβ3 is upregulated in most tumour cells and tumour vasculature. RGD, a 
potent antagonist of Integrin αvβ3 can be used to target tumor vasculature using 
peptide conjugated QDs. Cai et al successfully demonstrated use of RGD containing 
peptide bound to QD 705 to selectively target Integrin αvβ3 on the tumour vasculature  
in ex vivo and in vivo studies54. 
For early detection of cancer to improve survival, it is essential that multiple 
biomarkers can be detected with high sensitivity and specificity. It is possible to 
achieve this aim with quantum dot protein microarray. Combination of QDs with 
protein microarray allows detection of ultra-low levels of tumor markers in biological 
specimen (serum, plasma etc.).  Due to outstanding optical properties of QDs, 
multiplexed microarray is possible. Zajac and coworkers  were able to detect six 
different cytokines in a protein solution  such as TNF-α, IL-8, IL-6, MIP-1β, IL-13 and 
IL-1β down to picomolar concentration55. 
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Traditionally immunohistochemistry has been used for diagnostic and prognostic 
classification of human tumours for identification of tumour oncoproteins. Molecular 
profiling technologies enable us to read the molecular signature of individual 
patient’s tumour in order to predict the clinical outcome of personalized therapy. 
There are a few limitations of immunohistochemistry methods in the form of inability 
to perform multiplexed molecular profiling, significant inter -observer variations and 
need for destructive preparation of cells or tissues into homogenous solution leading 
to loss of 3D cellular and tissue molecular architecture. Yezhelyev et al successfully 
exhibited the use of QDs for multiplexed detection of five breast cancer biomarkers 
such as ER, PR, mTOR, EGFR and HER2. They also demonstrated  close 
correlation of  quantification of ER,PR and HER2 receptors with traditional methods 
such as Immunohistochemistry,  western blotting  and   FISH  (fluorescence  in  situ 
hybridization ) indicating successful use of QD based technology for molecular 
profiling of tumour biomarkers in vitro56.  
The property of tunable and narrow emission can successfully be applied to 
customize the emission between QD donors and fluorescent dye acceptors in 
Fluorescence resonance energy transfer (FRET) assay thereby QDs behaving as a 
new class of sensors. The theory of resonance energy transfer was first derived by 
Forster. This process involves transfer of fluorescence energy from the donor 
particle to an acceptor particle when the distance between the donor and acceptor 
particle is smaller than the critical Forster radius. This result in decrease in the 
donor’s excited state lifetime and an increase in the acceptor’s emission intensity. 
FRET is a distance dependent radiationless transmission of energy from donor to 
acceptor molecule. Due to its sensitivity to the distance, FRET has been used to 
investigate molecular interactions. The interacting pair of molecules involved in the 
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process of FRET is often referred to as donor/acceptor pair. For an efficient energy 
transfer, the donor and acceptor molecules must be in close proximity to one 
another.  FRET can occur when the emission spectrum of a donor fluorophore 
significantly overlaps (>30%) the absorption spectrum of an acceptor, provided that 
the donor and acceptor fluorophores dipoles are in favorable mutual orientation. 
FRET can be observed by monitoring quenching of donor fluorescence and by 
observing acceptor enhancement. Fluorescence Resonance Energy transfer was 
successfully demonstrated between CdSe−ZnS core−shell quantum dots energy 
donors and  engineered maltose binding protein (MBP) appended with an 
oligohistidine tail  labeled with an acceptor dye (Cy3) by Clapp et al57. Several recent 
studies have confirmed that CdSe and CdTe QDs are able to participate in the 
resonance energy transfer process due to their unique spectroscopic properties with 
potential application in the design of assays of ligand receptor binding, antibody-
antigen binding, DNA hybridization and enzyme-substrate interaction. QDs prepared 
in a single synthetic batch can vary in their structural and spectral characteristics due 
to variations and defects in either the core, shell or the organic layers during the 
complex process of their synthesis and the large number of atoms the QDs is made 
of. This would result in heterogeneity of the Forster radius R0 which may affect the 
precision of single molecule FRET measurement unless each individual QDs 
spectrum can be measured. 
Though quantum dots have exceptional potential for molecular imaging in vivo, their 
utility is limited because of need for excitation from external illumination source to 
fluoresce. Also, this results in strong autofluorescence and scarcity of excitation light 
at deeper locations. This drawback was overcome by bioluminescence resonance 
energy transfer (BRET) studies. In this, the QDs can emit fluorescence without an 
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external source of excitation when conjugated to enzymes (e.g., luciferase) that 
catalyze bioluminescent reactions8. The authors, in this study, coupled carboxylate- 
presenting QDs to a mutant of bioluminescent protein Renilla reniformis luciferase to 
reveal that the conjugates emit long-wavelength (from red to near-infrared) in the 
cells even in deep tissues.  Moreover, compared to fluorescence imaging, 
bioluminescence has extremely high sensitivity for in vivo imaging purposes 
associated with the fact that the energy comes from a chemical reaction catalyzed by 
the donor enzyme (BRET) rather than absorption of excitation photons (FRET). 
Table 1 provides a comprehensive summary of scientific studies of QD utilization  
using different cancer cells within the in vitro studies. Table 2 outlines a brief 
overview of recently published in vivo studies demonstrating successful use of QDs 
for cancer studies . These studies give a broad perspective of  the future potential of 
these QDs for early diagnosis of cancer at molecular level. 
 
Table 1. Comprehensive summary indicating scientific studies using Quantum Dots 
for the diagnosis of cancer – (in vitro studies) 
REFERENCE QD BIOCONJUGATION 
 
CELL 
LINES 
OUTCOME 
Wu 28 ZnS 
capped 
CdSe 
Antimouse IgG + 
monoclonal anti-Her2 
antibody 
 
 
 
Streptavidin 
+humanized  anti-     
Human Sk-
BR-3 breast 
cancer cells 
 
 
 
Fixed + live 
SK-BR-3 
Her2 labeling 
 
 
 
 
 
Her2 labeling 
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Her2 antibody and 
biotinylated goat anti-
human    IgG 
 
 
Streptavidin + 
biotinylated goat anti-
rabbit      IgG + 
antiserum reacting 
with cytoplasmic 
domain of Her2 
cells 
 
 
 
 
Her2 
positive 
mouse 
mammary 
tumor tissue 
sections 
 
 
 
 
 
 
Labeling of 
tumor  cells 
 
 
Nida58 ZnS 
capped 
CdSe 
Streptavidin  + 
Biotinylated anti-
EGFR monoclonal 
antibody 
SiHa 
cervical 
cancer cells 
 
 
Illumination of 
cervical cancer 
cells due to 
EGFR over-
expression 
Kaul53 ZnS 
capped 
CdSe 
Streptavidin + 
anti-mortalin 
antibodies 
Normal 
human fetal 
fibroblasts 
(WI-38) and 
osteogenic 
sarcoma 
(U2OS) 
 
Mortalin staining 
in normal and 
transformed 
cells. 
Qian59   CdSe/ 
CdS/ 
ZnS 
(QDs) 
Lysine coating. 
Transferrin and anti-
Claudin-4 (pancreatic 
cancer specific 
monoclonal antibody) 
as targeting ligands 
Live human 
pancreatic 
cancer cells 
 
 
Labeling of 
pancreatic 
cancer cells 
Yang60  CdSe 
QDs 
Mercaptoacetic acid 
+ 
HeLa cells Detection of 
CEA (carcino-
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Nhydroxy-
succinimide as a 
cross linker + rabbit 
anti-CEA8 as a 
primary antibody + 
goat anti-rabbit IgG 
as a secondary 
antibody 
embryonic 
antigen  on the 
membranes of 
HeLa cells 
Direct and 
indirect 
immunolabeling 
of HeLa cells 
Li61 
 
 
 
CdTe Biotin and 
polyethylene glycol 
Human 
tongue 
cancer cells 
Tca8113 
Immuno-
fluorescent 
labeling of 
cancer cells with 
water-soluble 
QDs 
Wang62 
 
 
QD 525 Streptavidin 
Anti EGFR antibodies 
SKMG-3, 
U87 Human 
glioma 
tumor cell 
lines with 
elevated 
EGFR 
expression 
+ 
Brain tumor 
tissue 
specimen 
Recognition and 
imaging of 
glioma cells 
Hu63 
 
 
CdTe 3-mercapto-propionic 
acid + Thiolated 
PEG+ Anti CEA 
monoclonal antibody 
CEA 
positive 
human 
colon 
carcinoma  
LS 180 cell 
lines 
Successful 
detection of CEA 
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Table 2. Comprehensive summary indicating scientific studies using Quantum Dots 
for the diagnosis of cancer – ( in vivo studies) 
REFERENCE QD BIOCONJUGATION CELL 
 LINES 
 
OUTCOME 
Akerman64 ZnS 
capped 
CdSe 
Mercaptoacetic acid + 
homing peptide 
coating 
Lung 
endothelial 
cells, 
Brain 
endothelial 
cells, 
Human 
breast 
carcinoma 
MDA-MB-
435 cells 
Selective 
targeting of 
peptide coated 
QDs  to the 
vasculature of 
normal lungs and 
tumors, 
 
Knapp65 
 
 
 
 
 
 
NIR 
CdTe 
(CdSe) 
core 
(shell) 
type II 
QDs 
Oligomeric phosphine Naturally 
occurring 
invasive 
transitional 
cell 
carcinoma  
of the 
urinary 
bladder 
 
 
Real time 
imaging of 
sentinel lymph 
node 
Wang51 
 
ZnS 
capped 
CdSe 
Streptavidin + Biotin 
labeled  Monoclonal 
anti-CA125 antibody 
Human 
ovarian 
carcinoma 
HO8910 
cells in fixed 
Detection of 
tumor marker 
CA125 
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cells, tissue 
sections, 
and 
xenograft 
piece 
Yu66 ZnS 
capped 
CdSe 
Mouse anti-human 
monoclonal alpha-
fetoprotein 
(AFP) antibody 
Hepato- 
carcinoma 
cell line 
HCCLM6 
 
Immuno-
fluorescent 
detection of 
hepatoma 
Gao67   
 
 
ZnS 
capped 
CdSe 
Tri-n-octylphosphine 
oxide (TOPO) capped 
QDs + Amphiphilic 
triblock polymer 
+PSMA monoclonal 
antibody 
PSMA-
positive 
human 
prostate 
cancer cells 
Imaging of cancer 
cells in vivo 
Estrada68 ZnS 
capped 
CdSe 
- TCCSUP 
and 253JBV 
bladder 
cancer cell 
lines- 
transitional 
cell 
carcinoma 
of the 
bladder 
 
Behavioral 
profiling of human 
TCC cells + 
Response to 
intravesical 
chemotherapy 
Diagaradjane69 
 
 
ZnS 
capped 
CdSeTe 
(NIR) 
QD 
Human recombinant 
EGF (Epidermal 
Growth Factor) 
using thiol-maleimide 
conjugation 
HCT116 
and DiFi 
colorectal 
cancer cell 
lines with 
EGFR over- 
EGFR  imaging 
nanoprobe 
characterization 
   74 
 
 
expression 
 
 
 
Tada70  
 
QD 800 Polyethylene glycol 
(PEG) Trastuzumab 
Human 
breast 
cancer cell 
line KPL-4, 
which over-
expresses 
HER2 
Real time 
tracking of single 
particle QD 
labeled with the 
monoclonal anti-
HER2 antibody in 
HER2- over-
expressing breast 
cancer 
Ballou71 
 
 
 
 
ZnS 
capped 
CdSe 
 
ZnS-
CdSe-
CdTe 
Amphiphilic polymer 
coating 
Polyethylene Glycol 
(PEG) 
M21 Human 
Melanoma 
tumour 
model, 
 
MH15 
Mouse 
terato-
carcinoma 
model 
Successful and 
rapid visualization 
of sentinel node. 
        Cai25 
 
 
QD 705 Polyethylene Glycol 
(PEG) + 
RGD (arginine-
glycine-aspartic acid) 
U87MG 
human glio-
blastoma 
And MCF-7 
human 
breast 
cancer cell 
 
Tumor 
vasculature 
targeted imaging 
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NANOTECHNOLOGY BASED DRUG DELIVERY SYSTEM- In order to 
effectively treat diseases in the human being it is imperative that highly efficient 
therapeutic compounds are efficiently delivered at the diseased sites. Conventional 
therapeutic agents tend to undergo nonspecific bio-distribution and active 
metabolism of free drug radicals prior to reaching their targeted sites resulting in their 
high dosage requirement. Using nanotechnology tools, drug delivery system can be 
developed using an array of nanoscaled polymeric, liposomal and inorganic 
materials. These nano drug delivery systems offer easier tissue penetration through 
biological and physiological barriers that are normally impermeable for larger 
particulate structures, due to their small size. In addition to this, they carry 
multifunctional capabilities of simultaneous imaging and therapeutic applications. 
Also their surfaces can be easily modified using conventional chemical techniques in 
order to alter and tune the pharmacokinetic or pharmacodynamic properties. e.g.  
Linkage with Polyethelene Glycol on the surface of these nanocrystals prolongs their 
circulation time within the body and reduces nonspecific uptake and destruction by 
the reticuloendothelial system. Surface modification enables conjugation of biological 
agents such as antibodies, peptides to their surfaces in order to target disease 
specific sites. By this methodology, significantly higher doses of drugs can be 
selectively targeted to the cancer specific sites with minimal adverse reactions, 
enhanced patient compliance and superior therapeutic efficacy10,72,73. 
However there are concerns about potential hazards of these nanodrug delivery 
systems. Limited data is available regarding pharmacokinetics & toxicological studies 
to assess the risk associated with this novel technology. Pharmaceutical sciences 
are exploiting the possibility of use of QDs for diagnosis and treatment of cancers 
minimizing the inherent risk of toxic Cadmium to human beings and the environment. 
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PHOTODYNAMIC THERAPY (PDT)- One such property of quantum 
dots is being explored for their potential use as photosensitizers in photodynamic 
therapy (PDT) for cancers. Photosensitizers are photosensitive molecules that can 
transfer the light energy to the surrounding molecular oxygen to generate reactive 
oxygen species (ROS) such as singlet oxygen(1O2), hydroxyl radicals (
-OH) , super 
oxide anions (-O2) and hydrogen peroxide ( H2O2) through a series of energy and 
electron transfer reactions initiated between photosensitizers  and dissolved oxygen 
(3O2). These reactive oxygen intermediates immediately react with and damage vital 
biomolecules in cell organelles leading to cell death. When photons are absorbed by 
these photosensitizers, they achieve excited triplet state from the ground state. 
Quantum dots can generate ROS and free radicals following long term optical 
irradiation. These ROS are able to induce tumor cell death through direct photo 
damage. These photosensitizers not only induce microvascular collapse from severe 
tumor tissue hypoxia but also cause immune response activation through IL-10 and 
IL-6 upregulation following ROS exposure. The main advantages of fluorescence 
imaging over other biomedical imaging techniques such as X-rays, CT and PET are 
that the fluorescence imaging is non-ionizing and less hazardous. 
Porphyrins, phthalocyanines and chlorine derivatives are the standard 
photosensitizer drugs used for the purpose of PDT. With the synthesis of new 
generation of photosensitizer drugs, targeted drug delivery, tunable and fiber-optic 
laser light source and image –guided PDT, skin cancers, Barrett’s oesophagus, 
bronchial cancers, head and neck cancers, lung cancer, prostate cancer and bladder 
cancers are being treated with superior results. 
The efficacy of photodynamic therapy is entirely determined by the ability of 
photosensitizers to generate ROS. The quantity of singlet oxygen generated using a 
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typical CdSe quantum dot is much lower in comparison to traditionally used 
photosensitizers. However, as the QDs are stable against photobleaching, prolonged 
irradiation with UV / visible light can potentially maintain similar level of steady state 
singlet oxygen generation.  
Alternatively, classic photosensitizers can be attached to the surface of  
functionalized QDs. Besides specifically targeting the disease specific sites, at 
closed proximity quantum dots can be used as energy donors and classical 
photosensitizers as energy acceptors to enhance the effectiveness of photodynamic 
therapy by Forster Resonance Energy Transfer (FRET) 73,74.  
There are several advantages of Quantum Dots- Photosensitizer conjugates over 
conventional photosensitizer drugs. Indirect photoactivation of photosensitizer drugs 
by photostable QDs permits prolonged imaging and PDT without photobleaching. In 
addition, larger surface area allows abundant space for conjugating multiple 
photosensitizers on the surface of the QDs and cancer markers for targeted cancer 
imaging and PDT74. 
 
2.5  CELL ADHESION MOLECULES- Adhesion to extracellular matrix  
(ECM) is necessary for the survival of epithelial cells. Inadequate or inappropriate 
cell–ECM interactions result in apoptosis, a phenomenon known as anoikis. These 
interactions are dependent on the cell surface receptors. Cell adhesion molecules 
(CAMs) are glycoproteins found on the cell surface. They are accountable for binding 
with the other cells or with the extracellular matrix in the process called ‘cell 
adhesion’. These CAMS have been found to have a fundamental role in 
phagocytosis, locomotion, mitosis and cytokinesis. CAMs have an important role in 
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diseases such as cancer, thrombosis, autoimmune diseases, bacterial and viral 
infections.  
These transmembrane receptors are composed of 3 domains- 
a) Intracellular domain- Interacts with the cytoskeleton. 
b) Transmembrane domain. 
c) Extracellular domain- Interacts with other similar CAMS ( Homophilic binding) 
or CAM of extracellular matrix ( Heterophilic binding).          
CAMs are divided into 4 classes- Integrins, cadherins, selectins and immunoglobulin 
superfamily.  
Integrins are a superfamily of cell adhesion receptors binding to extracellular matrix 
ligands, cell-surface ligands and soluble ligands. These are non-covalently linked 
heterodimeric molecules containing an α and a β subunit. These are type 1 
transmembrane proteins with large extracellular and short cytoplasmic domains. 
There are altogether 18 α and 8 β subunit genes in the mammalian genomes in total 
forming 24 α- β combinations at the protein levels. The cytoplasmic domain of 
integrins coordinates the assembly of cytoskeletal polymers and signaling 
complexes. The extracellular domains however engage either extracellular matrix 
macromolecules or counter-receptors on adjacent cell surfaces. In this way , they  
integrate cells with their microenvironment. The integrin-ligand pairs have been 
identified either by affinity chromatography or through the ability of subunit- cases, 
direct protein-protein binding specific monoclonal antibodies to block adhesion of 
cells to specific ligands. In some assays have been used to support biochemical or 
cell biological data.  
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In mammals some integrins are limited to certain cell types- 
αIIb β3 –  platelets 
α6 β4   -  keratinocytes 
αE β7    - T cells, dendritic cells & mast cells in mucosal tissues 
α4 β1    -  Leucocytes 
 α4 β7  -     Memory T cells 
αV β3  -  Widely expressed on the endothelial cells      
The mammalian integrins express ligand specificity to a significant extent. Based on 
this, they can be classified into following categories- 
1. Laminin binding integrins- α1 β1,  α2 β1,  α3 β1 ,  α6 β1,  α7 β1,  α6 β4 
2. Collagen- binding integrins- α1 β1,  α2 β1,  α3 β1 ,  α10 β1, α11 β1 
3. Leucocyte integrins- αL β2, αM β2, αX β2, αD β2, 
4. RGD recognizing integrins- α5 β1, αV β1, αV β3, αV β5, αV β6, αV β8, αIIb β3 
Some α subunits contain the I ( Inserted or Interactive) domain. These are – α1, α2, 
α10, α11, αL, αM, αX, αD and αE. The non I domain subunits are – α3, α4, α5, α6, 
α7, α8, α9, αV and  αIIb. In I-domain integrins, the I domain plays a vital role in 
ligand binding and intercellular adhesions. The α and β subunits have distinct 
domain structures with extracellular domain from each subunit contributing to the 
ligand binding site as demonstrated in Fig.2.7. The sequence arginine-glycine-
aspartic acid  (RGD)has been identified as a general integrin-binding motif. On 
ligand-binding, the integrins transduce signals into the cell interior75.  
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Fig. 2.7 .The leukocyte integrins76  
 
RGD binding integrins- All five αV integrins, α5 β1, α8 β1 and αIIb β3 have the ability 
to recognize ligands containing RGD tripeptide active site. RGD binds at an interface 
between the α and β subunits, the R residue fitting into a cleft in a β -propeller 
module in the α subunit, and the D coordinating a cation bound in a von Willebrand 
factor A-domain in the β  subunit77. 
Integrins serve as a transmembrane link between extracellular contacts ( other cells 
or extracellular matrix) and the actin microfilaments of the cytoskeleton. Upon 
binding the extracellular ligands, the integrins generate intracellular signal, modulate 
and regulate the cytoskeleton. At the same time, their functioning  can be regulated 
by signals from within the cells. 
Integrin-mediated adhesion to ECM triggers intracellular signaling pathways to 
modulate cell proliferation, morphology, migration, invasion, and survival. Among the 
various families of cell adhesion molecules, integrin expression patterns appear to 
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be directly implicated in the progression of malignant disease. During the process of 
cell aggregation, thrombosis, tumor migration and angiogenesis, integrins bind to 
various ECM proteins such as fibronectin, vitronectin or cell surface immunoglobulin 
proteins ICAM-1(intercellular adhesion molecule-1 or VCAM-1(vascular cellular 
adhesion molecule). During the process of cell locomotion, integrins can 
continuously undergo the process of endocytosis and exocytosis. During locomotion, 
the integrins form focal contacts at the front of the cell. This process is usually 
triggered by vascular endothelial growth factor (VEGF) and controlled by protein 
kinase C. Polarized distribution of αvβ3 has been demonstrated in migrating 
neutrophils. This process is regulated by Ca2+ dependent release of cell adhesion 
followed by endocytosis of integrins. Thus integrin endocytosis has been proposed 
as a mechanism for controlling cell signaling pathway which allows the cell to control 
the location and timing of integrin expression. 
GENERAL STRUCTURE OF INTEGRINS- 
Arg-Gly-Asp ( RGD) tripeptide was originally identified as a motif within the 
glycoprotein, fibronectin of extracellular matrices mediating cell adhesion. 
Subsequently   the RGD motif has been found in numerous other proteins supporting 
cell adhesion. All known RGD receptors are members of the integrin family of cell 
adhesion molecules. The term ‘ integrin’ was first applied to this family by Hynes in 
1987 to emphasize the ability of these receptors to integrate the actin containing 
cytoskeleton from within the cell to the extracellular matrix outside the cell. 
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Fig.2.8. The general structure of integrins showing  three possible conformations of 
integrins: (a) a bent conformation with a low affinity for the ligand, (b) an extended 
conformation with intermediate ligand affinity and closed headpiece, and (c) a high 
ligand affinity conformation with an extended conformation that has open headpiece 
when bound to RGD peptide.  
 
As observed in Fig. 2.8, integrins can adapt non-activated, intermediate activated or 
activated state. Integrins bind to their ligands in the intermediate activated or highly 
activated state. The activation process involves conformational changes followed by 
intracellular signaling processes regulating gene expression, cell growth, 
differentiation and survival. 
Historically, cell adhesion peptides were explored for suppressing cell adhesion-
mediated diseases such as thrombosis, inflammation, and tumor metastasis. Initially, 
the roles of ECM proteins were investigated in the adhesion of normal cells to 
tissues and the process of metastasis of cancer cells. During these investigations, 
Pierschbacher and Ruoslahti discovered that the RGD sequence found in 
Fibronectin was responsible for cell adhesion to Fibronectin. They also discovered 
that small RGD peptides derived from Fibronectin could block cell attachment to 
Fibronectin. Since then many other ECM proteins such as collagens, laminin, 
osteonectin, Vitronectin, fibrinogen, von Willebrand Factor and thrombospondin have 
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been found to have an RGD sequence(s); the cell surface receptors called integrins 
that recognized the RGD sequences were also discovered, including αvβ3, αvβ5, 
αvβ6, αvβ8, αIIbβ3, α5β1, and α8β1.  
Many synthetic peptides and peptidomimetics bind selectively to specific integrins. 
This property has been explored to block the cell adhesion to extracellular matrix. 
The well-known examples are antithrombotic drugs such as Integrilin and Aggarastat 
which selectively bind to gpIIb/IIIa receptors found on the surface of platelets. During 
the process of thrombosis, fibrinogen binds to these receptors resulting in platelet 
aggregation. These drugs Integrilin and aggarastat selectively block the fibrinogen 
binding to these receptors, preventing platelet aggregation. Similarly, cRGDfK, 
cRGDyK and RGDC4 selectively block αvβ3 and αvβ5  integrins. So, these RGD 
peptides have been used to inhibit angiogenesis in solid tumors which overexpress 
αv integrins that are not detectable in normal blood vessels. 
RGD peptide and peptidomimetic drugs are not orally bioavailable due to the 
presence of positive ( guanidinium or amine group) and negative ( carboxylic acid 
group) charges that prevents them from crossing the intestinal mucosal barrier. 
However cyclic prodrug of RGD peptidomimetics formed by linking the amino group 
and the carboxylic group via an esterase sensitive linker such as acyloxyalkoxy, 
trimethyl lock, or coumarinic acid has been found to cross the intestinal mucosal 
barrier with the anticipation that it can be converted to the drug by esterase found in 
the blood stream. 
Radiolabeled RGD peptides have been used to diagnose the presence of tumor cells 
in tissues over expressing αvβ3 and  αvβ5 integrins.
78 125I, 18F,64Cu  and 99mTc  have 
been successfully incorporated into Cyclo(RGDxK) and RGD C4 peptides for tumor 
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diagnosis. In animal experiments, cyclic RGD peptides (RGDyK and  RGD4C) after 
conjugation to paclitaxel and doxorubicin have been successfully demonstrated to 
suppress tumor progression selectively targeting αvβ3 and αvβ5  on the tumor 
vasculature during angiogenesis.79 
The deletion of individual genes by gene knockout in mice has shown that integrins 
play a critical role in development (the β1 integrins), vasculogenesis (αV integrins),    
lymphangiogenesis (α9β1), thrombus formation (αIIbβ3), the integrity of the skin 
(α6β4), and immune responses (the β2 integrins). Knockout of the gene for β3 
enhanced tumorigenesis and angiogenesis, enhanced wound healing and enhanced 
inflammation and atherosclerosis, suggesting that αVβ3 normally suppresses these 
processes. 
Large number of therapeutic drugs has been developed to exploit the properties of 
integrin binding to various ligands in the pathogenesis of various diseases. A 
humanized anti-β3 antibody (abciximab) that blocks the binding of platelet integrin 
αIIbβ3 to fibrinogen has been used to prevent thrombosis.  A humanized anti-α4 
antibody (natalizumab) that can block the α4β1-VCAM interaction or the α4β7-
mucosal addressin cell adhesion molecule (MAdCAM) interaction on mucosal 
endothelium has been tested in clinical trials. Natalizumab blocks leukocyte 
trafficking across the blood-brain barrier and thereby moderates inflammation in 
multiple sclerosis. Anti-α4 antibody is also effective in clinical trials in ameliorating 
inflammatory bowel diseases such as Crohn’s disease. Eptifibatide and tirofiban are 
being used as inhibitors of αIIbβ3 to reduce platelet aggregation and the formation of 
blood clots. 
The αvb6 integrin does not express itself within the normal epithelial tissues but only 
in those that have undergone malignant transformation. Research has confirmed that 
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heterologous expression of αvb6 in colon cancer cells promotes tumour cell growth 
in vitro and in vivo, moreover, αvb6 expression in colon cancer cells leads to 
increased gelatinase B secretion in a protein kinase C (PKC)-dependent manner and 
that integrin αvb6 up regulates its own expression via PKC mediated signaling as 
tumour cells become crowded through a system of integrin autoregulation. Inhibition 
of av integrin activity by monoclonal antibodies (mAbs), cyclic RGD peptide 
antagonists, and peptidomimetics has been shown to induce endothelial apoptosis, 
inhibit angiogenesis, and increase endothelial monolayer permeability. Inhibiting av 
integrin will probably reduce the expression level or block the function of integrin 
αvb1, αvb3, αvb5, αvb6, and αvb8, so they have a more broad-spectrum anti-integrin 
effect. In this study, the authors  used the monoclonal antibody against integrin αvb6 
to block the function of αvb6 integrin so as to investigate the role of integrin αvb6 in 
apoptosis of colon cancer cells and the related mechanisms in a more specific 
pathway80. 
 
Angiogenesis plays a vital role in tumour progression. The tumor angiogenesis is 
regulated by a fine balance between angiogenic factors and antiangiogenic factors 
secreted by tumour cells and host infiltrating cells. The clinical implications of tumour 
angiogenesis include the development of novel strategy of anticancer therapy 
targeting the tumour vessels instead of cancer cells. Monoclonal antibodies against 
vascular endothelial growth factor have been successfully used for the treatment of 
colon cancer in combination with conventional chemotherapy to prolong the patient 
survival. 
During tumour progression, environmental and genetic factors induce an angiogenic 
switch with either upregulation of angiogenic factors or downregulation of anti-
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angiogenic factors. The factors triggering angiogenesis include hypoxia, altered pH, 
metabolic stress, cytokines from inflammatory response and hormones such as 
androgens, progesterones  & oestrogens in hormone dependent cancers such as 
breast and prostate cancers. It has been proved that tumour growth depends on 
angiogenesis, the formation of new blood vessels from the existing host 
microvasculature. Antiangiogenesis can act synergistically with conventional 
chemotherapy.  
Table 3 provides a comprehensive list of various angiogenic factors. Table 4 
provides a list of  various anti-angiogenic factors. These factors play a pivotal role in 
tumor progression. 
 
Table 3. Angiogenic factors   
Vascular endothelial growth factor Acidic and basic fibroblast growth factors 
Transforming growth factor Platelet-derived endothelial cell growth factor 
Hepatocyte growth factor Tumor necrosis factor- 
Epidermal growth factor Placental growth factor 
Tissue factor Interleukin-6/8 
Angiogenin Angiopoietin-1 
Cyclooxygenase-2 Nitric oxide 
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Table 4. Antiangiogenic factors  
Thrombospondin-1, 2 Endostatin 
Angiostatin Interferon-α/β 
Interleukin-12 Platelet factor 4 fragment 
Human macrophage metalloelastase Tissue inhibitor of metalloproteinase-1/2 
Platelet factor 4 fragment Angiopoietin-2 
Vascular endothelial growth inhibitor Vasostatin 
Anti-thrombin III fragment Osteopontin fragment 
 
Strieth et al in their study  demonstrated a significant reduction in the anti-tumoural  
functional vessel density and regression of microvasculature after treatment with the 
combination of αV inhibitor cRGD and VEGFR 2 antagonist  as compared with 
antiangiogenic monotherapy81.  
During the process of angiogenesis, the angiogenic factors selectively bind to the 
specific receptors on the endothelial cells of pre-existing blood vessels. In addition to 
these factors proteinases such as matrix metalloproteinases and plasminogen 
activators help the process by dissolving the extracellular matrix surrounding the 
sprouting blood vessels. Also, endothelial cell adhesion molecules such as αvβ3 
integrins and vascular adhesion molecule-1 help to connect the newly formed 
vessels to the pre-existing blood vessels in order to produce rich intra-tumoral 
vascular network.  
During the process of angiogenesis, it was presumed that new blood vessels 
originate from the endothelial cells in the pre-existing blood vessels. However new 
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evidence suggests that bone marrow derived circulating endothelial precursor cells 
bone marrow progenitor cells such as haemopoietic progenitor cells may be 
responsible for this process. 
Tumour microvessel density has been proven to be a prognostic factor independent 
of conventional pathological prognostic factors on recurrence of different cancers 
after resection and survival. Traditionally, quantification of tumour neovascularization 
is done by immunohistochemistry using endothelial markers to stain microvessels as 
these vessels are not seen on conventional histological assessment. The commonly 
used endothelial markers are CD31, CD34 and von Willibrand  factor (vWF). 
Following immunostaining, the entire tumour section is scanned at low power ( x40) 
to identify the areas of highest neovascularization as ‘hot spots’. Individual 
microvessels are counted under high power (x200). The average microvessel count 
in 5 ‘hotspots’ is taken as microvessel density (MVD).Though several studies have 
shown the significance of degree of revascularization as a prognostic indicator in 
various human cancers, the lack of standardization and inter-observer variation has 
always been questioned. Automated computerized image analysis as well as 
selective immunostaining for over expressed integrins  has been recommended as a 
way forward. In order to avoid the bias linked with MVD assessment and to obtain 
functional information on tumour angiogenic activity, attention has now been focused 
to the various angiogenic factors. VEGF (vascular endothelial growth factor) has 
been a widely studied angiogenic factor of clinical significance. Various studies have 
documented significant relevance between over expression of VEGF and human 
cancer related  prognostic factors such as MVD, tumour invasiveness and advanced 
stage of the disease. 
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Majority of angiogenic factors are soluble and diffusible peptides. The measurement 
of circulating angiogenic factors  as a biomarker of tumour is a very convenient and 
less expensive method to monitor tumour angiogenesis before and after 
antiangiogenic therapy82. 
2.6. APPLICATION OF QDs FOR CELL LABELING-   Cell based 
therapeutics has emerged as an innovative tool with its potential applications in stem 
cells and progenitor cell based research in the regenerative medicine. Stem cells 
and progenitor cells are able to differentiate into a diverse range of specialized cell 
types. If harnessed well, they can proliferate and replace or repair the defective cell 
population. This approach could exhibit their potential benefit  in treating patients 
with degenerative neurological disorders such as demyelinating disorders, spinal 
cord injuries, Parkinson’s disease etc. as well as myocardial regeneration. It even 
may be possible to augment the antitumor power of immune cells such as Natural 
Killer cells (NK), T cells, B cells & dendritic cells towards alternative modality of 
treatment of malignancies. Quantum dots can be bioconjugated to variety of these 
cells by direct cell labeling method. This is relatively easy and less expensive. Once 
labeled, cells can be tracked by relevant imaging modality. The limitation include 
shorter observation period as a result of diminishing signal intensity during cell 
proliferation. 
 In this method of optical labeling, cells are labeled with a fluorescent tag ‘ex vivo’ 
and are subsequently grafted to the host site. These cells can be visualized based 
on the detection of fluorescence and their survival, migration, differentiation & 
regenerative potential can be tracked and monitored. The depth of tissue penetration 
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of these fluorescent labels is required to be taken into consideration as tracer more 
than 4-8 cm from the skin surface may not be detected. 
Slotkin et al performed direct QD labeling of in vivo mammalian stem cells & 
progenitor cells by injecting 620nm COOH- conjugated QDs into the ventral 
telencephalon of mouse embryos in utero. QDs were found in the principle cell types 
generated by these neural stem and progenitor cells substantial distance away from 
the site of primary injection without interrupting their migration and differentiation 
during the developmental cycle. 
Dendritic cells (DC) present antigens to the T cells in lymphoid organs, thereby 
initiating an adaptive immune response. Noh et al labeled DCs with QDs and 
observed dendritic cell migration into lymph nodes in vivo. This labeling did not affect 
the dendritic cell phenotype or maturation potential as observed by MTT assay and 
FACS analysis. The researchers observed migration of QD labeled DCs into 
popliteal and inguinal lymph nodes after injection into the footpad in experimental 
animals via NIR Fluorescent imaging. 
Lim et al labeled Natural Killer (NK) cells with QD 705 and observed that there was 
no influence on NK cell viability by FACS analysis.  
All these studies reliably confirmed that QD labeling can be used as a safe and 
effective means to facilitate in vivo therapeutic cell trafficking.  
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2.7.CYTOTOXICITY OF QUANTUM DOTS - CdTe QDs are 
synthesized from Cadmium and Telluride precursors. Elemental Cadmium gained 
major interest as a result of range of its technological uses. To protect steel and 
other alloys from corrosion (such as in aeronautics industry) Cadmium-coating by 
electroplating has been used consistently. Cadmium is a key component of several 
alloys as it improves mechanical and thermal properties of materials used in 
antifriction, soldering and electrical applications. Cadmium chalcogenides express 
optical properties subsequent to their interaction with photons. As a result their use 
has been justified as pigments in plastics, paintings, enamels and inks. Emitted light 
from these chalcogenides has been used in electronics and several display devices.  
2.7.1 CADMIUM TOXICITY- Manufacturing and disposing Cadmium containing 
compounds are the major causes of occupational exposure. Wind driven suspension 
of cadmium powder present on the surface of earth or dispersion of volcanic gases 
could result in air pollution. Agricultural activities through the use of fertilizers can 
introduce the metal into the food chain and water. Thus inhalation and ingestion 
predominantly become the source of human exposure to elemental cadmium. 
Due to the polluted atmosphere, upper respiratory tract and lungs become the major 
target for Cadmium dust and vapors. However ingested Cadmium generally target 
intestines, liver and kidneys resulting in toxic insult to these viscera. Once absorbed, 
cadmium has a very long half- life of more than 20 years in humans. So it can be 
efficiently trapped in the body and can escape detoxification. 
Different mechanisms exist demonstrating transport of Cadmium within the body 
based on the mode of exposure. Inhaled Cadmium particles are generally 
transported along the primary olfactory neurons to the olfactory bulb which is where 
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these particles are accumulated. Inhaled Cadmium particles are also accumulated in 
the lungs as in smokers. Despite of an efficient barrier for toxic molecules and heavy 
metals, Cadmium can  pass through alveolar cells and enter the circulation. Ingested 
Cadmium can accumulate in the enterocytes, the process favored in the iron 
deficient state. 
Cadmium is not only mutagenic  but is genotoxic and carcinogenic. When the cells 
are exposed to high concentration of Cadmium in a short duration, there is increased 
oxidative DNA damage as a result of creation of reactive oxygen species. In addition 
there is an evidence of inhibition of cellular DNA repair mechanism. Acute exposure 
to Cadmium results in cell necrosis and apoptosis mediated by various signaling 
pathways which trigger caspase dependent or caspase independent mechanisms. 
Cadmium exposure in humans can cause host of toxic manifestations based on 
mode of exposure. Inhalation exposure results in injury to the respiratory tract. 
Emphysema, anosmia and chronic sinusitis have been linked with pulmonary 
exposure. Large incidence of lung cancer in the occupationally exposed populations 
led to Cadmium being classified as human pulmonary carcinogen. 
Cadmium interferes with mineralization of bones. Toxicity is associated with 
osteomalacia, osteoporosis and bone fractures. Anaemia and eosinophilia have 
been associated with Cadmium toxicity. Renal toxicity results in nephropathy and 
proteinurea83. 
2.7.2 TELLURIUM TOXICITY- Tellurium is a naturally occurring element used 
in alloys of copper, steel, lead and bronze as it provide more resistance to corrosion. 
It is also used in vulcanization of rubber to provide increased resistance to heat, 
abrasion and aging. In addition, Tellurium is used in metal-oxidizing solutions to  
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blacken or tarnish metals e.g. in jewellery manufacturing. 
Elemental tellurium has relatively low toxicity. It is converted in the body to dimethyl 
telluride which imparts garlic like odor to breath and sweat. 
Accidental ingestion is the commonest mode of Tellurium toxicity in human beings 
which often manifests by metallic taste, nausea, vomiting, headache, drowsiness, 
garlic odor of the breath blackened oral mucosa & skin and corrosive gastrointestinal 
tract injury from acid solvent. Toxicity from exposure to hydrogen telluride gas leads 
to mucous membrane & pulmonary irritation, haemolysis, haemoglobinuria, anuria, 
jaundice, pulmonary oedema, tremors, convulsions and respiratory arrest84. 
Before the quantum dots can be applied in the clinical setting,  it is fundamental that 
their potential adverse effect on human being is fully established. Understanding the 
toxicity of QDs is mandatory as it carries significant implications on health of the 
population, environmental safety and public acceptance. Quantum dots are 
composed of heavy metals with known toxicity. Also because of their size, they are 
easily accessible to cells within the vital organs. Once administered, these 
nanoparticles may either remain adherent to the cell surface or may undergo  
internalization by diverse pathways such as translocation through the plasma 
membrane, receptor mediated endocytosis or pinocytosis. Once internalized, they 
may remain in endosomes, disperse within the cytosol to interact with subcellular 
organelles or are recycled to the cell surface. The localization of these quantum dots 
within the cell will eventually determine their  cytotoxicity.85 These promising 
nanoparticles  though possess invaluable diagnostic and therapeutic potentials, they 
contain heavy metals and demonstrate prolonged tissue retention causing concerns 
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for toxicity. Some of these quantum dots may be retained in the body for more than 
100 days86. 
Large number of in vitro studies observed cytotoxicity of QDs. The determinants of 
cytotoxicity are size, capping material, colour, dose of QDs, surface chemistry , 
coating bioactivity and processing parameters11 Besides these oxidative, photolytic 
and mechanical stability of the QDs contribute to the cytotoxicity potential. Their 
potential weakness is the very coating that makes them novel. Any compromise in 
the coating can expose the metalloid core. The toxicity of core elements may either 
be due to the composite materials such as CdSe / CdTe or to the constituent core 
element after their dissolution e.g. Cd. 
Occasionally the ligands added to render the probe biologically active may have 
toxic effects on the cells. The coating material such as mercaptoacetic acid,  
Mercaptopropionic acid has been found to be mildly cytotoxic. MUA, cysteamine and 
TOPO have all been shown to have the ability to damage DNA in the absence of QD 
core. 
Under proteolytic and oxidative conditions, QDs can become degradable resulting in 
disruption of core-coating biocomplexes rendering them cytotoxic. Several studies 
suggested QD cytotoxicity due to photolysis or oxidation. These processes can 
degrade the QDs , exposing either potentially toxic capping materials or core metal 
components as a result of dissolution of core complexes87. Several mechanisms 
have been attributed to be responsible for cytotoxicity of QDs which include QD core 
degradation, free radical formation and interaction of QDs with intracellular 
components. 
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Groups III-V QDs may provide  a more stable alternative to Groups II-VI QDs due to 
the presence of a covalent rather than an ionic bond and have been reported to have 
lower cytotoxicity. However these QDs are difficult to prepare on a competitive time 
scale and have much lower quantum efficiencies. 
Lovric et al studied subcellular localization and cytotoxicity of Cadmium Telluride 
(CdTe) Quantum dots in PC12 and N9 cell lines and effects of pharmacological 
agents to prevent cell death. They demonstrated marked cytotoxicity in both these 
cell lines in the form of chromatin condensation and membrane blebbing along with 
marked decrease in the metabolic activities observed by calorimetric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide( MTT) assay more 
pronounced with small (2r = 2.2 ± 0.1 nm) green emitting positively charged QDs 
than the large ( 2r = 5.2 ± 0.1 nm) red emitting equally charged  QDs.  They also 
noticed that pre-treatment with antioxidants N-acetylcysteine and with bovine serum 
albumin considerably reduced the QD induced cell death. They couldn’t demonstrate 
similar effect after pre-treatment with Trolox, similar antioxidant, the water soluble 
analog of vitamin E. The authors proposed that N-acetylcysteine could exert its effect 
by stabilizing the QDs as a result of its mercapto group being adsorbed on their 
surfaces or by activating the key antiapoptotic signal transduction pathways leading 
to transcription of genes involved in cell survival along with its antioxidant properties 
and its ability to enhance glutathione expression33. 
Yang et al quantitatively studied blood and tissue kinetics of QD 705 in mice 
following single tail vein injection of 40 pmol dose. Using Inductively Coupled Plasma 
Mass Spectrometry  (ICP-MS),they observed continuously increasing levels of QDs 
in spleen, liver and  kidneys 28 days after the intravenous injection with time 
dependent redistribution with no fecal or urinary excretion concluding a very long 
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plasma half-life potentially weeks or even months raising concerns over the health 
consequences40. 
Derfus et al observed  that liver is the primary site of acute injury as a result of 
cadmium exposure. Even in vitro studies demonstrated significant hepatotoxicity to 
very low levels (100-400µm) of cadmium ions. More than 25% of administered 
cadmium in rats was found to be accumulated in liver. The mechanism of injury has 
been attributed to Cadmium binding to sulfhydryl groups of critical mitochondrial 
proteins and inefficient detoxification of this Cadmium by relatively small amount of 
Metallothione protein in the cytoplasm. Authors demonstrated that CdSe core 
quantum dots are cytotoxic by means of formation of reduced Cd on the QD surface 
and release of free Cadmium ions. Capping CdSe core with Zns or coating with BSA 
virtually eliminates the cytotoxicity of QDs due to oxidation. 
Male et al  utilized the on line and continuous technique based on electric cell 
substrate impedance (ECIS) sensing to measure the concentration and time 
response functions of Chinese hamster lung fibroblast V 79 cells to various quantum 
dots and fluorescent gold particles. The cytotoxicity was estimated by measuring 
half-inhibition concentration(ECIS50), the required concentration to attain 50% 
inhibition of cytotoxic response. The authors noted direct cytotoxicity with cadmium 
selenide cores using the ECIS assay. They also indicated that cytotoxicity following 
CdTe quantum was assigned to free Cadmium as well as the QDs themselves. The 
QDs synthesized with indium gallium phosphide and the fluorescent gold 
nanoparticles were not cytotoxic88. 
Chen et al used 21.3 nm diameter QDs with CdSeS core coated with a shell of silica, 
network with multiple hydroxyl groups to promote water solubility and to ensure 
   97 
 
biocompatibility. The shell of silica effectively insulated the CdSeS core. During the 
experiment which lasted for 5 days with a QD dose of 5 nmol / mouse, no death or 
symptoms of illness were observed in the mice. During the in vitro experiments, the 
authors observed that the core-shell structure and fluorescent properties of the QDs 
remain unaltered in the environment of blood and kidney. During in vivo experiments 
in mice, the authors observed that these QDs coated with multiple Si-OH groups had 
an affinity for liver, kidney, spleen and lung after tail vein injection. Most of the QDs 
were metabolized and excreted in the kidney and liver. No Cadmium was 
demonstrated in the supernatant solution of the homogenized liver and kidney after 
ultracentrifugation implying stability of the QDs to maintain themselves in the core-
shell structure. The authors also state that after intravenous injection of these QDs, 
unbound QDs are rapidly excreted by the kidneys. Protein bound QDs are 
translocated to the liver and are excreted in faeces. A small fraction of QDs 
aggregated to larger particles are retained in the liver tissue for long term89. 
Biological interaction of quantum dots with the porcine skin was observed by Zhang 
et al using QD 621 nanoparticles containing Cadmium selenide core with Cadmium 
sulphide shell coated with polyethylene glycol (PEG). They noted that quantum dots 
were located primarily within the intercellular lipid bilayers of stratum corneum layer 
of the skin even at the highest concentration. Cell viability assay using human 
epidermal keratinocyte cells (HEK) using MTT assay revealed statistically significant 
decrease in the cell viability using higher doses at 24 and 48 hours. The researchers 
indicated that stratum corneum acts as a primary barrier for the skin and any types of 
breach in the epithelial integrity in the form of cuts and wounds would expose the 
QDs to the viable skin cells potentiating the cytotoxic risk38. 
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Further possibility of corneal toxicity produced by QDs following penetration of 
corneal epithelial barrier has been raised posing potential risk of eye exposure to 
these nanoparticles. Kuo et al studied permeability and distribution of CdSe/Zns QDs 
both in vitro and in vivo models using two photon microscopic imaging & observed 
that the fluorescent QDs can easily penetrate & reside within the interlamellar space 
following injury to the corneal epithelial barrier. They pointed  out that corneal 
stromal viability was inversely proportional to the concentration of these QDs and 
duration of exposure. During in vivo experiment, they noticed that these QDs can be 
retained within the cornea for up to 26 days long enough to cause consequential 
toxicity90. 
Wang et al studied cytotoxic effects of human umbilical vein endothelial cells 
(HUVEC) & demonstrated the dose dependent inhibitory effects on cell growth by 
generation of Reactive Oxygen Species( ROS). They also demonstrated that pre-
treatment with N-acetyl Cysteine (NAC) , a ROS scavenger inhibited the induction of 
ROS by QDs & thereby decreasing the QD induced DNA damage91. 
Clift et al published their results of cytotoxic effects of different surface coated QDs 
such as organic, carboxylated (COOH),amino & PEG coated QDs on J774A1 
macrophage cell viability. They analyzed MTT assay & LDH release study to 
conclude that organic QDs induced significant cytotoxicity up to 48 hours even at a 
particle concentration as low as 20 nm. Both (COOH & NH2 ) PEG QDs cause 
reduced cell viability & cell membrane permeability at a much higher concentration of 
80 nm. Also they suggested that surface coating and core material resulted in 
cytotoxicity92. 
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The influence of CdSe QDs on oocyte maturation, fertilization and subsequent pre & 
post implantation development was studied by Hsieh et al to observe that these QDs 
demonstrated significant teratogenic influence in the form of decrease in cell 
number, increased apoptosis and inhibition of post- implantation development. ZnS 
coated CdSe QDs seemed safer than uncoated ones93. 
In summary, both coated and noncoated QDs can exert their toxicity to various 
tissues depending on the chemical composition and mode of exposure. Careful 
evaluation of cytotoxicity potential of QDs is essential prior to their application in 
human population. 
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Chapter 3. 
Synthesis and characterization of CdTe 
Quantum dots 
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3.1 Introduction  
To date several methods of preparation of CdTe QDs have been described which 
include both organic synthesis and aqueous synthesis. The high quality CdTe 
nanocrystals prepared in the organic solvents cannot be utilized in the biosystems as 
they are hydrophobic. Several methods have been described to convert hydrophobic 
QDs into hydrophilic one such as ligand exchange, encapsulation into water soluble 
shell and arrested precipitation in water. However these processes indeed diminish 
their photoluminescence quantum yield (PL QY) during the transferring process. The  
aim of the study was to synthesize highly efficient and stable water soluble CdTe 
quantum dots from cheaper chemical precursors and to characterize these quantum 
dots. 
 
3.2 Synthesis of Cadmium Telluride ( CdTe) QDs 
Water soluble CdTe QDs were prepared using precursors Cadmium Chloride and 
Sodium Tellurite in presence of buffer solution of Mercaptosuccinic acid.  
15 mM solution of Borax (Na2B4O2 ) was prepared by dissolving 1.44 gm of borax to 
200 mls  of water. 15 mM solution of citrate acid was prepared by dissolving 0.88 gm 
of sodium citrate in 200 ml of water. All the reactions proceeded in the buffer solution 
composed of Na2B4O2 and citric acid adjusted to different pH values with 1 M 
Hydrochloric acid) (HCL) or 1 M Sodium Hydroxide (NaOH). The precursor solution 
was prepared by mixing a solution of 1 mM Cadmium chloride (CdCL2 – 18.3 mg in 
50 mls), 0.25 mM Sodium Tellurite (Na2TeO3- 6 mg in 50 mls) and 3 mM 
Mercaptosuccinic acid (MSA – 45 mg in 50 ml) in 50 ml of the above buffer solution 
in one-neck flask at room temperature (16±20C) at pH ~ 7.0. The molar ratio of 
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Cd:Te:MSA was 4:1:12..After vigorously stirring for 5 minutes, 20 mg of Sodium 
tetrahydridoborate (NaBH4) powder was added to the precursor solution. The flask 
was attached to a condenser and refluxed at 1000C under open air conditions as 
revealed in Fig. 3.1.  
 
Fig. 3.1. Experimental setup in the preparation of water soluble QDs. 
Once the development of CdTe nanocrystals was completed, the growth of CdTe 
nanocrystals during the refluxing was controlled by the Ostwald ripening process in 
which smaller particles dissolve and the monomers released are consumed by the 
larger once24. The  emission spectrum of quantum dots was precisely determined by  
size of the QDs. The preparation of QDs with different emission spectrums can be 
controlled by regulating the duration of condensation and refluxation of the mixture of 
QD precursors. The QDs thus prepared were water soluble and stable at room 
temperature.  
   103 
 
Fig. 3.2 demonstrate different colour emitting QDs in the ultraviolet scanner. These 
semiconductor nanoparticles emit fluorescence depending upon size of these 
particles as explained in Fig. 3.3. 
 
                                                     
 Fig.3.2  QDs in ultraviolet scanner. Fluorescence of difference colour based on  size  
             of the QDs. 
 
 
Figure 3.3  Size dependent fluorescence of semiconductor nanoparticles.2 nm 
quantum dots emit blue fluorescence but at 6 nm, they emit in the red. The size is 
inversely related the bandgap energy which dictates the fluorescence emission85 
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During the process of synthesis of CdTe QDs, in the initial phase when NaBH4 
powder was added to the precursor solution, this solution  turned green within few 
seconds depending upon the pH value of the precursor solution, the concentration of 
the solution and the reaction temperature. It was noted that lowering the pH value , 
increasing the concentration of the precursor solution or increasing the reaction 
temperature accelerated the formation of the CdTe nanocrystals. During the initial 
stage, no photoluminescence was observed from the crude solution presumably as a 
result of smaller size of the QDs. Weaker luminescence was noted after prolonged 
boiling when the solution turned dark green in colour. With prolonging of the reflux 
time, the absorption spectra as well as PL emission spectra shifted to longer 
wavelength with increase in the size of the CdTe nanocrystals  due to quantum 
confinement effect. These MSA- CdTe nanocrystals remained stable for months 
when stored in the refrigerator at 4ºC indicating attractive bio-labeling and bio-
imaging applications. 
 
3.3 Excitation and emission spectrum 
 An excitation spectrum (a plot of absorbance as a function of wavelength) was 
determined to select the optimal wavelength for analyzing a given compound. The 
optimal wavelength (Amax) for measuring absorbance is the wavelength that is most 
absorbed by the compound in question.  
The spectrophotometer analysis of excitation spectrum and emission spectrum of 
red photoluminescent mercaptosuccinic acid stabilized CdTe nanocrystals thus 
prepared in aqueous solution was analyzed.       
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Emission spectra of red emitting QDs
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        Fig 3.4.  Excitation spectrum of red emitting CdTe QDs 
 
When these QDs were subjected to spectrophotometry, the broad absorption 
spectrum was observed. The graph of absorbance vs. wavelength for CdTe quantum 
dots was plotted which demonstrated a wider range of absorbance with an  excitonic 
absorption peak  at 380 nm as shown in fig. 3.4. 
 
 
 
Fig.3.5.  Emission spectra of red emitting QDs 
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These red emitting water soluble CdTe quantum dots exhibited narrow and 
symmetrical emission. The emission spectrum suggests an  emission peak  at 630 
nm and is characterized by good symmetry and narrow spectral width as 
demonstrated in fig. 3.5. During the synthesis of quantum dots it was observed that 
the these quantum dots demonstrated  size dependent fluorescence emission. In the 
initial stages of QD synthesis, smaller diameter QDs revealed emission peak at 
lower wavelength however they were symmetrical with narrow spectral width. 
Progressively,  larger diameter CdTe QDS as in this study were red emitting ones at 
an emission peak of 630nm. 
3.4  QD size 
The transmission electron microscopic appearance of CdTe nanocrystals was 
analyzed. These quantum dots were observed to be present in different sizes and 
shapes. Majority of these nanocrystals were  contain single or clusters of these 
quantum dots measuring 5nm to 10 nm.in diameter.  Fig. 3.6 and 3.7 display 
transmission electron microscopic images of CdTe QDs.  
 
Fig.3.6.  Transmission electron microscopic appearance of CdTe Quantum dots. 
(white arrows indicate CdTe quantum dots),   
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Figure 3.6 indicate TEM appearance of CdTe quantum dots. The image was 
obtained at a magnification of  88000X. The uncoated Qds are randomly 
dispersed and appear in the form of single crystals or multiple clusters. White 
arrow indicate the presence of  QDs. 
 
Fig. 3.7 Size of CdTe nanocrystals  
 
The QDs were sized according to TEM criteria as demonstrated in fig. 3.7. Each 
single QDs  measured between 5-10nm in diameter. As observed in the figure, the 
tendency to form clusters was noted. These QDs were then subjected to X-ray 
microanalysis using transmission electron microscopy to establish the constituents of 
these QDs as observed in fig. 3.8.   
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 Fig.3.8. X-Ray Microanalysis of Quantum Dots 
 
Further analysis of these quantum dots was performed using X-ray microanalysis in 
order to establish and confirm  the chemical composition of these nanocrystals. X-
ray microanalysis is a technique used by electron microscopist to get an insight into 
elemental localization at cellular or even subcellular level. This technique is based 
upon spectral analysis of the scattered x-ray emission from the specimen induced by 
the electron beam.This  does confirm the presence of Cadmium and Tellurite in 
addition to chloride, copper and sulphur most probably contributed by 
mercaptosuccinic acid as observed in Fig.3.8. Though quantitative elemental 
analysis is feasible, the facilities to do so were unavailble. 
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Fig. 3.9. Fluorescence emitted by different colour emitting QDs in an experimental 
chicken leg under ultraviolet light. 
 
Above figure 3.9 demonstrates fluorescence emitted by different colour emitting QDs 
after injecting them in different muscle compartments of chicken leg and viewed 
under ultraviolet light. The fluorescence decay was extremely slow and persisted 
several days after storing the specimen in the deep freezer.  
3.5 Conclusion 
 It is possible to synthesize water soluble CdTe QDs form their presursors Cadmium 
Chloride and Sodium Tellurite in presence of Mercaptosuccinic acid acting as a 
buffer solution. These QDs are stable at room temperature for several days  and can 
be used for in vitro and in vivo experiments. Spectroscopic analysis revealed that 
these Qds have a wider absorbance with an excitonic absorption peak at 380nm and 
a narrow spectral emission peak at 630nm.These Qds measure between 5-10nm in 
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diameter.X-ray microanalysis of these nanocrystals confirm the presence of 
elemental Cadmium and Tellurite. 
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Chapter 4. 
Materials and methods 
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Introduction 
This chapter describes the experimental evaluation of cultures of HT29 colon cancer 
cells used to provide evidence of cancer cells binding of CdTe QD. Parallel 
experiments were conducted on C2C12 mouse skeletal muscle cells as normal 
controls. The chapter elaborates the method of water soluble CdTe QD synthesis, 
their conjugation to commercially purchased RGD peptides and transmission 
electron microscopic studies. Subsequent overview of cytotoxicity methodology of 
both nonconjugated and conjugated QDs concludes this chapter. 
 
4.1 Cell culture 
 
4.1.1 Culture of HT29 colon cancer cells lines 
HT29 cells were originally purchased from the European collection of cell cultures 
(ECACC, Sigma, and Dorset, UK). These cells were initially isolated from a primary 
tumor in a 44 year old Caucasian female. The cells form a well differentiated 
adenocarcinoma consistent with colony primary grade 1.The cells possesses the 
HLA profile of A1, 3; B12, 17; Cw5.  
4.1.1.1 Resuscitation of frozen HT29 cells 
HT29 cells were removed from the storage (Liquid Nitrogen) and quickly thawed in a 
water bath at 37ºC. 1 ml volume of the cell suspension containing 1 million cells was 
added to 15ml of McCoy’s 5A growth medium containing GlutaMAX (GIBCO).This 
solution was supplemented with 10% Fetal bovine serum and 1% Penicillin-
Streptomycin in tissue culture grade flasks with surface area of 96 cm2 and incubated 
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at 37ºC & 5%CO2 .in a humidified atmosphere to allow uniform cell growth for 3-5 
days. 
4.1.1.2 Cell Passaging of HT29 cells 
The procedure was carried out under sterile technique in a laminar flow cabinet to 
avoid contamination with bacteria, yeast or other cell lines. The previous growth 
media was removed. Cells were washed three times with phosphate buffered saline 
(PBS) – GIBCO. 3ml of 0.25% Trypsin- EDTA was added to detach the cells from 
the bottom of the flask. To optimize the function of trypsin, the flask was incubated at 
37ºC for 5 minutes. 10 mls of fully supplemented McCoy’s 5A growth medium was 
added to the flask to neutralize the effects of trypsin. The cells in the suspension of 
trypsin and growth medium were centrifuged with 350 revolutions per minute (RPM) 
at 4ºC for 5 minutes.  The supernatant was discarded and the remaining cell pellets 
were re-suspended in 5 ml fresh growth medium. After counting the cells, 
appropriate numbers of cells were transferred in a new sterile flask with an area of 
96 cm2 and fresh medium was added. The flask was subsequently maintained in an 
incubator to allow cell growth. Once the cells achieved approximately 85% 
confluence, they were passaged and counted for further experiment. 
4.1.2 Tissue culture of mouse skeletal muscle (C2C12) cell lines as 
a control 
Mouse skeletal muscle C2C12 cell lines were used as a normal control in the 
experiment for the study of bioconjugation of QDs and QD cytotoxicity. The original 
cell lines were obtained by subcloning of mouse myoblast cell lines conserved in the 
frozen storage. 
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4.1.2.1 Resuscitation of frozen C2C12 cells 
C2C12 cells were removed from the frozen storage and quickly thawed in a water 
bath at 37ºC. 1 ml volume of the cell suspension containing 1 million cells was added 
to 15ml of Dulbecco’s Modified Eagle Medium (DMEM) - GIBCO, supplemented with 
10% fetal bovine serum and 1% Penicillin-Streptomycin in a flask with surface area 
of 96 cm2 and incubated at 37ºC & 5%CO2.in a humidified to allow uniform cell 
growth. 
4.1.2.2 Cell passaging of C2C12 cells 
The procedure was carried out under sterile technique in a laminar flow cabinet to 
avoid contamination with bacteria, yeast or other cell lines. The previous growth 
media was removed from the flask. Cells were washed three times with phosphate 
buffered saline (PBS). 3ml Trypsin was added to detach the cells from the bottom of 
the flask. To optimize the function of trypsin, the flask was incubated at 37ºC for 5 
minutes. Fully supplemented Dulbecco’s Modified Eagle Medium (DMEM) was 
added to the flask to neutralize the effects of trypsin. The cells in the suspension of 
trypsin and growth medium were centrifuged at 350 revolutions per minute, 4ºC for 5 
minutes. The resulting supernatant was discarded and the remaining cells from the 
bottom of the centrifuge tube were re-suspended in 5 ml fresh growth medium. After 
counting the cells, appropriate number of cells was transferred in a new sterile flask 
with an area of 96 sq.cm and fresh medium added. The flask was subsequently 
maintained in an incubator to allow cell growth. Once the cells achieved 
approximately 85% confluence, they were passaged and counted.   
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4.1.3. Counting of cells prior to transferring into the 24 well plates 
The cells were counted in order to provide uniform monolayer of cells when grown in 
the 24 well plates and to avoid bias during in vitro experiments. Conventional 
haemocytometer containing counting chamber was used to count the number of cells 
per unit volume in cell suspension. A thick, specially designed coverslip was placed 
over the polished surface of the counting chamber. 20μl. solution of the cell 
suspension was placed into the V shaped wells with a fine pipette. The gap under 
the coverslip was noted to fill by capillary action. The charged counting chamber was 
placed on the microscope stage. The microscope was focused on the counting grid 
at low power. The cells were counted in the 4 larger corner squares. As each square 
has surface area of 1mm-squared and a depth of 0.1mm giving it a volume of 0.1 
mm3. The average cell count of 4 corner cells multiplied by 10000 provided the exact 
value of cell count per ml. The volume of cells was calculated accordingly in order to 
set up to 80,000 cells in each well of 24 well plate. The 24 well plate was then  
labeled and incubated at 37ºC and 5% CO2 to allow uniform cell growth. The 24 well 
plates prepared in this manner were used for subsequent serial experiments on 
semiconductor quantum dots.  
4.2 Interaction of RGD bioconjugated QDs with HT29 cells 
RGD PEPTIDES – 
Three types of RGD peptides were commercially ordered from Peptides 
International, Inc., Louisville, USA. They were- 
a. Cyclo (Arg-Gly-Asp-D-Phe-Lys) - c (RGDfK) (M.W. 603.68) C27H41N9O7- 
alphavbeta3 Integrin Binding RGD Peptide. 
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This peptide has been proven to bind specifically and with high affinity to αvβ3 
receptors on neovascular blood vessel sections of different major human 
cancers. The integrin alpha(IIb)beta(3)-specific cyclic hexapeptide contains an 
Arg-Gly-Asp (RGD) sequence. 
       
b. Cyclo(Arg-Gly-Asp-D-Phe-Cys) c(RGDfC) (M.W. 578.65) C24H34N8O7S 
RGD 
This is a cyclic RGDfC sequence, an integrin avb3-affine peptide. (linker 
additions via Cys) 
 
c. Cyclo(Arg-Ala-Asp-D-Phe-Val)- c(RADfV) (M.W. 588.68)      C27H40N8O7  
     This was used as a negative control. 
HT 29 cells were cultured in flasks with a surface area of 96 cm2. When the cells 
were 85% confluent, they were trypsinized for 5 minutes. Fully supplemented 
McCoy’s 5A growth medium was added to the flask to neutralize the effects of 
trypsin. The cells in the suspension of trypsin and growth medium were centrifuged 
at 350 revolutions per minute, 4ºC for 5 minutes. The resulting supernatant was 
discarded and the remaining cells from the bottom of the centrifuge tube were diluted 
with McCoy’s 5A growth medium. Cells were counted using the haemocytometer 
containing counting chamber. Cell suspension was prepared with a concentration of 
20,000cellls in 200 μl.solution. 96 well plate were prepared seeding 20,000 cells in 
each well ( 200 μl. solution per well). The first row contained only HT 29 cells without 
an addition of quantum dots. 20μl.solution of CdTe quantum dots was added to the 
second row. 20μl.solution of CdTe quantum dots bound to c (RGDfK) αvβ3 Integrin 
Binding RGD peptide was introduced in the third row. 20μl.solution of CdTe quantum 
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dots bound to c (RGDfC) RGD Tumor Targeting Peptide was introduced in the fourth 
row. 20 μl.solution of CdTe quantum dots bound to c (RADfV) Negative Control was 
added to the fifth row. The cells were incubated at 37ºC & 5%CO2 for 2 hours. 
Images were obtained with inverted microscope. 
 
4.3 TRANSMISSION ELECTRON MICROSCOPIC (TEM) STUDIES OF 
THE QUANTUM DOTS - 
10 µl solution of Red emitting CdTe QDs was collected in an eppendorph tube. The 
solution was centrifuged at 350rpm for 10 minutes. This resulted in aggregation of 
the QDs at the bottom of the eppendorph  tube. HT29 colon cancer cells were 
passaged and transferred into 3 flasks with a surface area 96cm2.Cells were allowed 
to grow in incubator at 37ºC & 5%CO2.  When cells were grown to 85% confluence, 
they were trypsinized for 5 minutes. Fully supplemented McCoy’s 5A growth medium 
was added to the flask to neutralize the effects of trypsin.  The cells in the 
suspension of trypsin and growth medium were centrifuged at 350 revolutions per 
minute, 4ºC for 5 minutes. The resulting supernatant was discarded and the 
remaining cells from the bottom of the centrifuge tube were kept ready to be mixed 
with QDs alone as well as different RGD peptide bound QDs. The first flask was 
used as a control flask containing only HT29 cells with no added QDs. 10 µl solution 
of CdTe QDs was added to the second flask. 10 µl solution of c (RGDfC) - RGD 
Tumour Targeting Peptide bound to the CdTe QDs. was added to the third flask. 
Eppendorph tube containing only CdTe QDs 
 With no cells was used as another control. All 4 flasks were incubated at 37ºC & 
5%CO2 for 2 hours. The cells were fixed in 1.5% glutaraldehyde for a minimum of 2 
hours, before being centrifuged to form a pellet in a 0.5 ml eppendorf. The cell 
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pellets were washed with two changes of phosphate buffer [Oxoid] and postfixed 
using osmium tetroxide. The cells were resuspended after each change of solution 
and allowed to stand for 10 minutes, before centrifugation and removal of the 
supernatant and addition of the next processing solution. Cells were washed using 
several changes of distilled water to remove the osmium tetroxide and dehydrated 
using alcohol 30%, 50%, 70%, 90% and 100%. The samples were left in 50% 
alcohol/50% Lemix (Taab) epoxy resin mixture on a mixer overnight to infiltrate with 
resin. They were then placed in 100% Lemix resin for a minimum of 4 hours, 
embedded in fresh Lemix Resin and polymerized at 70o C overnight. Semithin (1μm) 
sections were cut using glass knives on a Reichert-Jung ultracut microtome, 
collected on glass microscope slides and stained using 1% toluidene blue. Ultrathin 
sections were cut using a diamond knife (Diatome) and collected on 300HS, 3.05mm 
copper grids (Gilder). The ultrathin sections were stained using saturated alcoholic 
uranyl acetate (TAAB) for 5 mins. followed by Reynold=s lead citrate, also for 5 
mins. The ultrathin sections were viewed and photographed using a Philips CM120 
transmission electron microscope. 
Reagents used were as follows- 
a) Glutaraldehyde 
(20mls 20% paraformaldehyde [Analar BDH] + 16mls 25% glutaraldehyde [TAAB] + 
59mls phosphate buffered saline [Oxoid]) 
b) Osmium tetroxide 
1% osmium tetroxide [Analar BDH] + 1.5% potassium ferricyanide [BDH] in PBS 
[Oxoid] 
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c)Toluidene blue stain 
1% toluidine blue [Raymond Lamb] with 0.2% pyronine [Raymond Lamb]  in 1% 
sodium tetraborate [Analar BDH]. 
d) Reynolds lead citrate 
Dissolve 1.33g lead nitrate [BDH] in 15mls distilled water and 1.76g sodium citrate 
[BDH] in 15mls distilled water, mix solutions together and dissolve the resulting 
precipitate with 8 mls of 1M sodium hydroxide [BDH], make up to final volume of 
50mls 
e)Lemix epoxy resin 
Lemix A (25mls) + Lemix B (55mls) + Lemix D (20mls). Pour into plastic resin bottle 
and add 2 mls of BDMA, mix well.        
4.4 CYTOTOXICITY STUDIES   
4.4.1 Cytotoxicity of elemental Cadmium and Tellurium to cells  
C2 C12  cells were trypsinized from sub confluent cultures by adding 3 ml. of trypsin 
to 96 cm2. falcon culture flask with confluent cells. The flask was incubated at 37°C 
for 5 minutes with regular gentle shaking. The trypsin reaction was stopped by 
addition of 10 mls of fully supplemented Dulbecco’s Modified Eagle’s Medium 
(DMEM). Cell suspension was then centrifuged at 350rpm for 5min at 4°C. The cell 
pellet was resuspended in 20 mls. DMEM solution. Cells were counted with Fuchs-
Rosenthal haemocytometer and brought to a concentration of 1,00,000 cells /ml. By 
serial dilution, cell suspension was prepared containing 2x104 cells to be added to 
each well. Two 96 well plates were taken- one designated to test the cytotoxicity of 
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Cadmium and the second to investigate the cytotoxicity of Tellurium. After excluding 
the wells in the margin of the plate , total 10 columns of 6 rows of wells were used ( 
total  60 wells on each of the two plates). 200μl cell suspension containing 20,000 
cells was introduced in each well used for the experiment. Both 96 well plates were 
incubated at 37°C and 5%CO2 for 24 hours to allow uniform growth of cells . 
Cadmium Chloride and Sodium Telluride solution was prepared in sterile condition 
containing 1mg /ml. of Cadmium and Tellurium. Both solutions were passed through 
Sterile filters Scleicher & Schuell 0.45μm , 7 bar. Max. Serial dilution of Cadmium 
and Tellurium solutions in the growth medium were prepared to obtain the 
concentration of 0μg/ml, 0.01μg/ml, 0.05μg/ml, 0.1μg/ml, 0.5μg/ml, 1μg/ml, 5μg/ml, 
10 μg/ml, 50μg/ml and 100 μg/ml. After 24 hours in the incubator, both 96 well plates 
were removed and previous growth medium emptied. Each strength of Cadmium 
was added to each column of 6 wells. All 10 strengths of Cadmium was added  to a 
total of 60 wells on one 96 well plate. Same procedure was carried out on the 
second 96 well plate with serially diluted Tellurium. Both plates were further 
incubated for 24 hours at 37°C and 5%CO2. Cell Titer Blue Reagent G 808A 
(Promega) was used as an indicator of cell survival. 20 μl solution of this reagent 
was added to the upper 3 rows containing total 30 wells of each 96 well plates (First 
containing Cadmium and the second containing Tellurium). Yo Pro-1 Iodide 
(491/509)-Invitrogen 1mM solution in DMSO was diluted to obtain  20μM strength 
solution. This was used as an indicator of cell death. 20 μl solution of the reagent 
was added to the lower 3 rows containing total 30 wells of each of these two 96 well 
plates. The reagents were thoroughly mixed with the cells by placing the plates on R 
100 Rotatest shaker for 5 minutes. Both plates were incubated at 37°C and 5%CO2 
for 4 hours. Fluoroscan was used to calculate the percentage of cell survival and cell 
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death  respectively for these 2 reagents. For cell Titer Blue reagent, filter containing 
excitation of 530nm and emission of 620nm was used. For Yo Pro 1 Iodide reagent, 
filter containing excitation of 485nm and emission of 510nm was used. The results 
were analyzed by Ascent software for Fluoroscan. 
 
4.4.2 Cytotoxicity of nonconjugated and bioconjugated CdTe QDs  
C2C12  cells were trypsinized from subconfluent cultures by adding 3 ml. of trypsin 
to 96 cm2 falcon culture flask with confluent cells. The flask was incubated at 37°C 
for 5 minutes with regular gentle shaking. The trypsin reaction was stopped by 
addition of 10 mls of fully supplemented Dulbecco’s Modified Eagle’s Medium 
(DMEM). Cell suspension was then centrifuged at 800 rpm for 5 min at 4°C. The cell 
pellet was resuspended in 20 mls. of medium. Cells were counted with Fuchs-
Rosenthal haemocytometer and brought to a concentration of 1,00,000 cells /ml. By 
serial dilution, cell suspension was prepared containing 20,000 cells to be added to 
each well. Two 96 well plates were taken. 200μl cell suspension containing 20,000 
cells was introduced in each well used for the experiment. Both 96 well plates were 
incubated at 37°C and 5%CO2 for 24 hours to allow uniform growth of cells. After 24 
hours in the incubator, both 96 well plates were removed and previous growth 
medium emptied.  Only Dulbecco’s Modified Eagle’s Medium (DMEM ) medium was 
used in the outermost rows and columns. One row was designated for CdTe QDs. 
Second row was selected for RGD (Lysine) bound CdTe QDs. Third row was 
allocated for RGD (Cysteine) bound CdTe QDs. The fourth one selected for              
c( RGDfV)   negative control bound CdTe QDs. And the last one for the POSS 
polymer coated QDs. Serial dilution of these naked QDs and conjugated QDs in the 
growth medium were prepared to obtain the concentration of 0μg/ml, 0.01μg/ml, 
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0.05μg/ml, 0.1μg/ml, 0.5μg/ml, 1μg/ml, 5μg/ml, 10 μg /ml, 50μg/ml and 100 μg/ml. 
which was  added to each column. Both plates were further incubated for 24 hours at 
37°C and 5%CO2 After 24 hours in the incubator, both 96 well plates were removed 
and previous medium emptied. Cell Titer Blue Reagent G 808A (Promega) was used 
as an indicator of cell survival. 20 μl solution of this reagent was added to all the 
rows in the first 96 well plate.  Yo Pro-1 Iodide (491/509)-Invitrogen 1mM solution in 
DMSO was diluted to obtain  20 μM strength solution. This was used as an indicator 
of cell death. 20 μl solution of the reagent was added to all the rows in the second 96 
well plate. The reagents were thoroughly mixed with the cells by placing the plates 
on R 100 Rotatest shaker for 5 minutes. Both plates were incubated at 37°C and 
5%CO2 for 4 hours. Fluoroscan was used to calculate the percentage of cell survival  
and cell death respectively for these 2 reagents. For cell Titer Blue reagent, filter 
containing excitation of 530nm and emission of 620nm was used. For Yo Pro 1 
Iodide reagent, filter containing excitation of 485nm and emission of 510nm was 
used. The results were analyzed by Ascent software for Fluoroscan. 
 
Conclusion-   
This chapter summarizes cell studies in the laboratory setting. It elaborates detail 
methodology of culture of HT29 colon cancer  cells and C2C12 mouse skeletal 
muscle cells including method of cell counting prior to preparation of uniform sheet of 
cells in order to optimize and assess binding of QDs. After synthesis of water soluble 
CdTe QDs in the laboratory, these were bound to 3 RGD peptides, two of which 
mainly C(RGDfK) and c(RGDfC) have affinity to integrins overexpressed by the 
colon cancer cells. C(RADfV) was used as a negative control. Transmission Electron 
Microscopic studies were performed on the unbound and bound QDs. Following this, 
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the chapter explains method of evaluating cytotoxicity of elemental Cadmium, 
Tellurium, nonconjugated and bioconjugated CdTe QDs. 
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Chapter 5 
Cytotoxicity of quantum dots 
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5.1 Introduction - As Cadmium and Tellurium are the key components of CdTe 
QDs, the aim of the study was to evaluate minimal concentration of elemental 
Cadmium and elemental Tellurium that result in the cytotoxicity to the mouse skeletal 
muscle cells. Use of mouse skeletal muscle cells in this study formed the basis of 
subsequent in vivo study using these QDs. The study evaluated cytotoxicity of 
nonconjugated CdTe QDs, RGD bound CdTe QDs, RAD bound CdTe QDs (negative 
control) and polymer coated CdTe QDs. 
 
5.2 Materials and methods- In order to study the cytotoxicity of elemental 
Cadmium to the C2C12  mouse skeletal muscle cells, graded concentration of 
elemental Cadmium was prepared with concentration of 0 µg/ml, 0.01µg/ml, 0.05 
µg/ml, 0.1 µg/ml, 0.5 µg/ml, 1 µg/ml, 5 µg/ml, 10 µg/ml, 50 µg/ml and 100 µg/ml. 
Equal number of cells ( 2x104 ) were added to each well of 96 well plate. At the end 
of 24 hours of incubation period, Cadmium in graded concentration was added to the 
wells containing equal number of cells and incubated for further 4 hours following 
which both cell viability and cell death assay was performed and analyzed. The 
same procedure was applied to elemental Tellurium to assess baseline toxicity 
assay prior to utilizing CdTe QDs within this study.  
Subsequently equivalent assessments were performed using nonconjugated CdTe 
QDs, RGD bound CdTe QDs, RAD bound CdTe QDs (negative control) and polymer 
coated CdTe QDs for comparison. The detailed methodology has been explained in 
chapter 4.4.2. 
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5.3 Results-  
5.3.1 Cytotoxicity of elemental cadmium 
Cell viability assay with cadmium 
Graded concentration of elemental Cadmium ranging from 0.01µg/ml to 100µg/ml 
prepared by serial dilution in Dulbecco’s Modified Eagle Medium (DMEM) was used 
to assertain the cell viablility studies to mouse skeletal C2C12 cells. Only medium 
was used in the first column as a control. Cells were incubated for a period of 24 
hours, Fluoroscan analysis after incubation with Cell Titer-Blue reagent for 4 hours 
revealed  no obvious toxicity to these cells from 0.01 µg/ml to the concentration of 1 
µg/ml. At concentration of 5 µg/ml, obvious toxicity was evident. Further increasing 
the concentration from 10 µg/ml to 100 µg/ml revealed persistently significant toxicity 
as shown in table 5.1 and fig.5.1. Statistical analysis using one way ANOVA and 
Dunnett’s multiple comparison test revealed statistically significant difference in the 
cytotoxicity at the concentration of  of 5 µg/ml as shown in Appendix  table 1, page 
199. 
Table 5.1 Cell viability assay of mouse skeletal C2C12 cells with elemental 
Cadmium. Fluoroscan  readings with graded concentration of elemental Cadmium 
Medium 
only 
 0.01 
µg/ml  
  0.05 
µg/ml 
  0.1 
µg/ml 
 0.5 
µg/ml 
  1 
µg/ml 
  5 
µg/ml 
 1.0 
µg/ml 
  50 
µg/ml 
 100 
µg/ml 
98.28 119.40 121.30 114.80 127.00 115.20 64.76 17.29 13.57 13.45 
86.04 126.40 99.17 115.20 107.40 99.13 64.61 18.70 14.27 14.28 
134.70 114.40 99.92 99.03 93.31 98.86 67.61 20.16 15.79 14.28 
Mean 
106.35 120.09 106.79 109.70 109.22 104.41 65.66 18.72 14.54 14.00 
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Fig. 5.1 Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of Cadmium at  fluoroscan analysis. 
 
Cell death assay with cadmium   
Graded concentration of elemental Cadmium ranging from 0.01µg/ml to 100µg/ml 
prepared by serial dilution in  Dulbecco’s Modified Eagle Medium (DMEM) was used 
to assertain the cell death studies to mouse skeletal C2C12 cells. Only medium was 
used in the first column as a control. Cells were incubated for a period of 24 hours, 
Fluoroscan analysis after incubation with Yo Pro-1 Iodide (491/509)-Invitrogen 
reagent for 4 hours revealed  no obvious toxicity to these cells from 0.01 µg/ml to the 
concentration of 5 µg/ml. At concentration of 10 µg/ml, obvious toxicity was evident. 
Further increasing the concenration 100 µg/ml revealed persistently significant 
toxicity as shown in table 5.2 and fig.5.2. Statistical analysis using one way ANOVA 
and Dunnett’s multiple comparison test revealed statistically significant difference in 
the cytotoxicity at the concentration of  of 10µg/ml as revealed in Appendix,table 2 
Page 200. 
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Table 5.2. Cell death assay of mouse skeletal C2C12 cells with elemental Cadmium. 
Fluoroscan readings  at  graded concentration of elemental Cadmium 
Medium 
only 
0.01 
µg/ml 
0.05 
µg/ml 
0.1 
µg/ml 
0.5 
µg/ml 
1 
µg/ml 
5 
µg/ml 
10 
µg/ml 
50 
µg/ml 
100 
µg/ml 
1.359 1.350 1.306 1.440 1.328 1.622 1.953 2.602 2.574 2.956 
1.367 1.436 1.279 1.473 1.423 0.765 2.088 3.364 2.608 2.976 
1.581 1.563 1.461 1.529 1.615 0.779 2.369 3.932 3.669 2.724 
Mean 
1.435 1.450 1.349 1.481 1.455 1.055 2.137 3.299 2.950 2.885 
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Fig.5.2 Percentage of mouse skeletal C2C12 cell  death using graded concentration 
of Cadmium at fluoroscan analysis. 
The above studies using two reagents ( one to study the cell viability and the other to 
study cell death) revealed similar results. Both studies confirmed that elemental 
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Cadmium was safe to  mouse skeletal C2C12 cells only below the concentration of 5 
µg/ml. Any further increase in the concentration proved toxic to these cells. 
5.3.2 CYTOTOXICITY OF ELEMENTAL TELLURIUM 
Cell viability assay with Tellurium 
Graded concentration of elemental Tellurium ranging from 0.01µg/ml to 100µg/ml 
prepared by serial dilution in  Dulbecco’s Modified Eagle Medium (DMEM) was used 
to assertain the cell viablility studies to mouse skeletal C2C12 cells using Cell Titer-
Blue reagent as an indicator of cell survival. Only medium was used in the first 
column as a control. Cells were incubated with graded concentration of  tellurium for 
a period of 24 hours. Fluoroscan analysis after incubation with Cell Titer-Blue 
reagent for 4 hours followed by sstatistical analysis using one way ANOVA and 
Dunnett’s multiple comparison tests revealed statistically significant difference in the 
cytotoxicity at the concentration of 0.1 µg/ml as shown in Appendix  table 3 page 
201.This is demonstrated in  table 5.3 and fig.5.3.    
Table 5.3 Cell viability assay  of mouse skeletal C2C12 cells with elemental 
Tellurium –fluoroscan  readings with graded concentration of elemental Tellurium 
Medium 
only 
0.01 
µg/ml 
0.05 
µg/ml 
0.1 
µg/ml 
0.5 
µg/ml 
1 
µg/ml 
5 
µg/ml 
10 
µg/ml 
50 
µg/ml 
100 
µg/ml 
120.60 134.30 117.10 115.60 104.30 104.40 94.99 99.01 14.62 18.08 
139.80 134.70 130.80 121.00 112.40 110.80 104.50 96.56 15.60 18.79 
145.00 126.00 129.50 115.80 107.70 116.20 98.34 99.16 16.04 20.73 
Mean 
135.12 131.68 125.80 117.47 108.10 110.46 99.27 98.24 15.42 19.20 
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Fig. 5.3. Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of Tellurium  at  fluoroscan analysis. 
 
Cell Death assay with Tellurium 
Graded concentration of elemental Tellurium ranging from 0.01µg/ml to 100µg/ml 
was used to assertain the cell viablility studies to mouse skeletal C2C12 cells using 
Yo Pro-1 Iodide (491/509)-Invitrogen reagent as an indicator of cell survival. Only 
medium was used as a control. Fluoroscan analysis confirmed that elemental 
Tellurium was toxic at the concentration of 50µg/ml as demonstrated in table 5.4 and 
fig 5.4. This was confirmed by Statistical analysis using one way ANOVA and 
Dunnett’s multiple comparison tests which  revealed statistically significant difference 
in the cytotoxicity at the concentration of 50µg/ml as shown in Appendix, table 4, 
page 202. 
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Table 5.4  Cell death assay of mouse skeletal C2C12 cells with elemental tellurium. 
Fluoroscan readings  at  graded concentration of elemental Tellurium 
Medium 
only 
0.01 
µg/ml 
0.05 
µg/ml 
0.1 
µg/ml 
0.5 
µg/ml 
1 
µg/ml 
5 
µg/ml 
10 
µg/ml 
50 
µg/ml 
100 
µg/ml 
1.352 1.445 1.497 1.497 1.506 1.589 1.569 1.644 2.881 3.227 
1.449 1.526 1.472 1.409 1.541 1.605 1.545 1.631 3.234 3.544 
1.636 1.522 1.621 1.624 1.652 1.683 1.841 1.739 2.957 3.927 
Mean 
1.479 1.497 1.530 1.510 1.566 1.626 1.652 1.671 3.024 3.566 
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Fig. 5.4. Percentage of mouse skeletal C2C12 cell death using graded concentration  
of tellurium at fluoroscan analysis. 
 
Following this analysis, it was demonstrated that both elemental Cadmium and 
Tellurium were toxic to mouse skeletal C2C12 cell lines using both cell survival and 
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cell death assay at fluoroscan analysis. This study was a baseline analysis to 
compare cytotoxicity of both unconjugated and conjugated CdTe Qds  to the C2C12 
cells. 
 
 
5.3.3 Cytotoxicity of CdTe  QDs 
Cell Viability Assay with CdTe QDs – Sample 1.  
Graded concentration of unconjugated CdTe QDs ranging from 0.01µg/ml to 50µg/ml 
as described above was used to assertain the cell viablility of QDs to C2C12 mouse 
skeletal muscle cells using Cell Titer-Blue reagent as an indicator of cell survival. 
Only Dulbecco’s Modified Eagle Medium (DMEM) was used as a control and 
elemental Cadmium was used at a concentration of 50µg /ml to compare the toxicity 
of QDs with Cadmium. Cells were incubated with graded concentration of CdTe QDs 
for a period of 24 hours. Fluoroscan analysis after incubation with Cell Titer-Blue 
reagent for 4 hours confirmed obviously significant toxicity of nonconjugated CdTe 
QDs at 50µg /ml. However, CdTe Qds were nontoxic below the concentration of  
50µg /ml as shown in table 5.5 and fig 5.5. Statistical analysis using one way 
ANOVA and Dunnett’s multiple comparison tests revealed statistically significant 
difference in the cytotoxicity at the concentration of 50µg/ml as shown in Appendix, 
table 5 page 203. 
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Cell Viability Assay with CdTe QDs – Sample 1.  
Table 5.5  Cell viability assay of mouse skeletal C2C12 cells with nonconjugated  
CdTe QDs. fluoroscan  readings with graded concentration of nonconjugated CdTe 
QDs 
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Fig. 5.5.  Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of nonconjugated QDs at  fluoroscan analysis. 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
78.84 89.11 85.63 92.88 88.20 84.56 78.04 69.82 39.46 11.25 
79.49 85.18 82.31 81.50 82.53 89.90 87.35 78.41 49.41 12.60 
82.82 83.08 88.71 81.88 85.56 84.32 87.31 75.83 48.56 11.65 
Mean 
80.38 85.79 85.55 85.42 85.43 86.26 84.23 74.69 45.81 11.83 
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Cell Viability Assay with CdTe QDs – Sample 2 
The experiment was repeated on a completely different batch of cells separately 
grown from their precursors. Exactly similar number of cells were harvested and 
used for this experiment. The graded concentrations as described previously for 
sample 1 were used and the toxicity analysis performed in comparison with toxicity 
of elemental Cadmium at the concentration of 50µg /ml. The results are revealed in 
table 5.6 and fig. 5.6. Statistical analysis using one way ANOVA and Dunnett’s 
multiple comparison tests revealed statistically significant difference in the 
cytotoxicity at the concentration of 0.1 µg/ml as shown in table 6 on page 204. 
However it was observed that the toxicity pattern was not uniform. 
Table 5.6 Cell viability assay of mouse skeletal C2C12 cells with nonconjugated 
CdTe QDs. Fluoroscan  readings with graded concentration of nonconjugated CdTe 
QDs. 
 
 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
67.54 76.07 80.18 91.19 90.35 104.4 88.71 69.96 42.39 11.94 
75.80 86.07 83.26 90.56 65.03 94.02 84.73 72.58 37.63 11.78 
82.29 78.41 81.48 86.68 88.00 93.13 89.54 80.56 36.29 11.18 
Mean 
75.21 80.18 81.64 89.48 81.13 97.18 87.66 74.37 38.77 11.64 
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Cell viability assay with CdTe Qds
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Fig.5.6.Percentage of mouse skeletal C2C12 cell survival using graded  
concentration of nonconjugated QDs. compared with Cadmium alone at 50 µg/ml at 
fluoroscan analysis. 
 
 
 
Cell Death Assay with CdTe QDs – Sample 1.  
Cell death  analysis using Yo Pro-1 Iodide (491/509)-Invitrogen reagent confirmed 
similar findings to cell viability assay. The quantum dots were nontoxic even at the 
concentration of 50 µg/ml to mouse skeletal C2C12 cells. Cadmium toxicity was 
obviously noted at similar concentration as shown in table 5.7 and Fig. 5.7. Statistical 
analysis using one way ANOVA and Dunnett’s multiple comparison test revealed no 
statistically significant difference in the cytotoxicity even at the maximum 
concentration of 50 µg/ml  as shown in Appendix   table 7, page 205.  
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Table 5.7. Cell death assay of mouse skeletal C2C12 cells with nonconjugated QDs. 
compared with Cadmium alone at 50 µg/ml at fluoroscan analysis. 
 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
1.417 1.477 1.356 1.487 1.670 1.410 1.116 1.743 1.795 3.567 
1.342 1.472 1.377 1.463 1.415 1.439 1.389 1.705 1.727 3.787 
1.540 1.339 1.475 1.482 1.461 2.045 1.960 2.057 2.317 3.937 
Mean 
1.433 1.429 1.402 1.477 1.515 1.631 1.488 1.834 1.946 3.763 
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Fig. 5.7. Percentage of mouse skeletal C2C12 cell death using graded concentration 
of nonconjugated CdTe QDs at fluoroscan analysis.  
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Cell death assay with CdTe QDs – Sample 2. 
Cell death assay using second sample at the same concentration gradient revealed 
following results. For statistical analysis, only medium was used for comparison. 
Cadmium at the concentration of 50 µg/ml with an obvious toxicity was used at the 
other extreme. No obvious toxicity was observed below the concentration of 50 µg/ml  
as shown in  table 5.8 and fig. 5.8. Statistical analysis using one way ANOVA and 
Dunnett’s multiple comparison tests revealed no statistically significant difference in 
the cytotoxicity at the maximum concentration of 50 µg/ml as shown in Appendix, 
table 8 page 206. 
 
Table 5.8.  Cell death assay of mouse skeletal C2C12 cells with nonconjugated   
QDs. compared with Cadmium alone at 50 µg/ml . Fluoroscan readings  at  graded 
concentration of nonconjugated QDs. 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
1.320 1.407 1.316 1.426 1.339 1.657 1.582 1.744 1.605 2.876 
1.306 1.420 1.258 1.384 1.301 1.439 1.337 1.502 1.718 3.118 
1.411 1.385 1.687 1.419 1.439 1.658 1.358 1.559 1.594 2.936 
Mean 
1.346 1.404 1.420 1.409 1.360 1.585 1.425 1.601 1.639 2.977 
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Cell death assay with CdTe Qds
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Fig.5.8. Percentage of mouse skeletal C2C12 cell death using graded concentration 
of nonconjugated CdTe compared with Cadmium alone at 50 µg/ml at fluoroscan 
analysis  
 
5.3.4 Cytotoxicity of conjugated  CdTe QDs 
Cell Viability Assay with RGD (Lysine) bound CdTe QDs- Sample1 
After establishing the relatively nontoxic nature of CdTe QDs to the mouse skeletal 
C2C12 cells, the experiment was focused on RGD bound quantum dots as these 
were the basis of in vitro and in vivo studies involving  colon cancer cells. In order to 
prove nontoxic nature of RGD (Lysine) bound CdTe complexes, the same 
experiment was repeated using graded concentration of these complexes and 
toxicity assay performed using Cell Titer- Blue reagent. This study  was able to prove 
that CdTe –RGD(Lysine) compound was nontoxic at the concentration of 5 µg/ml as 
compared to elemental Cadmium at the concentration of 50 µg/ml. CdTe-RGD 
(Lysine)compound was nontoxic to C2C12 cells  from the concentration of 0.01µg/ml 
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to 5 µg/ml. Table 5.9 and fig. 5.9 confirm the above mentioned observations. 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed statistically significant difference in the cytotoxicity at the concentration of 5 
µg/ml as shown in Appendix, table 9, page 207. 
Table 5.9. Cell viability assay of mouse skeletal C2C12 cells with conjugated CdTe 
QDs.. Fluoroscan  readings with graded concentration of  CdTe QDs conjugated to 
RGD ( Lysine). 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
72.10 72.59 81.20 83.24 78.03 91.15 78.15 96.45 112.10 13.84 
73.18 88.19 86.78 88.19 87.80 86.02 87.63 105.40 104.80 12.95 
73.07 74.65 86.64 84.44 85.67 87.24 105.60 92.27 95.47 12.96 
Mean  
72.78 78.48 84.87 85.29 83.83 88.13 90.47 98.05 104.13 13.25 
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Fig 5.9 Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of RGD (Lysine) conjugated QDs. compared with Cadmium alone 
at 50 µg/ml at fluoroscan analysis..    
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Cell Viability Assay with RGD (Lysine) bound CdTe QDs- Sample 2  
The experiment was repeated using second batch of cells with graded concentration 
of RGD ( Lysine) bound CdTe QDs and toxicity assay was performed using Cell 
Titer- Blue reagent. The pattern of cell viability assay has been shown in table 5.10 
and fig. 5.10. Statistical analysis using one way ANOVA and Dunnett’s multiple 
comparison tests revealed no statistically significant difference in the cytotoxicity 
even at the maximum concentration of 50 µg/ml as shown in Appendix, table 10, 
page 208. 
 
Table 5.10. Cell viability assay of mouse skeletal C2C12 cells with (Lysine) 
conjugated CdTe QDs.. Fluoroscan  readings with graded concentration of  CdTe 
QDs conjugated to RGD ( Lysine). 
 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
89.18 85.04 77.52 86.70 89.09 87.10 100.4 99.15 101.1 12.94 
95.31 99.66 92.47 93.13 55.52 89.30 86.72 101.1 98.49 13.87 
96.36 86.53 83.67 84.09 85.94 90.11 90.31 92.48 102.1 13.12 
Mean 
93.62 90.41 84.55 87.97 76.85 88.84 92.47 97.56 100.58 13.31 
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Cell viability assay with RGD ( Lysine) conjugated  CdTe Qds
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Fig 5.10. Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of RGD (Lysine) conjugated QDs compared with Cadmium alone at 
50 µg/ml at fluoroscan analysis.  
 
Cell Death Assay with RGD (Lysine) bound CdTe QDs-Sample 1 
Comparative results were obtained using cell death analysis with Yo Pro-1 Iodide 
(491/509)-Invitrogen reagent to substantiate nontoxic nature of CdTe QD + RGD 
(Lysine).The toxicity of elemental Cadmium was stationary at the reference range as 
demonstrated in table 5.11 and fig. 5.11. Statistical analysis using one way ANOVA 
and Dunnett’s multiple comparison tests revealed no statistically significant 
difference in the cytotoxicity even at the maximum concentration of 50 µg/ml as 
shown in Appendix, table 11, page 209. 
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Table 5.11 Cell death assay of mouse skeletal C2C12 cells with RGD (Lysine)  
conjugated   QDs. compared with Cadmium alone at 50 µg/ml. Fluoroscan readings  
at  graded concentration of RGD (Lysine) conjugated QDs. 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
1.204 1.347 1.162 1.373 1.108 1.351 1.222 1.341 1.310 2.889 
1.204 1.335 1.150 1.343 1.323 1.343 1.271 1.590 1.250 3.018 
1.327 1.331 1.321 1.325 1.247 1.092 1.306 1.280 1.284 3.041 
Mean  
1.245 1.338 1.211 1.347 1.226 1.262 1.266 1.404 1.281 2.983 
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Fig 5.11. Percentage of mouse skeletal C2C12 cell death using graded 
concentration of RGD (Lysine) conjugated CdTe QDs. Fluoroscan analysis of CdTe 
QD compared with Cadmium alone at 50 µg/ml. 
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Cell Death Assay with RGD (Lysine) bound CdTe QDs- Sample 2 
In this study, second batch of cells were used with similar number of C2 C12 cells at 
graded concentration. Cell death assay was analyzed using Yo Pro-1 Iodide 
(491/509)-Invitrogen reagent. The comparison was made to control cells not 
exposed to QDs. Elemental Cadmium was used at a concentration of 50 µg/ml for 
comparison being aware of its cytotoxic nature. The results are shown in table 5.12 
and fig. 5.12. 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed no statistically significant difference in the cytotoxicity even at the maximum 
concentration of 50 µg/ml as shown in Appendix, table 12, page 210. 
 
Table 5.12 Cell death assay of mouse skeletal C2C12 cells with RGD (Lysine) 
conjugated   QDs. compared with Cadmium alone at 50 µg/ml at fluoroscan analysis. 
Fluoroscan readings at graded concentration of RGD (Lysine) conjugated QDs. 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
1.204 1.347 1.162 1.373 1.108 1.351 1.222 1.341 1.310 2.889 
1.204 1.335 1.150 1.343 1.323 1.343 1.271 1.590 1.250 3.018 
1.327 1.331 1.321 1.325 1.247 1.092 1.306 1.280 1.284 3.041 
Mean 
1.245 1.338 1.211 1.347 1.226 1.262 1.266 1.404 1.281 2.983 
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Cell death assay with RGD(Lysine) conjugated CdTe Qds
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Fig 5.12. Percentage of mouse skeletal C2C12 cell death using graded 
concentration of RGD (Lysine) conjugated CdTe QDs. Fluoroscan analysis using 
graded concentration of CdTe QD compared with Cadmium alone at 50 µg/ml. 
. 
Cell Viability Assay with RGD (Cysteine) bound CdTe QDs-Sample 1  
Graded concentration of RGD (Cysteine) conjugated to CdTe quantum dots from 
0.01µg/ml to 50µg/ml prepared by serial dilution in the Dulbecco’s Modified Eagle 
Medium (DMEM) was used to assertain the cell viablility studies to mouse skeletal 
C2C12 cell lines. Only medium was used in the first column as a control. Elemental 
Cadmium at a concentration of 50 µg/ml was used in the last column to compare the 
toxicity. Fluoroscan analysis after incubation with Cell Titre Blue reagent revealed  
no obvious toxicity to these cells from 0.01 µg/ml to the concentration of 5 µg/ml as 
shown in table 5.13 and fig. 5.13. 
   145 
 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed statistically significant difference in the cytotoxicity at the concentration of 5 
µg/ml as shown in Appendix, table 13, page 211. 
Table 5.13. Cell viability assay of mouse skeletal C2C12 cells with RGD (Cysteine) 
conjugated CdTe QDs. Fluoroscan readings with graded concentration of CdTe 
QDs.conjugated to RGD (Cysteine). 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
88.06 89.34 91.39 99.14 93.93 92.05 96.87 98.42 117.20 14.59 
89.76 89.07 88.36 94.42 90.52 96.30 107.30 109.0 114.1 13.02 
87.29 91.88 87.01 88.47 88.88 91.68 101.50 96.00 99.18 12.95 
Mean 
88.37 90.10 88.92 94.01 91.11 93.35 101.87 101.15 110.14 13.52 
  
Cell viability assay with RGD ( Cysteine) conjugated CdTe Qds
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Fig.5.13. Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of RGD (Cysteine) conjugated QDs. compared with Cadmium  at 50 
µg/ml at fluoroscan analysis 
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Cell Viability Assay with RGD (Cysteine) bound CdTe QDs-Sample 2  
Graded concentration of RGD (Cysteine) conjugated to CdTe quantum dots from 
0.01µg/ml to 50µg/ml prepared by serial dilution in the Dulbecco’s Modified Eagle 
Medium (DMEM) was used to assertain the cell viablility studies to mouse skeletal 
C2C12 second batch of cells. Only medium was used in the first column as a control. 
Elemental Cadmium at a concentration of 50 µg/ml was used in the last column to 
compare the toxicity. No obvious toxicity was noted at the maximum concentration of 
50 µg/ml using Cell Titer- Blue reagent as shown in table 5.14 and fig. 5.14.  
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed no statistically significant difference in the cytotoxicity even at the maximum 
concentration of 50 µg/ml as shown in Appendix, table 14,page 212. 
Table 5.14.  Cell viability assay of mouse skeletal C2C12 cells with (Cysteine) 
conjugated CdTe QDs. Fluoroscan readings with graded concentration of CdTe 
QDs. conjugated to RGD (Cysteine). 
 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
79.79 77.26 75.05 97.60 86.44 93.60 95.49 103.0 80.39 14.42 
77.03 83.22 94.04 95.99 98.61 96.93 90.86 108.7 104.7 13.67 
88.88 86.13 107.8 80.45 107.0 87.22 70.44 89.94 110.0 12.85 
Mean 
81.90 82.20 92.30 91.35 97.33 92.58 85.60 100.54 98.34 
 
 
13.64 
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Cell viability assay with RGD (Cysteine)conjugated CdTe Qds
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Fig 5.14. Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of RGD (Cysteine) conjugated QDs compared with Cadmium alone at 
50 µg/ml at fluoroscan analysis. 
Cell Death Assay with RGD (Cysteine) bound CdTe QDs- Sample 1 
In this study, graded concentration of RGD (Cysteine) conjugated CdTe QDs was 
used to assess cytotoxicity to C2C12 cells. Cell death assay was analyzed using Yo 
Pro-1 Iodide (491/509)-Invitrogen reagent. The comparison was made with cells 
immersed in the DMEM (Dulbecco’s Modified Eagle Medium). Elemental Cadmium 
was used at a concentration of 50 µg/ml for comparison being aware of its cytotoxic 
nature. The result of cell death assay revealed nontoxic nature of this complex at a 
concentration of 50 µg/ml. The elemental Cadmium continued to prove its toxicity at 
similar concentration as shown in table 5.15 and fig. 5.15. 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed no statistically significant difference in the cytotoxicity even at the maximum 
concentration of 50 µg/ml as shown in Appendix, table 15, page 213. 
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Table 5.15. Cell death assay of mouse skeletal C2C12 cells with RGD (Cysteine) 
conjugated   QDs  compared with Cadmium alone at 50 µg/ml at fluoroscan analysis. 
Fluoroscan readings at graded concentration of RGD (Cysteine) conjugated QDs. 
 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
1.225 1.334 1.131 1.295 1.135 1.338 1.159 1.329 1.382 2.982 
1.268 1.331 1.241 1.349 1.229 1.397 1.251 1.401 1.329 3.067 
1.365 1.350 1.323 1.349 1.339 1.401 1.365 1.454 1.477 3.510 
Mean 
1.286 1.338 1.232 1.331 1.235 1.379 1.258 1.395 1.396 3.186 
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Fig. 5.15. Percentage of mouse skeletal C2C12 cell death using graded 
concentration of RGD (Cysteine) conjugated CdTe QDs. Fluoroscan analysis using 
graded concentration of CdTe QD compared with Cadmium alone at 50 µg/ml. 
 
. 
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Cell Death Assay with RGD (Cysteine) bound CdTe QDs- Sample 2 
In this study, graded concentration of RGD (Cysteine) conjugated CdTe QDs was 
used to assess cytotoxicity to the second sample of mouse C2C12 cells. Cell death 
assay was analyzed using Yo Pro-1 Iodide (491/509)-Invitrogen reagent. The 
comparison was made with cells immersed in the DMEM (Dulbecco’s Modified Eagle 
Medium). Elemental Cadmium was used at a concentration of 50 µg/ml for 
comparison being aware of its cytotoxic nature. The result of cell death assay 
revealed no obvious cytotoxicity at a concentration of 50 µg/ml. The elemental 
Cadmium continued to prove its toxicity at similar concentration. The results are 
shown in table 5.16 and fig. 5.16. 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed no statistically significant difference in the cytotoxicity even at the maximum 
concentration of 50 µg/ml as shown in Appendix, table 16, page 214. 
Table 5.16. Cell death assay of mouse skeletal C2C12 cells with RGD (Cysteine) 
conjugated   QDs. compared with Cadmium alone at 50 µg/ml at fluoroscan analysis. 
Fluoroscan readings at graded concentration of RGD (Cysteine) conjugated QDs. 
 
Medium 
only 
QD0.01 
µg/ml  
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
1.235 1.354 1.192 1.348 1.169 1.297 1.270 1.487 1.359 2.809 
1.267 1.369 1.089 1.377 1.412 1.327 1.348 1.420 1.411 2.717 
1.400 1.324 1.363 0.9504 1.568 1.324 1.362 1.478 1.521 2.965 
Mean 
1.301 1.349 1.215 1.225 1.383 1.316 1.327 1.461 1.430 2.830 
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Cell death assay with RGD ( Cysteine) conjugated CdTe Qds
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Fig. 5.16. Percentage of mouse skeletal C2C12 cell death using graded 
concentration of RGD (Cysteine) conjugated CdTe QDs. Fluoroscan analysis 
using graded concentration of CdTe QD compared with Cadmium alone at 50 
µg/ml. 
 
Cell viability assay with negative control c (RADfV) bound CdTe 
QDs- Sample 1  
c (RADfV) was used as a negative control in the experiment. They do not bind to 
integrins overexpressed by the colon cancer cells. Graded concentration of RAD  
conjugated to CdTe quantum dots from 0.01µg/ml to 50µg/ml prepared by serial 
dilution in the Dulbecco’s Modified Eagle Medium (DMEM) was used to assertain the 
cell viablility studies to mouse skeletal C2C12 cells. Only medium was used in the 
first column as a control. Elemental Cadmium at a concentration of 50 µg/ml was 
used in the last column to compare the toxicity. Fluoroscan analysis after incubation 
with Cell Titre Blue reagent revealed  no obvious toxicity to these cells from 0.01 
µg/ml to the concentration of 0.5 µg/ml as demonstrated in table.5.17 and fig. 5.17. 
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Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed statistically significant difference in the cytotoxicity at the concentration of 
0.5 µg/ml as shown in Appendix, table 17, page 216. 
Table 5.17. Cell viability assay of mouse skeletal C2C12 cells with c (RADfV) 
conjugated CdTe QDs. fluoroscan readings with graded concentration of CdTe QDs. 
conjugated to negative control c (RADfV)  
 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
79.39 85.39 86.50 84.66 95.14 103.20 99.08 104.60 105.20 14.40 
78.65 80.34 93.76 88.19 97.04 86.26 101.00 106.80 96.04 13.18 
79.70 84.56 85.87 84.18 86.35 88.66 95.25 88.60 96.92 12.87 
Mean 
79.24 83.43 88.71 85.68 92.84 92.70 98.43 99.99 99.37 13.48 
     
Cell viability assay with RAD bioconjugated CdTe Qds
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    Fig. 5.17 Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of RAD conjugated QDs  compared with Cadmium alone at 50 µg/ml 
at fluoroscan analysis. 
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Cell viability assay with negative control c (RADfV) bound CdTe 
QDs- Sample 2  
Graded concentration of RAD conjugated to CdTe quantum dots from 0.01µg/ml to 
50µg/ml prepared by serial dilution in the  Dulbecco’s Modified Eagle Medium 
(DMEM) was used to assertain the cell viablility studies to mouse skeletal C2C12 cell 
lines  of the second batch of sample. Only medium was used in the first column as a 
control. Elemental Cadmium at a concentration of 50 µg/ml was used in the last 
column to compare the toxicity. Fluoroscan analysis after incubation with Cell Titre 
Blue reagent revealed  no obvious toxicity to these cells from 0.01 µg/ml to the 
concentration of 0.5 µg/ml as shown in table 5.18 and fig. 5.18. 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed statistically significant difference in the cytotoxicity at the concentration of 
0.5 µg/ml as shown in Appendix, table 18, page 216. 
Table 5.18. Cell viability assay of mouse skeletal C2C12 cells with c (RADfV) 
conjugated CdTe QDs. Fluoroscan readings with graded concentration of CdTe 
QDs. conjugated to negative control c (RADfV) 
Medium 
only 
QD0.01 
µg/ml  
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
79.39 85.39 86.50 84.66 95.14 103.2 99.08 104.6 105.2 14.40 
78.65 80.34 93.76 88.19 97.04 86.26 101.0 106.8 96.04 13.18 
79.70 84.56 85.87 84.18 86.35 88.66 95.25 88.60 96.92 12.87 
Mean 
79.24 83.43 88.71 85.68 92.84 92.70 98.43 99.99 99.37 13.48 
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cell viablility assay with RAD conjugated CdTe Qds
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Fig. 5.18 Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of RAD conjugated QDs. compared with Cadmium alone at 50 µg/ml 
at fluoroscan analysis 
Cell death assay with negative control c (RADfV) bound CdTe QDs- 
Sample 1 
In this study, graded concentration of RAD conjugated CdTe QDs was used to 
assess cytotoxicity to the mouse C2C12 cells. Cell death assay was analyzed using 
Yo Pro-1 Iodide (491/509)-Invitrogen reagent. The comparison was made with cells 
immersed in the DMEM (Dulbecco’s Modified Eagle Medium). Elemental Cadmium 
was used at a concentration of 50 µg/ml for comparison being aware of its cytotoxic 
nature. Cell death assay for QD-RAD complexes equally proved nontoxic at the 
study concentration level up to 50 µg/ml. Elemental Cadmium continued its trend of 
cytotoxicity to the skeletal muscle cells at similar concentration of 50 µg/ml. as 
shown  in table 5.19 and fig.5.19. 
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Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed no statistically significant difference in the cytotoxicity even at the maximum 
concentration of 50 µg/ml as shown in Appendix, table 19, page 217. 
Table 5.19 Cell death assay of mouse skeletal C2C12 cells with RAD conjugated   
QDs. compared with Cadmium alone at 50 µg/ml at fluoroscan analysis. Fluoroscan 
readings at graded concentration of RAD conjugated QDs. 
 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium  
50 µg/ml 
1.196 1.331 1.257 1.338 1.219 1.321 1.203 1.375 1.436 3.573 
1.286 1.441 1.080 1.394 1.347 1.423 1.303 1.473 1.462 3.681 
1.386 1.414 1.416 1.388 1.557 1.377 1.366 1.461 1.453 2.900 
Mean 
1.289 1.395 1.251 1.373 1.374 1.374 1.290 1.436 1.450 3.385 
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Fig. 5.19. Percentage of mouse skeletal C2C12 cell death using graded 
concentration of RAD conjugated CdTe QDs. Fluoroscan analysis compared with 
Cadmium alone at 50 µg/ml 
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Cell Death Assay with Negative control c (RADfV) bound CdTe QDs- 
Sample 2 
In this study, graded concentration of RAD conjugated CdTe QDs was used to 
assess cytotoxicity to the second sample of mouse C2C12 cells. Cell death assay 
was analyzed using Yo Pro-1 Iodide (491/509)-Invitrogen reagent. The comparison 
was made with cells immersed in the DMEM (Dulbecco’s Modified Eagle Medium). 
Elemental Cadmium was used at a concentration of 50 µg/ml for comparison being 
aware of its cytotoxic nature. The result of cell death assay revealed no obvious 
cytotoxicity at a concentration of 50 µg/ml. The elemental Cadmium continued to 
prove its toxicity at similar concentration. The results are shown in table 5.20 and fig. 
5.20. 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed no statistically significant difference in the cytotoxicity even at the maximum 
concentration of 50 µg/ml as shown in Appendix, table 20, page 218. 
Table 5.20. Cell death assay of mouse skeletal C2C12 cells with RAD conjugated   
QDs compared with Cadmium alone at 50 µg/ml at fluoroscan analysis. Fluoroscan 
readings at graded concentration of RAD conjugated QDs. 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium  
50 µg/ml 
1.272 1.400 1.346 1.382 1.224 1.365 1.217 1.403 1.392 3.257 
1.207 1.344 1.162 1.414 1.696 1.364 1.233 1.401 1.392 3.391 
1.351 1.360 1.386 1.473 1.716 1.420 1.264 1.496 1.559 3.570 
Mean 
1.277 1.368 1.298 1.423 1.545 1.383 1.238 1.433 1.448 3.406 
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Fig. 5.20. Percentage of mouse skeletal C2C12 cell death using graded 
concentration of RAD conjugated CdTe QDs. Fluoroscan analysis using graded 
concentration of CdTe QD compared with Cadmium alone at 50 µg/ml. 
 
Cell viability assay with POSS polymer coated CdTe- Sample 1 
Polymer coating has proven to improve photophysical properties including stability, 
In order to study the range of cytotoxicity, POSS polymer coated CdTe quantum dots 
were bound to the mouse skeletal muscle cells in ascending concentration gradient. 
Graded concentration of polymer conjugated to CdTe quantum dots from 0.01µg/ml 
to 50µg/ml prepared by serial dilution in the Dulbecco’s Modified Eagle Medium 
(DMEM) was used to assertain the cell viablility studies to mouse skeletal C2C12 cell 
lines. Only medium was used in the first column as a control. Elemental Cadmium at 
a concentration of 50 µg/ml was used in the last column to compare the toxicity. 
Fluoroscan analysis after incubation with Cell Titre Blue reagent revealed  no 
obvious toxicity to these cells from 0.01 µg/ml to the concentration of 50 µg/ml in 
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comparison to the elemental Cadmium at similar concentration as observed in table 
5.21 and fig.5.21. 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed inconsistent cytotoxicity which was being evident from the concentration of 
0.05 µg/ml as demonstrated in Appendix, table 21, page 219. 
Table 5.21. Cell viability assay of mouse skeletal C2C12 cells with POSS polymer 
coated CdTe QDs. fluoroscan readings with graded concentration of CdTe QDs. 
conjugated to POSS polymer. 
 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
79.52 95.00 99.22 89.96 85.80 91.16 99.86 103.40 94.56 14.82 
80.74 100.10 102.60 97.90 98.75 115.40 106.90 107.90 101.90 14.17 
87.64 91.39 109.90 100.70 125.20 100.30 103.70 96.22 92.90 14.98 
Mean 
82.63 95.49 103.92 96.18 103.26 102.31 103.48 102.52 96.43 14.66 
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Fig. 5.21. Percentage of mouse skeletal C2C12 cell survival using graded 
concentration of POSS polymer conjugated QDs compared with Cadmium alone at 
50 µg/ml at fluoroscan analysis 
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Cell Viability Assay with POSS Polymer coated CdTe- Sample 2 
Graded concentration of polymer conjugated to CdTe quantum dots from 0.01µg/ml 
to 50µg/ml prepared by serial dilution in the  Dulbecco’s Modified Eagle Medium 
(DMEM) was used to assertain the cell viablility studies to mouse skeletal C2C12 cell 
lines within the second sample of cells. Only medium was used in the first column as 
a control. Elemental Cadmium at a concentration of 50 µg/ml was used in the last 
column to compare the toxicity. Fluoroscan analysis after incubation with Cell Titre 
Blue reagent revealed  no obvious toxicity to these cells from 0.01 µg/ml to the 
concentration of 50 µg/ml in comparison to the elemental Cadmium at similar 
concentration as observed in table 5.22 and fig.5.22. 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed inconsistent cytotoxicity which was being evident from the concentration of 
0.05 µg/ml as demonstrated in Appendix, table 22, page 220. 
Table 5.22. Cell viability assay of mouse skeletal C2C12 cells with POSS polymer 
coated CdTe QDs. Fluoroscan readings with graded concentration of CdTe QDs. 
conjugated to POSS polymer. 
  
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 
79.52 95.00 99.22 89.96 85.80 91.16 99.86 103.4 94.56 14.82 
80.74 100.1 102.6 97.90 98.75 115.4 106.9 107.9 101.9 14.17 
87.64 91.39 109.9 100.7 125.2 100.3 103.7 96.22 92.90 14.98 
Mean 
82.63 95.49 103.92 96.18 103.26 102.31 103.48 102.52 96.43 14.66 
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Cell viability assay with POSS polymer bioconjugated CdTe Qds
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Fig. 5.22. Average cell survival using graded concentration of POSS polymer coated 
               CdTe QD compared with Cadmium alone at 50 µg/ml at fluoroscan analysis 
  
Cell death Assay with POSS Polymer coated CdTe- Sample 1 
In this study, graded concentration of polymer conjugated CdTe QDs were used to 
assess cytotoxicity to the mouse C2C12 cells. Cell death assay was analyzed using 
Yo Pro-1 Iodide (491/509)-Invitrogen reagent. The comparison was made with cells 
immersed in the DMEM (Dulbecco’s Modified Eagle Medium). Elemental Cadmium 
was used at a concentration of 50 µg/ml for comparison being aware of its cytotoxic 
nature. Cell death assay for polymer coated QDs equally proved nontoxic at the 
study concentration level up to 50 µg/ml. Elemental Cadmium continued its trend of 
cytotoxicity to the skeletal muscle cells at similar concentration of 50 µg/ml. as 
shown  in table 5.23 and fig.5.23. 
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Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed no statistically significant difference in the cytotoxicity even at the maximum 
concentration of 50 µg/ml as shown in Appendix, table 23, page 221. 
Table 5.23. Cell death assay of mouse skeletal C2C12 cells with POSS polymer 
conjugated   QDs. compared with Cadmium alone at 50 µg/ml at fluoroscan analysis. 
Fluoroscan readings  at  graded concentration of RGD (Lysine) conjugated QDs. 
 
Medium 
only 
QD0.01 
µg/ml 
QD0.05 
µg/ml 
QD0.1 
µg/ml 
QD0.5 
µg/ml 
QD1 
µg/ml 
QD5 
µg/ml 
QD10 
µg/ml 
QD50 
µg/ml 
Cadmium 
50 µg/ml 
1.470 1.503 1.347 1.508 1.307 1.374 1.298 1.432 1.497 3.752 
1.332 1.442 1.336 1.440 1.306 1.433 1.308 1.470 1.510 3.531 
1.374 1.386 1.387 1.396 1.350 1.372 1.390 1.448 1.607 4.395 
Mean 
1.392 1.444 1.357 1.448 1.321 1.393 1.332 1.450 1.538 3.892 
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Fig. 5.23. Percentage of mouse skeletal C2C12 cell death using graded 
concentration of POSS polymer conjugated CdTe QDs. Fluoroscan analysis using 
graded concentration of CdTe QD compared with Cadmium alone at 50 µg/ml. 
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Cell death Assay with POSS Polymer coated CdTe- Sample 2 
In this study, graded concentration of polymer conjugated CdTe QDs were used to 
assess cytotoxicity to the second sample of mouse C2C12 cell lines. Cell death 
assay was performed using Yo Pro-1 Iodide (491/509)-Invitrogen reagent. 
Comparison was made with cells immersed in the DMEM (Dulbecco’s Modified 
Eagle Medium). Elemental Cadmium was used at a concentration of 50 µg/ml for 
comparison being aware of its cytotoxic nature. Cell death assay for polymer coated 
QDs equally proved nontoxic at the study concentration level up to 50 µg/ml. 
Elemental Cadmium continued its trend of cytotoxicity to the skeletal muscle cells at 
similar concentration of 50 µg/ml. as shown  in table 5.24 and fig.5.24. 
Statistical analysis using one way ANOVA and Dunnett’s multiple comparison tests 
revealed no statistically significant difference in the cytotoxicity even at the maximum 
concentration of 50 µg/ml as shown in Appendix, table 24,page 222. 
 
Table 5.24. Cell viability assay of mouse skeletal C2C12 cells with POSS polymer 
conjugated CdTe QDs. fluoroscan readings with graded concentration of CdTe QDs. 
conjugated to POSS polymer 
Medium 
only QD0.01 QD0.05 QD0.1 QD0.5 QD1 QD5 QD10 QD50 
Cadmium 
50 
1.312 1.415 1.275 1.441 1.237 1.394 1.268 1.388 1.471 2.974 
1.352 1.416 1.313 1.403 1.309 1.445 1.338 1.474 1.498 3.711 
1.453 1.433 1.425 1.450 1.440 1.409 1.422 1.547 1.613 3.701 
Mean 
1.372 1.421 1.338 1.431 1.329 1.416 1.343 1.470 1.527 3.462 
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Cell death assay with POSS polymer bioconjugated CdTe Qds
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Fig. 5.24. Percentage of mouse skeletal C2C12 cell death using graded 
concentration of POSS Polymer conjugated CdTe QDs. Fluoroscan analysis  
concentration of CdTe QD compared with Cadmium alone at 50 µg/ml. 
 
5.4 Discussion - Elemental Cadmium and Tellurium are known to be cytotoxic to 
the living cells. Prior to the analysis of cytotoxicity of CdTe quantum dots, it was 
deemed necessary to quantify the minimum concentration required to produce 
toxicity to the C2C12 mouse skeletal muscle cells by the individual QD components. 
Elemental Cadmium was found to be toxic to these cells at a concentration of 5 
µg/ml.  Using Yo Pro-1 Iodide reagent and Cell titre blue reagent, elemental 
Tellurium was found to be cytotoxic at a concentration of 0.1 µg/ml. 
Nonconjugated CdTe quantum dots were nontoxic to the cells below the 
concentration of 50 µg/ml.  QDs conjugated to RGD (Lysine) and RGD (Cysteine) 
were nontoxic to mouse C2C12 cells below the concentration of 50 µg/ml. 
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Negative control RAD conjugated QDs revealed inconsistent results in cell survival 
studies from both samples but also revealed no cytotoxicity in cell death assay below 
the concentration of 50 µg/ml. 
POSS Polymer coated peptides also revealed inconsistent results in the cell survival 
studies with toxicity evident from concentration as low as 0.05 µg/ml. Cell death 
studies however suggested these to be safe below the concentration of 50 µg/ml. 
5.5 Conclusion- Unconjugated water soluble CdTe QDs are safe below the 
concentration of 50 µg/ml to be applied for in vitro studies involving noncancer cells 
and in vivo studies. RGD Lysine and RGD Cysteine conjugated QDs are safe below 
the concentration of 50 µg/ml. and can be applied for in vitro and in vivo 
experiments.  
RAD and Polymer coated QDs revealed inconsistent results with discrepancy 
between cell viability and cell death assay. 
Further studies involving systemic biodistribution of these QDs in animal experiments 
and long term follow up studies will have to prove nontoxic nature of these QDs prior 
to their application in human population. 
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Chapter 6 
 
Interaction of quantum dots with HT-29 
cells  in vitro 
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6.1 Introduction - The aim of the study was to demonstrate that QDs are capable 
of binding to HT29 colon cancer cells. As these cells overexpress integrins, the study 
was aimed to exploit this property for significant and stable binding using RGD 
(Lysine) and RGD (Cysteine) peptides. 
6.2 Materials and Methods- RGD peptides were commercially obtained as 
discussed in details in chapter 4.2. RGD bound CdTe QDs were bioconjugated with 
HT29 colon cancer cells. Their interaction with the cells were studied using inverted 
microscope and transmission electron microscope (TEM) as explained in chapter 4.3 
6.3 Results- Fig.6.1 and 6.2 illustrate inverted microscopic image of HT29 colon 
cancer cells at 10X and 40X magnification respectively at approximately 80-85% 
confluence. The monolayer of cells was studies after fixed number of cells were used 
in each well for optimal visualization of the QDs and to avoid bias. The cell growth 
was observed on daily basis. Generally 85% confluence of cell growth was observed 
on day 4 after maintaining these flasks containing HT29 cells at 370 C, 5% CO2 in a 
humidified atmosphere. 
 
Fig. 6.1  Inverted microscopic image of HT29 cells (10x)  
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Fig. 6.2  Inverted microscopic image of HT29 cells (40x) 
 
 
 
After the CdTe QDs were conjugated to HT29 cells for a period of 2 hours in the 
incubator, inverted microscopic appearance at a magnification of 40X revealed 
presence of sparse fluorescent QDs as noted in fig.6.3. 
As the HT29 cells overexpress integrins95-98, RGD tumour targeting peptides showed 
more significant binding in comparison to passive binding noted after addition of 
CdTe QDs alone. Fig.6.4 demonstrates more significant binding of  RGD (Lysine) 
bioconjugated QDs to colon cancer cells. Similar stable and prolonged binding was 
noted after the use of RGD (Cysteine) for bioconjugation with the QDs as illustrated 
in fig.6.5.              
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Fig.6.3. Inverted microscopic image of HT-29 cells-(40x) with CdTe QDs.  (Arrows 
indicate the fluorescent QDs) 
 
 
    
 
Fig.6.4  Inverted microscopic image of HT-29 cells-(40x) with CdTe QDs  bound to 
c(RGDfK) αVβ3 Integrin binding RGD peptide. (Arrow indicate the  fluorescent QDs) 
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Fig.6.5 Inverted microscopic image of HT-29 cells-(40x) with CdTe QDs bound to     
            c(RGDfC) RGD tumour targeting peptide. (Arrow indicate the QDs) 
 
 
The binding of conjugated QDs to the HT29 colon cancer cells were noted to be 
more abundant, prolonged and stable than unconjugated QDs. After 24 hours of 
further incubation, and washing with PBS solution, when these flasks were observed 
under inverted microscope, the flasks with QDs bound to RGD peptides 
demonstrated unchanged appearance. Scanty QDs were noted in the flask 
containing unconjugated QDs passively bound to HT 29 colon cancer cells. 
Fig.6.6, 6.7 and 6.8 illustrates TEM appearance of HT 29 cells with magnifications 
from 2650 to 40,000.These were used as baseline prior to comparison with QD 
labeled cells. 
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 Fig. 6.6 TEM (Transmission Electron Microscopic) Appearance of HT29  
              Cells (Magnification -2650x), 
 
 
 
 
  Fig.6.7 TEM (Transmission Electron Microscopic) appearance of HT29  
              Cells (Magnification -19,500x) 
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Fig. 6.8. Transmission electron microscopic appearance of HT29 cells     
              (Magnification -40,000 x) 
 
 
Fig.6.9 and 6.10 represents TEM appearance of HT 29 cells after labeling with CdTe 
QDs. These were obtained with magnifications ranging from 2650 to 19,500 times 
normal. Studying these images and comparing them with baseline images of cells, 
visible presence of quantum dots were noted along the cell membranes. These were 
confirmed with X-ray microanalysis as well. 
 
Fig.6.9 Transmission electron microscopic appearance of HT 29 cells with CdTe  
            QDs (Magnification -2650x) 
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Fig.6.10. Transmission electron microscopic appearance of HT 29 cells with CdTe  
                QDs (Magnification -19,500 x) 
  
Further magnification of QDs labeled HT29 cells at 40,000 and 88,000 times normal 
was obtained for further delineation of QDs as demonstrated in Fig. 6.11 and 6.12. 
Abundant presence of QDs was observed as labeled with white arrows. X-ray 
microanalysis confirmed these dots to be CdTe QDs. 
 
Fig. 6.11.  Transmission electron microscopic appearance of HT 29 cells with CdTe  
                 QDs. (Magnification -40,000 x) 
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Fig. 6.12.  Transmission electron microscopic appearance of HT 29 cells 
                 with CdTe QDs (Magnification -88,000 x) (Arrow indicate        
                 presence of QDs) 
 
 
HT29 cells were then labeled with RGD tumour targeting peptide bound to the CdTe 
QDs and TEM images were obtained with magnifications varying from 2650 to 
19,500 times normal as demonstrated in Fig.6.13 and 6.14.RGD labeled peptides 
confirmed more significant binding of QDs to the cell membrane of HT 29 cells. 
 
Fig. 6.13 Transmission electron microscopic appearance of HT- 29 cells with         
               c(RGDfC)- RGD tumour targeting peptide bound to the CdTe  QDs 
              (Magnification –2650X) 
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Fig. 6.14. Transmission electron microscopic appearance of HT- 29 cells with  
                c (RGDfC) - RGD tumour targeting peptide bound to the CdTe QDs –  
               (Magnification –19,500X)  
 
Further magnification of RGD bound QD labeled HT 29 cells at 40,000 and 88,000 
times normal was obtained for further delineation of QDs as demonstrated in 
Fig.6.15 and 6.16. Abundant presence of QDs was observed as labeled with white 
arrow. X-ray microanalysis confirmed these dots to be CdTe QDs.                                                                                                                                                                                                                        
                           
Fig. 6.15 Transmission electron microscopic appearance of  HT29 cells with       
                c(RGDfC)- RGD tumour targeting peptide bound to the CdTe  QDs  
               (Magnification –40000 X)   
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 Fig. 6.16  Transmission electron microscopic appearance of  HT29 cells with  
                 c(RGDfC)- RGD tumour targeting peptide bound to the CdTe QDs –  
                (Magnification –88,000 X)(Arrow indicate presence of QDs) 
 
 
6.4 Discussion - CdTe QDs were able to conjugate to the HT29 colon cancer 
cells during in vitro experiment. Passive binding was less stable and marginal. 
Application of RGD peptide conjugated QDs resulted in more stable and prolonged 
binding to the HT29 colon cancer cells. This was observed under both inverted and 
transmission electron microscopy confirmed by X-ray microanalysis. 
 
6.5 Conclusion – CdTe QDs were able to bind to the HT29 colon cancer cells. 
Minimal binding was noted after the cells were washed with phosphate buffered 
saline (PBS).More significant stable and prolonged binding of QDs was noted to 
these colon cancer cells after bioconjugation with RGD (Lysine) and RGD 
(Cysteine). 
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Chapter 7 
 
Feasibility of quantum dots for in vivo 
application 
 
 
 
 
 
 
 
 
 
 
 
   176 
 
7.1 Introduction – Several studies have demonstrated successful application of 
QDs in animal experiments for sentinel lymph node identification based on their 
biodistribution properties. As the cytotoxicity assay concluded nontoxic nature of 
these CdTe QDs to normal cells at low concentration, it was decided to study 
biodistribution properties of these water soluble QDs in animal experiments. The aim 
of this procedure was to assess the feasibility of these synthetic water soluble CdTe 
QDs for the purpose of identification of sentinel node lymph nodes after 
subcutaneous injection of QDs in vivo. 
 
7.2 Materials and methods- To observe the distribution of red emitting CdTe 
QDs in vivo, animal experiment was performed using SD (Sprague Dawley) rat. The 
Sprague Dawley rat is an outbred multipurpose breed of albino rat used extensively 
in medical research. Its main advantage is calmness and ease of handling. The 
animal handling was in accordance with standard animal husbandry practice and 
regulation. The animal was treated humanely and with regard for alleviation of 
suffering throughout the study.  The rat used for this purpose was under 12 hour 
light-dark cycle, 23 ± 1°C, 39–43% relative humidity; water and food was available 
ad libitum. 
The animal experiment was carried out in the animal lab at the University 
Department of Surgery, University College Medical School, Royal Free Campus in 
accordance with the Animal ( scientific procedures) Act 1986 (ASPA) regulation 
implemented by the home office in England. The experiment was conducted by the 
supervisor holding personal license to carry out procedure on animals. 
The rat was anaesthetized with isofluorane using a face mask and transferred into 
the UV chamber. The animal was placed supine. Vital parameters were monitored 
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throughout the procedure. QD conjugates were injected in the interdigital web space 
of hind limb. Evidence of uptake by the inguinal nodes in the groin was observed 
using Ultraviolet probe. Dissection of groin performed and lymph node fluorescence 
observed as a result of red emitting QDs. 
                                             
Fig.7.1 Anaesthetized rat using isofluorene with face mask.  
 
7.3 Results- As demonstrated in Fig 7.1 the experiment was conducted in the 
animal laboratory under aseptic technique.  The caged SD rat was obtained and 
anaesthetized using isofluorene via well-fitting face mask. Continuous monitoring of 
vital parameters such as heart rate, blood pressure and temperature was performed 
throughout the experiment. Red emitting CdTe QDs were used at a concentration of 
10µg / ml. The aim of this experiment was to trace the QDs after injection into the 
subcutaneous tissue till the fluorescence is demonstrated within the regional lymph 
node. The experiment was performed under ultraviolet radiation exposure. Efforts 
were made to observe live tracking of QDs within the lymphatics. The QDs were 
injected in the interdigital web space. The total volume of QD solution used was 1 ml. 
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Fig. 7.2 and 7.3 observe the procedure of QD injection in the interdigital web space.  
Red emission is obtained from the solution of QDs in the syringe used for injection at 
the background of external source of ultraviolet irradiation.           
                         
Fig. 7.2 Injection of red emitting CdTe quantum dots in the interdigital web space of  
             the rat. 
 
 
                                         
   Fig 7.3 Red Fluorescence under UV exposure 
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Fig 7.4 Fluorescence due to injected quantum dots at the primary site and sentinel  
            lymph node 
 
As seen in Fig. 7.3 and fig.7.4, red emitting QDs were noted at the site of primary 
injection in the interdigital web space with subsequent glow in the right groin under 
UV exposure indicating the uptake by the regional lymph node, 10 minutes after 
primary injection of the quantum dots. The lymph node was dissected off following 
skin incision in the groin and was observed under ultraviolet exposure to 
demonstrate red emission as seen in Fig. 7.5. 
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Fig 7.5 Dissected sentinel lymph node under UV exposure. 
 
Tail vein injection of the quantum dot conjugates done with a concentration of 10µg / 
ml. performed. Distribution of fluorescence was observed by careful dissection of the 
rat 60 minutes after injection.  No obvious systemic distribution of the QDs could be 
demonstrated as illustrated in fig. 7.6.  
QDs were injected in the small bowel wall and the distribution of quantum dots to the 
mesenteric nodes analyzed. After 60 minutes, there was no obvious evidence of 
sentinel node uptake of quantum dots was observed. The procedure was terminated 
after 4 hours and the animal was killed by high dose of isofluorane humanely. 
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Fig.7.6   Injection of QD solution into the tail vein of the rat. 
 
                      
                                                      
Fig.7.7   Fluorescence after injection of QDs in the lateral tail vein.  
 
7.4 Discussion - Animal experiment performed in the SD rat demonstrated 
feasibility of bio-distribution studies using red emitting CdTe QDs. Distribution of QDs 
to inguinal node was observed 10 minutes after injecting into the interdigital web 
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space of hind limbs. Penetration of UV radiation using ultraviolet probe was found to 
be inadequate in the SD rat due to the depth of the inguinal lymph nodes and 
inability for the UV light to penetrate the skin to demonstrate the fluorescence without 
dissection. Inguinal lymph node dissection was required to identify lymph node with 
red fluorescence. 
Injection of quantum dots into the tail vein of the rat and small bowel was found to be 
inconclusive. It was not possible to identify visceral distribution of the quantum dots. 
Further experiments using higher dose of QDs within their toxicity limit in was 
considered to be appropriate for bio-distribution studies.  
 
7.5 Conclusion- Application of water soluble CdTe QDs is feasible in 
biodistribution studies using animal experiments. The lymph node with the QD 
uptake was more than likely to have been the sentinel lymph node however blue dye 
and radio-isotopes can be used simultaneously to assess if their activity within the 
sentinel node can be coordinated with the activity due to CdTe QDs. Due to low 
cytotoxic potential, these QDs can safely be utilized for in vivo studies. Due to limited 
depth of penetration, NIR light could be used instead of UV light for sentinel lymph 
node identification to detect fluorescence activity through the skin. This will allow for 
precise skin incision over the fluorescent lymph node for harvesting rather than 
formal groin dissection for its identification. 
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Chapter 8 
Discussion 
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To date several methods of preparation of CdTe QDs have been described which 
include both organic synthesis and aqueous synthesis14;18,21. The high quality CdTe 
QDS prepared in the organic solvents cannot be utilized in the biosystems as they 
are hydrophobic. Several methods have been described to convert hydrophobic QDs 
into hydrophilic one such as ligand exchange, encapsulation into water soluble shell 
and arrested precipitation in water. However these processes indeed diminish their 
photoluminescence quantum yield (PL QY) during the transferring process. 
Ying et al 24 in 2008 published a simpler approach of synthesis of luminescent 
cysteine–coated CdTe QDs with QY of 10% using Sodium Tellurite as the Te source. 
This eliminated the need for highly toxic H2Te or highly unstable NaHTe as a 
Tellurium precursor for the aqueous synthesis of Thiol-capped CdTe QDs in the inert 
atmospheric conditions. Using  thiol stabilizer Mercaptosuccinic acid (MSA) as a 
capping ligand and  by optimizing the growth conditions, such as pH of solution and 
the concentration of precursor solutions, the QY could be dramatically improved up 
to 83% at pH 5 without any post-treatment and up to in excess of 70% at pH 6-8.  
CdTe QDs in this study were prepared using precursors Cadmium Chloride and 
Sodium Tellurite in presence of buffer solution of Mercaptosuccinic acid. The 
emission spectrum of quantum dots was precisely determined by the size of the 
QDs. The preparation of QDs with different emission spectrums could be controlled 
by regulating the duration of condensation and refluxation of the mixture of QD 
precursors. The QDs thus prepared were water soluble and stable at room 
temperature and could be  safely be used for in vitro and in vivo experiments. 
During the process of synthesis of CdTe quantum dots, in the initial phase when 
NaBH4 powder was added to the precursor solution, this solution turned green within 
few seconds depending upon the pH value of the precursor solution, the 
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concentration of the solution and the reaction temperature. Lowering the pH value, 
increasing the concentration of the precursor solution or increasing the reaction 
temperature accelerated the formation of the CdTe QDS. During the initial stage, no 
photoluminescence was observed from the crude solution presumably as a result of 
smaller size of the QDs. Weaker luminescence was noted after prolonged boiling 
when the solution turned dark green in colour. With prolonging of the reflux time, the 
absorption spectra as well as PL emission spectra shifted to longer wavelength with 
increase in the size of the CdTe QDs due to quantum confinement effect. These 
MSA- CdTe QDs remained stable for months when stored in the refrigerator at 4ºC 
indicating attractive bio-labeling and bio-imaging applications. 
In this experiment, Red emitting CdTe QDs stabilized in Mercaptosuccinic acid had a 
wide absorption spectrum with an excitonic absorption peak of 380 nm and a very 
narrow symmetrical emission spectrum of 630nm at spectrophotometeric analysis. 
They were present in the form of isolated crystals or clusters measuring 5nm to 10 
nm in diameter. Their elemental localization at the cellular or sub-cellular level could 
be confirmed successfully using transmission Electron Microscopy supplemented by 
X-ray Microanalysis.  
CdTe QDs were able to bind to the HT29 colon cancer cells. Minimal binding was 
noted after the cells were washed with phosphate buffered saline (PBS).More 
significant, stable and prolonged binding of QDs was noted to these colon cancer 
cells after bioconjugation with RGD (Lysine) and RGD (Cysteine). This is in line with 
reports on  successful binding of QDs to cancer cells over-expressing various tumor 
markers such as CEA63, Ca 12551, PSMA67, Her228,70 and others. 
Elemental Cadmium and Tellurium are known to be cytotoxic to the live cells. Prior to 
the analysis of cytotoxicity of CdTe QDs, it was deemed necessary to assess the 
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minimum concentration necessary to produce cytotoxicity to the C2C12 mouse 
skeletal muscle cells. Elemental Cadmium was found to be toxic to these cells at a 
concentration of 5 µg/ml. Using Yo Pro-1 Iodide reagent and Cell titer blue reagent, 
elemental Tellurium was found to be cytotoxic at a concentration of 50 µg/ml. 
However both unconjugated and conjugated QDs were nontoxic to C2C12 mouse 
skeletal muscle cells at a concentration of 50 µg/ml. 
Animal experiment performed in the brown rat demonstrated feasibility of bio-
distribution studies using red emitting CdTe QDs with a very small dose equivalent to 
10µg/ml. Distribution of QDs to inguinal node was observed 10 minutes after 
injecting into the interdigital web space of hind limbs. Penetration of UV radiation 
using ultraviolet probe was found to have been inadequate in brown rat due to the 
depth of the inguinal lymph nodes. Inguinal lymph node dissection was required to 
identify first illuminating lymph node with red fluorescence which was presumed to 
have been the sentinel lymph node. 
Injection of QDs into the tail vein of the rat and small bowel was found to have been 
inconclusive. It was not possible to identify visceral distribution of the QDs. Further 
experiments using higher dose of QDs within their toxicity limit in nude mice was 
considered to be appropriate for bio-distribution studies.  
The translation of QDs in in vivo applications has been limited not only because of 
questions related to possible toxicity, but also due to restricted penetration of light 
into the tissues under investigation41,42.   
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Chapter 9 
Summary and future direction 
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According to the office for national statistics, cancers remain third leading cause of 
death in England and Wales following ischaemic heart diseases and cerebrovascular 
diseases. Early detection of cancers is associated with >90% 5 year survival. 
However for majority of the patients cancer is discovered only after it has spread 
extensively for curative treatment to improve the life expectancy and quality of life. 
The conventional anatomical imaging modalities are unable to detect most cancers 
until they reach > 1cm in diameter. Molecular imaging, especially with QDs 
covalently linked to bio-recognition molecules such as peptides, antibodies, nucleic 
acids, or small-molecule ligands is expected to play an important role in detecting 
cancer early enough in the disease process that the treatment could prove 
successful.. Current treatment strategy involves subjecting the patients to the highly 
toxic compounds which are not specific to the cancer cells. As a result serious side 
effects are common and can be debilitating to the patients. With the help of 
nanotechnology it may be possible to deliver these drugs selectively to the cancer 
cells while avoiding excessive toxicity to the surrounding healthy cells. 
QDs are semiconductor nanoparticles with structural and functional properties that 
are not available from discrete molecules or bulk materials. They encompass large 
surface areas for the attachment of multiple diagnostic (optical, magnetic or radio 
isotopic) and therapeutic agents. When conjugated with biomolecular affinity ligands 
such as antibodies, peptides or small molecules, they can be used to target 
malignant tumors with high affinity and specificity. Most commonly used QDs are 
CdSe or CdTe with a passivation shell made of ZnS which protect the core from 
oxidation and increases the photoluminescence quantum yield. The surface of the 
QD is further coated with solubilization ligand making them water soluble for their 
use in cell biology. 
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High temperature synthesis using pyrolysis of organometallic precursors has been 
the most frequently used method for synthesis of high quality QDs in organic 
solvents. However using alternative cheaper and safer Cadmium precursors, QDs 
with reasonable photoluminescence can be synthesized in the organic solvents. 
Aqueous synthesis although result in fabrication of QDs with poor size distribution 
and low fluorescence efficiency, it carries the advantage of being simple, less toxic 
and reproducible.  
For efficient biodistribution of the QDs, they can be covalently conjugated to various 
biomolecules to specifically target the cellular organelle of interest. For a stable 
bioconjugation, various transmembrane proteins such as integrins can be targeted 
using QDs as a binding and delivery vehicle. 
Despite of successful binding of QDs to cancer cells over-expressing various tumor 
markers such as CEA63, Ca 12551, PSMA67, Her228,70 etc., exploitation of this 
technique in vivo has been limited due to restricted tissue penetration of light. Near 
infrared imaging has presented itself as a powerful diagnostic technique with a 
potential to serve as a minimally invasive, nonionizing method for sensitive 
diagnostic imaging for up to 2-3 cm depth in vivo experiments41,42.  NIR QDs 
demonstrate superior optical performance with exceptional fluorescence, brightness 
and stability. However, the heavy metal composition and high propensity for toxicity 
hinder future application in clinical environments. Cancer specific application of this 
include- Image guided resection of cancer, real time assessment of surgical margins, 
intra-operative sentinel lymph node mapping, intra-operative detection of occult 
metastatic lesions, and identification of surgical anatomy. The implications of NIRF 
imaging in cancer surgery would be as follows- 
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1. Breast cancer- Intra-operative NIR Fluorescent imaging has a potential to replace 
the radioisotope (Technetium 99M sulphur colloid) and blue dye (Isosulfan blue) 
which has been traditionally injected around the tumour for identification of the 
sentinel lymph nodes. Using NIR fluorescent imaging, not only the real time sentinel 
lymph node mapping would be possible but by using breast cancer specific targeting 
molecules, adequacy of cancer resection and lymph node clearance would be 
ascertained.  
2. Colon cancer - NIRF imaging using specific markers such as CEA, surgical 
resection of occult tumor extension and lymph node mapping would be possible. 
3. Lung cancer- Adequacy of surgical excision, identification of occult lesions and 
real time imaging of lymph node drainage would be possible with NIRF imaging. 
4. Prostate cancer- Besides adequate surgical clearance of the cancer, it may even 
be possible to directly visualize the nerves by the use of NIRF nerve targeting 
module. 
To improve the therapeutic efficacy of chemotherapeutic agents, nanotechnology 
based formulations are already in use. The commonest example being Abraxane, an 
albumin-bound nanoparticle formulation of paclitaxel being used for metastatic 
breast cancer and Doxil, a long circulating liposomal formulation of doxorubicin being 
used in ovarian cancer. Using nanotechnology tools, drug delivery system can be 
developed using an array of nanoscaled polymeric, liposomal and inorganic 
materials. These nano drug delivery systems offer easier tissue penetration through 
biological and physiological barriers that are normally impermeable for larger 
particulate structures, due to their small size. In addition to this, they carry 
multifunctional capabilities of simultaneous imaging and therapeutic applications. 
With ongoing research in the field of nanomedicine, the same principles could be 
   191 
 
applied to QDs. These QDs are almost always conjugated to some form of ligand for 
solubilization or functionalization purpose. Therefore adding tumor specific targeting 
ligand, cancer cells can selectively be targeted for delivering chemotherapeutic 
agents for maximum efficacy. 
Despite of their novel biological properties, QDs can pose cytotoxic risk to the living 
cells due to their chemical composition and prolong half-life.  Further research into 
methods of elimination of QDs from the biological environment after their successful 
application would encourage safer use of these nanoparticles in human population 
for oncological application. 
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Appendix 
Table 1.  Statistical analysis of percentage of cell survival using graded 
concentration of Cadmium-           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 45.78         
R square 0.9537         
            
ANOVA Table SS df MS     
Treatment (between columns) 53568 9 5952     
Residual (within columns) 2600 20 130.0     
Total 56168 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -13.73 1.474 No ns -41.16 to 13.70 
medium only vs 0.05 -0.4567 0.04905 No ns -27.89 to 26.97 
medium only vs 0.1 -3.337 0.3584 No ns -30.77 to 24.09 
medium only vs 0.5 -2.897 0.3111 No ns -30.33 to 24.53 
medium only vs 1 1.943 0.2087 No ns -25.49 to 29.37 
medium only vs 5 40.68 4.369 Yes ** 13.25 to 68.11 
medium only vs 10 87.62 9.411 Yes *** 60.19 to 115.1 
medium only vs 50 91.80 9.860 Yes *** 64.37 to 119.2 
medium only vs 100 92.34 9.918 Yes *** 64.91 to 119.8 
   200 
 
Table 2. Statistical analysis of percentage of cell death using graded concentration of             
Cadmium-           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 16.33         
R square 0.8802         
            
ANOVA Table SS df MS     
Treatment (between columns) 17.62 9 1.958     
Residual (within columns) 2.398 20 0.1199     
Total 20.02 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.01400 0.04952 No ns -0.8470 to 0.8190 
medium only vs 0.05 0.08700 0.3077 No ns -0.7460 to 0.9200 
medium only vs 0.1 -0.04500 0.1592 No ns -0.8780 to 0.7880 
medium only vs 0.5 -0.01967 0.06956 No ns -0.8527 to 0.8133 
medium only vs 1 0.3804 1.345 No ns -0.4526 to 1.213 
medium only vs 5 -0.7010 2.479 No ns -1.534 to 0.1320 
medium only vs 10 -1.864 6.592 Yes *** -2.697 to -1.031 
medium only vs 50 -1.515 5.357 Yes *** -2.348 to -0.6817 
medium only vs 100 -1.450 5.128 Yes *** -2.283 to -0.6167 
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Table 3. Statistical analysis of percentage of cell survival using graded concentration 
of Tellurium-           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 168.3         
R square 0.9870         
            
ANOVA Table SS df MS     
Treatment (between columns) 50748 9 5639     
Residual (within columns) 670.2 20 33.51    
Total 51418 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 3.467 0.7334 No ns -10.46 to 17.39 
medium only vs 0.05 9.333 1.975 No ns -4.593 to 23.26 
medium only vs 0.1 17.67 3.738 Yes ** 3.741 to 31.59 
medium only vs 0.5 27.00 5.712 Yes *** 13.07 to 40.93 
medium only vs 1 24.67 5.219 Yes *** 10.74 to 38.59 
medium only vs 5 35.86 7.586 Yes *** 21.93 to 49.78 
medium only vs 10 36.89 7.805 Yes *** 22.96 to 50.82 
medium only vs 50 119.7 25.33 Yes *** 105.8 to 133.6 
medium only vs 100 115.9 24.53 Yes *** 102.0 to 129.9 
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Table 4. Statistical analysis of percentage of cell death using graded concentration              
of Tellurium. 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 69.79         
R square 0.9691         
            
ANOVA Table SS df MS     
Treatment (between columns) 14.90 9 1.655     
Residual (within columns) 0.4744 20 0.02372     
Total 15.37 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.01867 0.1484 No ns -0.3892 to 0.3518 
medium only vs 0.05 -0.0510 0.4056 No ns -0.4215 to 0.3195 
medium only vs 0.1 -0.03100 0.2465 No ns -0.4015 to 0.3395 
medium only vs 0.5 -0.08733 0.6945 No ns -0.4578 to 0.2832 
medium only vs 1 -0.1467 1.166 No ns -0.5172 to 0.2238 
medium only vs 5 -0.1727 1.373 No ns -0.5432 to 0.1978 
medium only vs 10 -0.1923 1.529 No ns -0.5628 to 0.1782 
medium only vs 50 -1.545 12.29 Yes *** -1.916 to -1.174 
medium only vs 100 -2.087 16.60 Yes *** -2.458 to -1.716 
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Table 5. Statistical analysis of percentage of cell survival using graded concentration 
of CdTe Qds – Sample 1 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 111.8         
R square 0.9805         
            
ANOVA Table SS df MS     
Treatment (between columns) 16403 9 1823     
Residual (within columns) 326.1 20 16.30     
Total 16729 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs QD0.01 -5.407 1.640 No ns -15.12 to 4.307 
medium only vs QD0.05 -5.167 1.567 No ns -14.88 to 4.547 
medium only vs QD0.1 -5.037 1.528 No ns -14.75 to 4.677 
medium only vs QD0.5 -5.047 1.531 No ns -14.76 to 4.667 
medium only vs QD1 -5.877 1.782 No ns -15.59 to 3.837 
medium only vs QD5 -3.850 1.168 No ns -13.56 to 5.864 
medium only vs QD10 5.697 1.728 No ns -4.017 to 15.41 
medium only vs QD50 34.57 10.49 Yes *** 24.86 to 44.29 
medium only vs Cadmium 50 68.55 20.79 Yes *** 58.84 to 78.26 
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Table 6.  Statistical analysis of percentage of cell survival using graded                
concentration of CdTe Qds – Sample 2 
 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 110.7         
R square 0.9708         
            
ANOVA Table SS df MS     
Treatment (between columns) 24765 9 2752     
Residual (within columns) 745.7 30 24.86     
Total 25511 39       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -4.973 1.410 No ns -15.04 to 5.095 
medium only vs 0.05 -6.430 1.824 No ns -16.50 to 3.637 
medium only vs 0.1 -14.27 4.047 Yes ** -24.33 to -4.200 
medium only vs 0.5 -5.918 1.679 No ns -15.98 to 4.150 
medium only vs 1 -21.97 6.233 Yes *** -32.04 to -11.91 
medium only vs 5 -12.45 3.531 Yes ** -22.52 to -2.383 
medium only vs 10 0.8425 0.2390 No ns -9.225 to 10.91 
medium only vs 50 36.44 10.34 Yes *** 26.37 to 46.51 
medium only vs Cadmium 50 63.58 18.03 Yes *** 53.51 to 73.64 
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Table 7.  Statistical analysis of percentage of cell death using graded concentration 
of CdTe Qds – Sample 1 
            
 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 29.10         
R square 0.9291         
            
ANOVA Table SS df MS     
Treatment (between columns) 13.86 9 1.540     
Residual (within columns) 1.058 20 0.05290     
Total 14.91 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 0.003667 0.01953 No ns -0.5496 to 0.5570 
medium only vs 0.05 0.03033 0.1615 No ns -0.5230 to 0.5836 
medium only vs 0.1 -0.04433 0.2361 No ns -0.5976 to 0.5090 
medium only vs 0.5 -0.08233 0.4384 No ns -0.6356 to 0.4710 
medium only vs 1 -0.1983 1.056 No ns -0.7516 to 0.3550 
medium only vs 5 -0.05533 0.2947 No ns -0.6086 to 0.4980 
medium only vs 10 -0.4020 2.141 No ns -0.9553 to 0.1513 
medium only vs 50 -0.5133 2.734 No ns -1.067 to 0.03995 
medium only vs Cadmium 50 -2.331 12.41 Yes *** -2.884 to -1.777 
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Table 8.  Statistical analysis of percentage of cell death using graded concentration                
of CdTe Qds 
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 53.47         
R square 0.9601         
            
ANOVA Table SS df MS     
Treatment (between columns) 6.462 9 0.7180     
Residual (within columns) 0.2686 20 0.01343     
Total 6.730 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.05833 0.6165 No ns -0.3371 to 0.2204 
medium only vs 0.05 -0.07467 0.7892 No ns -0.3534 to 0.2041 
medium only vs 0.1 -0.06400 0.6764 No ns -0.3428 to 0.2148 
medium only vs 0.5 -0.01400 0.1480 No ns -0.2928 to 0.2648 
medium only vs 1 -0.2390 2.526 No ns -0.5178 to 0.03976 
medium only vs 5 -0.08000 0.8455 No ns -0.3588 to 0.1988 
medium only vs 10 -0.2560 2.706 No ns -0.5348 to 0.02276 
medium only vs 50 -0.2933 3.100 Yes * -0.5721 to -0.01457 
medium only vs Cadmium 50 -1.631 17.24 Yes *** -1.910 to -1.352 
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Table 9. Statistical analysis of percentage of cell survival using graded concentration 
             of RGD (Lysine) conjugated CdTe Qds 
 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 43.70         
R square 0.9516         
            
ANOVA Table SS df MS     
Treatment (between columns) 16978 9 1886     
Residual (within columns) 863.3 20 43.17     
Total 17841 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs QD0.01 -5.693 1.061 No ns -21.50 to 10.11 
medium only vs QD0.05 -12.09 2.254 No ns -27.90 to 3.715 
medium only vs QD0.1 -12.51 2.331 No ns -28.31 to 3.299 
medium only vs QD0.5 -11.05 2.060 No ns -26.86 to 4.755 
medium only vs QD1 -15.35 2.862 No ns -31.16 to 0.4520 
medium only vs QD5 -17.68 3.295 Yes * -33.48 to -1.871 
medium only vs QD10 -25.26 4.708 Yes ** -41.06 to -9.451 
medium only vs QD50 -31.34 5.842 Yes *** -47.15 to -15.53 
medium only vs Cadmium 50 59.53 11.10 Yes *** 43.73 to 75.34 
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Table 10.  Statistical analysis of percentage of cell survival using graded                  
concentration of RGD (Lysine) conjugated CdTe Qds 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 33.03         
R square 0.9370         
            
ANOVA Table SS df MS     
Treatment (between columns) 17198 9 1911     
Residual (within columns) 1157 20 57.85     
Total 18355 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 3.207 0.5164 No ns -15.09 to 21.50 
medium only vs 0.05 9.063 1.459 No ns -9.233 to 27.36 
medium only vs 0.1 5.643 0.9087 No ns -12.65 to 23.94 
medium only vs 0.5 16.77 2.700 No ns -1.530 to 35.06 
medium only vs 1 4.780 0.7697 No ns -13.52 to 23.08 
medium only vs 5 1.140 0.1836 No ns -17.16 to 19.44 
medium only vs 10 -3.960 0.6377 No ns -22.26 to 14.34 
medium only vs 50 -6.947 1.119 No ns -25.24 to 11.35 
medium only vs Cadmium 50 80.31 12.93 Yes *** 62.01 to 98.60 
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Table 11.  Statistical analysis of percentage of cell death using graded concentration 
of RGD (Lysine) conjugated CdTe Qds 
 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 103.1         
R square 0.9789         
            
ANOVA Table SS df MS     
Treatment (between columns) 7.863 9 0.8736     
Residual (within columns) 0.1695 20 0.008476     
Total 8.032 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs QD0.01 -0.09267 1.233 No ns -0.3141 to 0.1288 
medium only vs QD0.05 0.03400 0.4523 No ns -0.1875 to 0.2555 
medium only vs QD0.1 -0.1020 1.357 No ns -0.3235 to 0.1195 
medium only vs QD0.5 0.01900 0.2528 No ns -0.2025 to 0.2405 
medium only vs QD1 -0.01700 0.2262 No ns -0.2385 to 0.2045 
medium only vs QD5 -0.02133 0.2838 No ns -0.2428 to 0.2001 
medium only vs QD10 -0.1587 2.111 No ns -0.3801 to 0.06281 
medium only vs QD50 -0.03633 0.4833 No ns -0.2578 to 0.1851 
medium only vs Cadmium 50 -1.738 23.12 Yes *** -1.959 to -1.516 
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Table 12.  Statistical analysis of percentage of cell death using graded concentration 
of RGD (Lysine) conjugated CdTe Qds 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 103.1         
R square 0.9789         
            
ANOVA Table SS df MS     
Treatment (between columns) 7.863 9 0.8736     
Residual (within columns) 0.1695 20 0.008476     
Total 8.032 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.09267 1.233 No ns -0.3141 to 0.1288 
medium only vs 0.05 0.03400 0.4523 No ns -0.1875 to 0.2555 
medium only vs 0.1 -0.1020 1.357 No ns -0.3235 to 0.1195 
medium only vs 0.5 0.01900 0.2528 No ns -0.2025 to 0.2405 
medium only vs 1 -0.01700 0.2262 No ns -0.2385 to 0.2045 
medium only vs 5 -0.02133 0.2838 No ns -0.2428 to 0.2001 
medium only vs 10 -0.1587 2.111 No ns -0.3801 to 0.06281 
medium only vs 50 -0.03633 0.4833 No ns -0.2578 to 0.1851 
medium only vs Cadmium 50 -1.738 23.12 Yes *** -1.959 to -1.516 
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Table 13.  Statistical analysis of percentage of cell survival using graded 
concentration of RGD (Cysteine) conjugated CdTe Qds 
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 344.1         
R square 0.9810         
            
Bartlett's test for equal variances           
Bartlett's statistic (corrected) 52.29         
P value < 0.0001         
P value summary ****         
Do the variances differ signif. (P < 0.05) Yes         
            
ANOVA Table SS df MS     
Treatment (between columns) 45346 9 5038     
Residual (within columns) 878.6 60 14.64     
Total 46224 69       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -1.727 0.8444 No ns -7.391 to 3.936 
medium only vs 0.05 -0.5500 0.2689 No ns -6.213 to 5.113 
medium only vs 0.1 -5.640 2.757 No ns -11.30 to 0.02348 
medium only vs 0.5 -2.740 1.340 No ns -8.403 to 2.923 
medium only vs 1 -4.974 2.432 No ns -10.64 to 0.6892 
medium only vs 5 -13.52 6.609 Yes *** -19.18 to -7.854 
medium only vs 10 -12.77 6.244 Yes *** -18.43 to -7.108 
medium only vs 50 -21.79 10.65 Yes *** -27.45 to -16.12 
medium only vs Cadmium 50 74.85 36.59 Yes *** 69.19 to 80.51 
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Table 14.  Statistical analysis of percentage of cell survival using graded 
concentration of RGD (Cysteine) conjugated CdTe Qds 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 18.10         
R square 0.8907         
            
ANOVA Table SS df MS     
Treatment (between columns) 17439 9 1938     
Residual (within columns) 2141 20 107.0     
Total 19579 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.3033 0.03591 No ns -25.19 to 24.58 
medium only vs 0.05 -10.40 1.231 No ns -35.28 to 14.49 
medium only vs 0.1 -9.447 1.118 No ns -34.33 to 15.44 
medium only vs 0.5 -15.45 1.829 No ns -40.34 to 9.438 
medium only vs 1 -10.68 1.265 No ns -35.57 to 14.20 
medium only vs 5 -3.697 0.4376 No ns -28.58 to 21.19 
medium only vs 10 -18.65 2.207 No ns -43.53 to 6.241 
medium only vs 50 -16.46 1.949 No ns -41.35 to 8.424 
medium only vs Cadmium 50 68.25 8.080 Yes *** 43.37 to 93.14 
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Table 15.  Statistical analysis of percentage of cell death using graded concentration 
of RGD (Cysteine) conjugated CdTe Qds 
 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 83.02         
R square 0.9739         
            
ANOVA Table SS df MS     
Treatment (between columns) 9.545 9 1.061     
Residual (within columns) 0.2555 20 0.01278     
Total 9.801 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.05233 0.5671 No ns -0.3242 to 0.2196 
medium only vs 0.05 0.05433 0.5887 No ns -0.2176 to 0.3262 
medium only vs 0.1 -0.04500 0.4876 No ns -0.3169 to 0.2269 
medium only vs 0.5 0.05167 0.5598 No ns -0.2202 to 0.3236 
medium only vs 1 -0.09267 1.004 No ns -0.3646 to 0.1792 
medium only vs 5 0.02767 0.2998 No ns -0.2442 to 0.2996 
medium only vs 10 -0.1087 1.177 No ns -0.3806 to 0.1632 
medium only vs 50 -0.1100 1.192 No ns -0.3819 to 0.1619 
medium only vs Cadmium 50 -1.900 20.59 Yes *** -2.172 to -1.628 
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Table 16.  Statistical analysis of percentage of cell death using graded concentration 
of RGD (Cysteine) conjugated CdTe Qds 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 45.65         
R square 0.9536         
            
ANOVA Table SS df MS     
Treatment (between columns) 6.212 9 0.6902     
Residual (within columns) 0.3024 20 0.01512     
Total 6.514 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.04833 0.4814 No ns -0.3441 to 0.2475 
medium only vs 0.05 0.08600 0.8566 No ns -0.2098 to 0.3818 
medium only vs 0.1 0.07553 0.7523 No ns -0.2203 to 0.3713 
medium only vs 0.5 -0.08233 0.8201 No ns -0.3781 to 0.2135 
medium only vs 1 -0.01533 0.1527 No ns -0.3111 to 0.2805 
medium only vs 5 -0.02600 0.2590 No ns -0.3218 to 0.2698 
medium only vs 10 -0.1610 1.604 No ns -0.4568 to 0.1348 
medium only vs 50 -0.1297 1.292 No ns -0.4255 to 0.1661 
medium only vs Cadmium 50 -1.530 15.24 Yes *** -1.825 to -1.234 
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Table 17.  Statistical analysis of percentage of cell survival using graded 
concentration of RAD conjugated CdTe Qds – Sample1. 
 
 
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 69.50         
R square 0.9690         
            
ANOVA Table SS df MS     
Treatment (between columns) 17617 9 1957     
Residual (within columns) 563.3 20 28.16     
Total 18180 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -4.183 0.9654 No ns -16.95 to 8.583 
medium only vs 0.05 -9.463 2.184 No ns -22.23 to 3.303 
medium only vs 0.1 -6.430 1.484 No ns -19.20 to 6.337 
medium only vs 0.5 -13.60 3.138 Yes * -26.36 to -0.8300 
medium only vs 1 -13.46 3.106 Yes * -26.23 to -0.6934 
medium only vs 5 -19.20 4.430 Yes ** -31.96 to -6.430 
medium only vs 10 -20.75 4.789 Yes *** -33.52 to -7.987 
medium only vs 50 -20.14 4.648 Yes ** -32.91 to -7.373 
medium only vs Cadmium 50 65.76 15.18 Yes *** 53.00 to 78.53 
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Table 18. Statistical analysis of percentage of cell survival using graded 
concentration of RAD conjugated CdTe Qds- Sample 2. 
 
 
 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 69.50         
R square 0.9690         
            
ANOVA Table SS df MS     
Treatment (between columns) 17617 9 1957     
Residual (within columns) 563.3 20 28.16     
Total 18180 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -4.183 0.9654 No ns -16.95 to 8.583 
medium only vs 0.05 -9.463 2.184 No ns -22.23 to 3.303 
medium only vs 0.1 -6.430 1.484 No ns -19.20 to 6.337 
medium only vs 0.5 -13.60 3.138 Yes * -26.36 to -0.8300 
medium only vs 1 -13.46 3.106 Yes * -26.23 to -0.6934 
medium only vs 5 -19.20 4.430 Yes ** -31.96 to -6.430 
medium only vs 10 -20.75 4.789 Yes *** -33.52 to -7.987 
medium only vs 50 -20.14 4.648 Yes ** -32.91 to -7.373 
medium only vs Cadmium 50 65.76 15.18 Yes *** 53.00 to 78.53 
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Table 19. Statistical analysis of percentage of cell death using graded concentration 
of RAD conjugated CdTe Qds 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 47.42         
R square 0.9552         
            
ANOVA Table SS df MS     
Treatment (between columns) 11.19 9 1.243     
Residual (within columns) 0.5243 20 0.02621     
Total 11.71 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.1060 0.8019 No ns -0.4955 to 0.2835 
medium only vs 0.05 0.03833 0.2900 No ns -0.3511 to 0.4278 
medium only vs 0.1 -0.08400 0.6354 No ns -0.4735 to 0.3055 
medium only vs 0.5 -0.08500 0.6430 No ns -0.4745 to 0.3045 
medium only vs 1 -0.08433 0.6380 No ns -0.4738 to 0.3051 
medium only vs 5 -0.001333 0.01009 No ns -0.3908 to 0.3881 
medium only vs 10 -0.1470 1.112 No ns -0.5365 to 0.2425 
medium only vs 50 -0.1610 1.218 No ns -0.5505 to 0.2285 
medium only vs Cadmium 50 -2.095 15.85 Yes *** -2.485 to -1.706 
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Table 20.  Statistical analysis of percentage of cell death using graded concentration 
of RAD conjugated CdTe Qds 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 90.78         
R square 0.9761         
            
ANOVA Table SS df MS     
Treatment (between columns) 11.31 9 1.257     
Residual (within columns) 0.2770 20 0.01385     
Total 11.59 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.09133 0.9506 No ns -0.3744 to 0.1918 
medium only vs 0.05 -0.02133 0.2220 No ns -0.3044 to 0.2618 
medium only vs 0.1 -0.1463 1.523 No ns -0.4294 to 0.1368 
medium only vs 0.5 -0.2687 2.796 No ns -0.5518 to 0.01442 
medium only vs 1 -0.1063 1.107 No ns -0.3894 to 0.1768 
medium only vs 5 0.03867 0.4024 No ns -0.2444 to 0.3218 
medium only vs 10 -0.1567 1.631 No ns -0.4398 to 0.1264 
medium only vs 50 -0.1710 1.780 No ns -0.4541 to 0.1121 
medium only vs Cadmium 50 -2.129 22.16 Yes *** -2.412 to -1.846 
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Table 21. Statistical analysis of percentage of cell survival using graded 
concentration of polymer conjugated CdTe Qds.- Sample 1 
 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 30.91         
R square 0.9329         
            
ANOVA Table SS df MS     
Treatment (between columns) 20098 9 2233     
Residual (within columns) 1445 20 72.25     
Total 21543 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -12.86 1.853 No ns -33.31 to 7.585 
medium only vs 0.05 -21.27 3.065 Yes * -41.72 to -0.8248 
medium only vs 0.1 -13.55 1.953 No ns -34.00 to 6.895 
medium only vs 0.5 -20.62 2.971 Yes * -41.07 to -0.1681 
medium only vs 1 -19.65 2.832 No ns -40.10 to 0.7952 
medium only vs 5 -20.85 3.005 Yes * -41.30 to -0.4048 
medium only vs 10 -19.87 2.863 No ns -40.32 to 0.5752 
medium only vs 50 -13.82 1.991 No ns -34.27 to 6.629 
medium only vs Cadmium 50 67.98 9.794 Yes *** 47.53 to 88.43 
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Table 22. Statistical analysis of percentage of cell survival using graded 
concentration of polymer conjugated CdTe Qds= Sample 2 
 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 30.91         
R square 0.9329         
            
ANOVA Table SS df MS     
Treatment (between columns) 20098 9 2233     
Residual (within columns) 1445 20 72.25     
Total 21543 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -12.86 1.853 No ns -33.31 to 7.585 
medium only vs 0.05 -21.27 3.065 Yes * -41.72 to -0.8248 
medium only vs 0.1 -13.55 1.953 No ns -34.00 to 6.895 
medium only vs 0.5 -20.62 2.971 Yes * -41.07 to -0.1681 
medium only vs 1 -19.65 2.832 No ns -40.10 to 0.7952 
medium only vs 5 -20.85 3.005 Yes * -41.30 to -0.4048 
medium only vs 10 -19.87 2.863 No ns -40.32 to 0.5752 
medium only vs 50 -13.82 1.991 No ns -34.27 to 6.629 
medium only vs Cadmium 50 67.98 9.794 Yes *** 47.53 to 88.43 
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Table 23.  Statistical analysis of percentage of cell death using graded concentration 
of polymer conjugated CdTe Qds – Sample 1 
 
 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 83.92         
R square 0.9742         
            
ANOVA Table SS df MS     
Treatment (between columns) 16.78 9 1.864     
Residual (within columns) 0.4443 20 0.02222     
Total 17.22 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.05167 0.4246 No ns -0.4102 to 0.3069 
medium only vs 0.05 0.03533 0.2903 No ns -0.3232 to 0.3939 
medium only vs 0.1 -0.05600 0.4602 No ns -0.4146 to 0.3026 
medium only vs 0.5 0.07100 0.5834 No ns -0.2876 to 0.4296 
medium only vs 1 -0.001000 0.008217 No ns -0.3596 to 0.3576 
medium only vs 5 0.06000 0.4930 No ns -0.2986 to 0.4186 
medium only vs 10 -0.05800 0.4766 No ns -0.4166 to 0.3006 
medium only vs 50 -0.1460 1.200 No ns -0.5046 to 0.2126 
medium only vs Cadmium 50 -2.501 20.55 Yes *** -2.859 to -2.142 
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Table 24.  Statistical analysis of percentage of cell death using graded concentration 
of polymer conjugated CdTe Qds.- Sample 2 
Table Analyzed Data 1         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ****         
Are means signif. different? (P < 0.05) Yes         
Number of groups 10         
F 58.23         
R square 0.9632         
            
ANOVA Table SS df MS     
Treatment (between columns) 11.53 9 1.281     
Residual (within columns) 0.4399 20 0.02200     
Total 11.97 29       
            
Dunnett's Multiple Comparison Test Mean Diff. q Significant? P < 0.05? Summary 95% CI of diff 
medium only vs 0.01 -0.04900 0.4046 No ns -0.4058 to 0.3078 
medium only vs 0.05 0.03467 0.2863 No ns -0.3221 to 0.3915 
medium only vs 0.1 -0.05900 0.4872 No ns -0.4158 to 0.2978 
medium only vs 0.5 0.04367 0.3606 No ns -0.3131 to 0.4005 
medium only vs 1 -0.04367 0.3606 No ns -0.4005 to 0.3131 
medium only vs 5 0.02967 0.2450 No ns -0.3271 to 0.3865 
medium only vs 10 -0.09733 0.8038 No ns -0.4541 to 0.2595 
medium only vs 50 -0.1550 1.280 No ns -0.5118 to 0.2018 
medium only vs Cadmium 50 -2.090 17.26 Yes *** -2.446 to -1.733 
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Publication and presentation from the 
thesis 
 
1. Conjugation of quantum dots with RGD peptides: Colon cancer cell targeting and 
toxicity assay. S Taribagil, SY Yang, B Ramesh, AM Seifalian and MC. Winslet  
SARS Annual Conference 2010 ,London                                                                    
poster presentation 
 
2. Quantum Dots- Past, Present and Future? – Submitted for publication to 
nanomedicine.  In the process of resubmission after corrections. 
